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Whole exome sequencing (ES) is an extensive form of genetic testing and
increasingly used as a diagnostic tool. Clinical uptake of genome-scale sequencing
occurred without clear guidelines for application or robust information regarding
potential impact on patient health outcomes or cost of care. For infants in intensive
care with suspected genetic conditions, ES can be especially powerful to identify a
specific diagnosis and inform crucial decisions about medical care. However, little is
known about the cost-effectiveness of ES compared to other diagnostic strategies.
This project first assessed the literature on pediatric clinical ES. Then, using
electronic medical record, diagnostic laboratory, and hospital cost data, we analyzed
and compared outcomes and costs of care for patients with suspected genetic
etiologies admitted to intensive care within the first year of life in two patient cohorts:
those who had ES (ES, n=368) and did not have ES (No-ES, n=368) as part of a
diagnostic workup at a large children’s hospital. Molecular diagnostic yield (25.8%
No-ES, 27.7% ES; p=0.56) and 1-year survival (84.8% No-ES, 80.2% ES; p=0.10)
were similar between cohorts, while ES patients had higher total cost, diagnostic

investigation cost, and genetic test cost during the index admission and for the year
after the date of first inpatient genetics consultation (all p<0.01). ES demonstrated
important diagnostic utility for patients with monogenic disease, yet other genetic
tests, especially chromosomal microarray, remain important given the burden of
chromosomal abnormalities in this population. As clinically applied over the first 5
years, ES does not appear to be a cost-effective diagnostic tool for the broad
population of newborns and infants with suspected genetic disease compared to
standard diagnostic tests such as chromosomal microarray analysis and
panel/single gene testing. Further work is needed to develop outcome measures to
capture utility of ES results – both diagnostic and non-diagnostic – for clinicians,
patients, and patients’ families, and to specify clinical guidelines for appropriate ES
application.
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INTRODUCTION
Completion of the Human Genome Project in 2003 marked a major
accomplishment in the field of biological research. It fostered an ambitious goal
within the scientific and medical community to translate genetic knowledge from the
research setting to the clinical setting and use an individual patient’s genetic makeup
to guide medical decision-making.1 Rapid reductions in the cost of sequencing,
along with identification of clinically relevant gene variants though accumulation of
sequence information, have made genome-scale sequencing increasingly relevant
for patient care. In clinical practice, whole exome sequencing (ES) has been
successfully applied as a diagnostic tool.2,3
ES is a powerful test because it can identify a molecular-level diagnosis
based on a broad picture of a patient’s most clinically relevant genetic sequence
information. Using next-generation sequencing techniques, ES simultaneously
analyzes the deoxyribonucleic acid (DNA) sequence of the exons in each gene,
collectively referred to as the exome. The exome is the subset of the genome that
codes for protein products and is most well-understood.4 ES can potentially replace
a wide range of other diagnostic tests and may both reduce the time required to
establish a diagnosis and increase the probability that a specific diagnosis is made
in a particular patient.
ES is especially useful for individuals with rare diseases or diseases that are
difficult or impossible to diagnose with other diagnostic modalities.5 Care providers
can order ES from a clinical genetic laboratory in three different forms: sequencing
of the patient only (proband ES), sequencing of the patient and both biological
12

parents (trio ES) and sequencing of the patient and both parents with a reduced
turnaround time (critical trio ES).
While clinical uptake of genomic sequencing is increasing, there is very little
evidence on the impact of ES on patient health outcomes or the cost-effectiveness
of using ES as a diagnostic test compared to other diagnostic strategies. Moreover,
specific and measurable patient outcomes following clinical genomic sequencing
(cGS) have not yet been systematically explored or defined. Measurement and
analysis of the effectiveness of ES to achieve relevant and specific health outcomes
can provide important evidence of clinical utility. Moreover, effectiveness data is a
necessary precursory step to economic evaluation. Generation of an evidence base
to help understand where and how ES fits into medical care is essential to guide
practical and efficient technology translation from the laboratory bench to the patient
bedside. In turn, evaluation of bedside use – and the development of appropriate
methods for conducting such evaluations – is an increasingly important topic for
health services research.

Study Aims
This research addressed the following overarching question: What is the
impact of exome sequencing (ES) as a clinical diagnostic tool for critically ill infants
with suspected genetic conditions? To investigate this question, three sub-questions
were asked: (1) What is currently known about the effectiveness and costeffectiveness of clinical genomic sequencing (cGS)?; (2) How do relevant and
measurable outcomes for infants in intensive care settings compare between
13

patients who did and did not have ES?; and (3) How does cost of care compare
between patients who did and did not have ES, and what is the cost-effectiveness of
ES for diagnosis of infants in intensive care compared to usual diagnostic care?
Research aims were developed to investigate each sub-question in turn. Motivations
for each aim of this research, the aims, and the specific objectives to achieve each
aim are listed below.

Motivation 1: A comprehensive review of publications reporting on cGS has not yet
been published. cGS use has not been summarized by clinical setting or patient
type, and reported outcomes such as diagnostic yield of these tools has not yet been
synthesized across studies. Knowledge of how cGS has been applied in practice to
date can inform uptake and direct further research.

Aim 1. Synthesize the available clinical and economic evidence from the literature
on genomic sequencing as a clinical diagnostic tool in pediatric patient populations
Objectives:
a. Perform a scoping review of published peer-reviewed literature on the
use of genome sequencing (GS) and exome sequencing (ES) in
clinical practice for pediatric patients (0–18 years of age)
b. Summarize disease areas, and associated molecular diagnostic yield,
in which diagnostic cGS has been used, and identify commonalities
and differences in what has been reported
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c. Identify and describe categories of reported sources of clinical utility of
cGS and medical management changes following results, as well as
how these categories were defined and operationally measured
d. Summarize the level of evidence in the literature on effectiveness and
cost-effectiveness from a health services research perspective

Motivation 2: Identification of an appropriate patient population, comparison
population, and outcome measures to use as endpoints in health economic analyses
has been identified as a major hurdle for value assessments of cGS. A robust,
comparative analysis of the effectiveness of ES to achieve specific outcomes is
lacking. Construction of an appropriate cohort of comparison group patients and
determination of important and feasibly measurable outcomes are crucial elements
of study design to assess the value of cGS.

Aim 2. Identify and describe a population of undiagnosed infants with suspected
genetic etiology in intensive care settings, define and measure relevant clinical
outcomes, and compare outcomes for patients who did and did not have ES.
Objectives:
a. Provide an overview of practical challenges associated with outcome
measurement in cGS
b. Describe methods for identification of the patient population and
procedures used for matching patients who had ES to patients who did
not have ES based on clinically relevant features
15

c. Provide descriptive statistics on demographics and clinical features of
patients included in the study sample
d. Identify relevant outcomes, conduct retrospective electronic medical
record review to compile data on candidate outcome measures, and
describe how outcomes were measured
e. Perform statistical analyses to compare outcomes between cohorts of
patients who did and did not have ES and other relevant subgroups

Motivation 3: There is very little evidence on the cost-effectiveness of clinical
diagnostic ES for infants in intensive care settings. Evidence from economic
evaluation is needed to inform the clinical use of the test and payers’ medical
coverage policy.

Aim 3. Compare cost of care for patients who did and did not have ES as part of a
diagnostic workup and calculate incremental cost-effectiveness of ES, compared to
a diagnostic pathway that does not include ES, for critically ill infants less than 1
year of life with a suspected genetic etiology at Texas Children’s Hospital
Objectives:
a. Analyze costs for cohorts of patients who did and did not have ES over
the index admission and one year following the initial genetics
consultation for categories of total cost, hospital billing code, diagnostic
pathway, and genetic tests.
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b. Compare costs and outcomes over the time horizon of the index
admission and one year following the initial genetics consultation using
the hospital perspective. Primary outcomes by which to measure
effectiveness include molecular diagnostic yield and survival.
c. Calculate incremental cost-effectiveness ratios (ICERs) for ES for
relevant outcome measures

BACKGROUND
Whole exome sequencing (ES) demonstrated proof of concept to diagnose a
patient in the research setting in 2009.6 ES became commercially available as a
clinical test in 2011, meaning that a clinician could order it from a diagnostic
laboratory. It generally utilizes a blood sample to generate the deoxyribonucleic acid
(DNA) sequence of the patient’s exome – a word used to collectively refer to the
approximately 180,000 exons, the portion of the genome that encodes instructions
for making protein products that is made up of about 30 million base pairs, or 1-2%
of the total genome sequence.6
ES was first available as a test for the proband (i.e., the patient for whom the
genetic investigation is being performed). Two additional forms of ES, trio ES
introduced in October 2014 and critical trio ES introduced in April 2015, require
blood or saliva samples from both biological parents of the proband. Parental
sequence information increases the ability of medical geneticists to differentiate
between inherited sequence variants and de novo mutations in the child.7 For
example, a sequence variant detected in the patient is less likely to be causal of
17

disease presentation if it was inherited from a healthy parent. The proband’s DNA
sequence is compared to a reference sequence and the sequence of both parents,
and sequence variants are interpreted alongside clinical phenotype, variant
databases, and disease gene literature.
Critical trio ES was developed for use in critically ill patients and has a two to
three week turnaround time, compared to eight to ten weeks for return of results
from proband-only and trio ES. Reduced turnaround time is important when the
results of the test are needed to guide urgent medical management decisions.
Definitive knowledge of the genetic basis of disease within a short timeframe may be
especially influential in the neonatal intensive care unit (NICU) and pediatric
intensive care unit (PICU).
Establishment of a molecular diagnosis can inform critical medical decisions
that impact health outcomes, and time to diagnosis can impact the availability or
effectiveness of clinical intervention.3,8-10 A correct molecular diagnosis can guide
the initiation or discontinuation of therapy, medication, or diet. It can also inform the
need for further testing, prognosis, anticipatory care, and whether palliative care
initiation or withdrawal of support is appropriate.3,10 Length of hospital stay may also
be directly or indirectly affected by quicker result reporting. Therefore, in high-cost,
high-intensity care settings such as the NICU and PICU, turnaround time of a
diagnostic test can potentially affect both costs and outcomes.
Quantification of the effect of incorporating ES into a diagnostic pathway is
needed to inform both clinical policy and health care payer policy. A diagnostic
workup for infants with a suspected genetic etiology may include many diagnostic
18

modalities (e.g., imaging, metabolite screening, targeted genetic testing), which we
refer to as usual diagnostic care. There are no clearly delineated diagnostic
pathways for the heterogeneous population of NICU patients. The diagnostic
pathway may include only usual diagnostic care or one of the three ES forms.
Patient outcomes following alternative strategies for diagnosis and the cost per
measure of effect can be calculated and compared to quantify the value of clinical
diagnostic ES.
This project provided a practical approach to outcome measurement and
incorporated those outcome measures into a full economic evaluation of ES for
infants in intensive care settings. It specifically evaluated clinical uptake and
application of ES as a diagnostic tool. As such, it did not include analysis of other
genomic applications, such as pharmacogenetic testing, tumor genotyping, prenatal
genetic testing, or direct-to-consumer genetic tests.

Conceptual Framework
This study can be positioned within conceptual models of technology
translation from laboratory science to clinical application, commonly referred to as
“bench to bedside.” The Office of Public Health Genomics at the Centers for Disease
Control and Prevention was the first to apply a translation research framework to the
field of genetic medicine.11,12 The framework takes a public health perspective and
emphasizes the need for multidisciplinary research in genetics. Beyond basic
science research, there are four stages of translation research associated with
connecting advances in basic science genetics to patient care and ultimately
19

population health. The feedback loop between stages of translational research is
depicted in Figure 1. As characterized by Khoury, Gwinn, Yoon, Dowling, Moore,
Bradley 12 the stages of research are as follows:
T0 – Basic science research
T1 – Development of basic science research into an application, a product
such as a genetic test, for use in the clinical setting
T2 – Assessment of a genomic application in clinical practice and
development of evidence-based practice guidelines for its use
T3 – Analysis of the clinical implementation of a genomic application
according to evidence-based practice guidelines through delivery,
dissemination, and diffusion research
T4 – Evaluation of the population health impact of a genomic application
through outcomes research

20

Figure 1. Translation of genomic research to clinical and public health applications
11

Adapted from: Figure 1 in Khoury MJ, Gwinn M, Bowen SM, Dotson DW. Beyond base pairs to
bedside: a population perspective on how genomics can improve health. American Journal of Public
Health. 2012;102(1):34-37.

The crux of T2 stage research is to determine the impact of a genomic
application on patient health and the associated value. Results of such analyses are
then used to inform development of evidence-based practice guidelines. Thus,
economic evaluations used to determine the value of a test or intervention are
situated in the continuum of translation of genetic research at the T2 stage.
Full economic evaluations of a health care intervention consider both the
costs and health outcomes of two or more strategies.13 Cost-effectiveness analysis
(CEA) is a framework used to compare the cost of alternative courses of action with
21

associated health outcomes, which are measured in natural units. A CEA can inform
decision-makers about the value of a genomic application and provide evidence for
consideration in practice guideline development. There are defined criteria for CEAs
conducted in the realm of health and medicine, and Table 1 displays a checklist of
items that should be considered and reported in a formal CEA.

Table 1. Cost-Effectiveness Analysis Framework – A Checklist of Necessary Components
Well-defined question in answerable form
Comprehensive description of the competing alternatives
Effectiveness of the service established
All important and relevant costs and consequences for each alternative identified
Costs and consequences measured accurately in appropriate physical units
Costs and consequences valued credibly
Costs and consequences adjusted for differential timing
Incremental analysis of costs and consequences of alternatives
Allowance made for uncertainty in the estimates of costs and consequences
Presentation and discussion of study results includes all issues of concern to users
Adapted from Box 3.1, p. 28 of

13

Literature Review
Whole Exome Sequencing in Clinical Practice
Provision of medical care based on a patient’s genetic sequence information
has been an ambitious goal of the scientific and medical community since the idea of
the Human Genome Project was first conceived. The ability to relate basic science
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research in the field of genetics to patient care requires development of genomic
applications that are useful in the clinical setting. Translation of genomic
technologies from the research setting to the clinical setting is a hallmark of the
beginning of a new era of clinical care – the era of genomic medicine – exemplified
by clinical diagnostic ES.1 Ultimately, the intent of genomic medicine is to improve
the health of individual patients by tailoring therapy to their specific genetic makeup.
A combination of advances in genetic basic science and development of
corresponding clinical applications have created the conditions for translation of
genomic sequencing into the patient care setting. The rapid decline of technical
costs of DNA sequencing, development of faster next-generation sequencing (NGS)
technologies, and increased understanding of molecular biology of disease have
made genetic sequencing increasingly relevant to medical practice. Unlike whole
genome sequencing (WGS) which sequences the more than three billion bases in
the entire human genome, only the exome is sequenced in ES. Because ES
involves sequencing fewer chemical bases, it also costs less to perform than WGS.
The cost to sequence an exome is now near $1,000 – the benchmark cost at which
scientists have long held that the sequencing of every patient is justified.14 The
exome is the protein-coding region of the genome, meaning that it contains
information required to make the “material” end products of genetic sequence
information. Although the exome only constitutes less than two percent of the entire
genome, it is where approximately 85% of disease-causing mutations lie and is the
most well-understood portion.4,15 Therefore, the most clinically meaningful sequence
information, with the greatest potential for medical actionability based on findings, is
23

obtained through ES. At reasonably attainable costs and accompanied by a greater
understanding of the genetic basis of disease (due largely to accumulation of
sequence information itself as more patients are sequenced, leading to discovery of
new disease-causing genes), ES is anticipated to have widespread application to
clinical diagnosis in the future.
As a result of the volume of information ES provides, it may be used to
diagnose any number of conditions across multiple disease categories. ES has a
broad scope as a diagnostic tool because it simultaneously analyzes all of the
coding variation in a human genome, even in areas that are not yet well understood
clinically. This makes it particularly powerful in the context of rare diseases, and
results from ES are a major source of information on rare disease-related gene
variation.16 ES can provide insight that would not be possible using more targeted
genetic tests, such as single gene or gene-panel tests that only provide information
on specific coding regions. ES conveys information on pathogenic genetic variants
that may occur anywhere in the exome, including in genes for which single gene
tests do not exist or a clinician may not know to order.17 It is especially useful for
individuals with rare diseases or diseases that are difficult or impossible to diagnose
using other diagnostic modalities such as imaging, biopsies, cerebrospinal fluid
examination, and electromyography or even other types of genetic testing such as
chromosomal microarray and targeted single or gene panel tests.4
ES has demonstrated molecular diagnostic proof-of-concept and clinical utility
to impact the course of patient care in clinical practice.2,7,17-27 Most studies are on
pediatric populations with undiagnosed disease with suspected genetic etiology,
24

particularly patients with neurodevelopmental disabilities or some other neurologic
phenotype. Obtaining sequence information for parent-child trios often results in a
higher diagnostic yield (i.e., larger proportion of patients diagnosed out of all patients
sequenced).2,28 The reported molecular diagnostic yield ranges from approximately
25% to 58%. Results of ES have reportedly influenced changes in drug therapy,
surgery decisions, understanding of inheritance pattern, palliative care initiation, and
understanding of risk for future pregnancies (i.e., risk for potential future siblings of
the proband to also be affected by an inherited disorder).
The potential for ES to impact patient care has received special attention in
the neonatal intensive care unit (NICU) setting, where it may be distinctly valuable
as a diagnostic tool. ES is helpful in diagnosing congenital malformations, especially
for newborns in which the clinical presentation is atypical or the phenotype is not yet
fully developed, which hinders the ability of clinicians to make a clinical
diagnosis.10,29 Although ES may reduce the length and cost of the diagnostic
odyssey in patient populations for which other forms of testing do not yield a
diagnosis, the time required to generate the data and format a clinical report can
limit the utility of non-rapid ES diagnostic test for critically ill patients. Turnaround
time can be crucial in the NICU and PICU, where time to diagnosis and
establishment of a molecular diagnosis can inform critical medical decisions.
In addition to ES, other forms of next-generation sequencing are being
applied in the NICU, including WGS and rapid, expanded panel sequencing.9,30-32
WGS has demonstrated proof-of-concept for diagnosis in the NICU.10,33 Researchbased rapid trio WGS in the level 4 NICU and PICU at Children’s Mercy Hospital
25

provided diagnosis for 20 of 35 (57%) acutely ill infants less than four months of age
with suspected genetic disease. Standard genetic testing failed to identify 18 of the
20 diagnoses. Studies of this patient population suggest that WGS can increase 28
day mortality while decreasing one year mortality, most likely through its impact on
the decision of whether to withdraw life support.10,23 Of the molecular diagnoses,
20% led to a positive clinical impact and 30% led to the initiation of palliative care.23

Methodology and Measurement Challenges in Economic Evaluations of
Clinical Genomic Sequencing
Very little is known about the cost-effectiveness of cGS. The need for robust
evidence from economic evaluations has been widely recognized, and implementing
institutions often identify the need for cost-effectiveness information when describing
their initial applications of clinical ES.17,19,20,22,34 Further study and more robust
evidence are considered requisite by some institutions before cGS is incorporated
into routine clinical care plans.23 Most peer-reviewed literature on applications of ES
is written from a clinical genetics perspective. These studies usually have a small
sample size (typically 40 or fewer) of heterogeneous patients from a single
institution. Molecular diagnostic yield is a commonly reported outcome measure,
which is usually presented as a raw calculation and does not account for the
influence of a multitude of factors by which it may be affected.35 If any change in
clinical management is discussed, it is typically reported in the style of a case report
or case series. Most studies are retrospective and do not include a comparison
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group. However, one recent prospective analysis of diagnostic ES suggests that it is
cost-effective, and potentially even cost-saving as a first-line test.36
Outcomes research and economic evaluations of cGS are sparse because
they face a host of methodological issues. There is no consensus among health
economists as to what the methodological approach should be, and there is a
question as to whether traditional economic evaluation approaches are applicable to
genetic services or whether new methodology must be developed.37,38 In a review of
published discussions of methodological challenges surrounding the economic
evaluation of genomic services, Buchanan, Wordsworth, and Schuh39 summarized
the specific challenges as development of methods to incorporate effectiveness
data, costing of sequencing platforms, and measurement of health outcomes. The
Institute of Medicine’s Roundtable on Translating Genomic-Based Research for
Health identified four categories of challenges that surround the economic evaluation
of genomic medicine: (1) incongruent disciplinary perspectives and language
barriers between economists and geneticists; (2) insufficient outcomes evidence and
lack of standardized thresholds for evidence and willingness to pay; (3) dynamic
nature of genome data and inability of traditional economic assessments to keep
pace; (4) need for development of methods to incorporate personal utility.38
Costing of genomic sequencing procedures presents a unique set of
challenges. The appropriate unit of analysis for costs is the testing service, which
includes the cost of medical geneticists’ effort involved in interpretation of results and
pre- and post-test genetic counseling, plus lab costs such as chemical reagents
required for sequencing, bioinformatics pipeline development, data storage, and
27

quality assurance/quality control practices.40-42 Moreover, the cost of ES and
placement in the diagnostic pathway, which is determined by provider behavior,
impacts the cost per diagnosis. Parameter values change quickly as a result of
relatively rapid changes in basic science in genomics and clinical practice in the field
of genomics.40
Outcome measurement has been identified as a major challenge in
evaluating clinical genetic services and providing evidence of medical benefit to
payers.12,38,43-46 Because genomic testing has created a new paradigm for clinical
diagnosis, it does not conform to the established method of comparing a new test to
the existing gold standard.47 In a systematic literature review of 342 health
technology assessments and economic evaluations of genetic testing technologies,
the majority (62%) of reviewed studies were CEAs, and 75% of the CEAs used
intermediate outcome measures such as the number of cases detected.48 An
intermediate measure is not traditionally regarded as an appropriate endpoint in a
CEA. Ideally, such analyses of alternative interventions compare final health
consequences, measured in natural units such as life-years gained.13 In the case of
genetic testing where information is the immediate outcome, arriving at a final health
outcome measure is methodologically challenging and may not be pragmatic
because it requires systematically measuring not only immediate changes in medical
management but also impacts on health over a long term.49 However, establishment
of a molecular diagnosis may be regarded as an appropriate endpoint because it
can have some value in and of itself, apart from its potential effects on care
rendered. Moreover, for conditions without available treatment, the value of a
28

diagnostic test may be determined by its ability to correctly identify the underlying
cause of disease.50 The objectives of decision-makers and stakeholders for whom
the analysis is performed determine whether a molecular diagnosis is an acceptable
outcome measure.13 The clinical utility for any specific molecular diagnosis is
partially determined by current availability of treatment options, and thus may
change over time as new therapeutics become available.
Measurement of effectiveness and the concept of utility in the realm of genetic
medicine have been widely discussed. Two main perspectives on the concept of
clinical utility have emerged. Narrowly defined, clinical utility is the impact of a test
on medical management of the patient. A more broad definition of clinical utility
encompasses other aspects of genetic tests for the patient and family, and the
relevant factors depend upon which stakeholders’ perspective the analysis is
conducted from.
Under the first view, clinical utility of a test or service is determined strictly by its
impact on health outcomes of the patient via guidance of a change in medical
management. In the context of ES, results from the test may inform clinical decisions
that have direct implications for the patient; multiple scenarios have been
documented in practice.20-22,26,51,52 ES may lead the provider to initiate a change in
management or treatment plan, such as initiation or discontinuation of medications,
therapy or other diagnostic tests. Results may also guide anticipatory or palliative
care. Additionally, knowledge of sequence information may avert a potentially
harmful misdiagnosis. Establishment of a molecular diagnosis enables providers to
make a more accurate prognosis. For patients with certain molecular diagnoses,
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genotype information may make them eligible for clinical trials of a relevant
therapeutic.21,25
Under the second view, clinical utility depends upon the stakeholder’s
perspective from which the analysis is conducted. For example, third-party payers
are interested in test results providing an accurate, timely diagnosis that impacts
clinical management or ends the “diagnostic odyssey” – the prolonged search for the
cause of illness which often involves numerous forms of invasive testing, multiple
specialist visits, and can last for years. Establishment of a molecular diagnosis via
ES may lessen the duration, expense, and invasiveness of the diagnostic
odyssey.20,25,52-54 From a healthcare payer perspective, the ability of ES to shorten
the diagnostic odyssey is key because paying for one test early in the diagnostic
pathway might potentially avoid charges for multiple unsuccessful tests and
consultations later on, and it can also replace multiple specific tests. Thus, a receipt
of a diagnosis is a relevant endpoint.
Genetic sequence information obtained through ES can also have impacts that
extend beyond the patient to other members of the family. ES results can inform
reproductive risk assessment and reproductive options for the proband, but they can
also aid in family planning decisions for the parents of the proband. Results may
also guide disease screening for family members, especially if the genetic
information leads to a change in the presumed inheritance pattern of the condition
that implicates disease risk in a family member.21 Families might value information
for career and residential planning.55 Receipt of a diagnosis may have value in and
of itself, even if the diagnosis does not affect health outcomes directly.46 In addition
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to providing information useful for planning in various aspects of familial life and the
possibility to engage in disease support groups, ending the diagnostic odyssey can
relieve the family of a significant psychological and financial burden that comes with
continued searching for the cause of a child’s illness.56,57
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP)
working group, established by the Office of Public Health Genomics of the Centers
for Disease Control and Prevention, has stated that “hard” clinical outcomes
conventionally used in evaluation of diagnostic tests should be considered alongside
“soft” (i.e., behavioral) outcomes when evaluating genomic technologies.46 This is
based on the notion that genomic sequencing involves many more aspects of the
patient’s life – and the lives of family members – than just their health state.
Capturing such broad effects is not possible with outcome measures commonly
used in economic evaluations, such as quality-adjusted life years (QALYs), which do
not incorporate non-health related outcomes. Thus, most economic evaluations of
genetic testing have been CEAs rather than cost-utility analyses because
appropriate metrics for utility in the genomic arena have not yet been developed.37 In
addition, measurement of psychological effects requires longitudinal assessment,
which is difficult in practice. Such psychological effects may be important, however,
especially when assessing the value of newborn genetic sequencing. The BabySeq
project, a randomized controlled trial of newborn genomic sequencing funded by the
National Institutes of Health, is evaluating psychological impacts on the family as
well as clinical and economic outcomes.58,59
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The Evaluation of Genomic Applications in Practice and Prevention (EGAPP)
Working Group (EWG), an independent panel supported by the CDC’s National
Office of Public Health Genomics, specified the components of evaluation of a
genetic test. Known as the ACCE criteria, the factors for consideration are analytic
validity, clinical validity, clinical utility, and ethical social, and legal implications.60
Analytic validity is defined as the ability of the test to accurately and reliably measure
the genotype of interest in the lab, which includes analytic sensitivity, specificity, and
reliability. Clinical validity is defined as the ability of the test to accurately and reliably
predict the clinically defined disorder or phenotype of interest, which includes clinical
sensitivity and specificity (that incorporate analytic sensitivity and specificity),
positive and negative predictive values considering characteristics of the population
of interest, and the molecular attributes of the genotype. Clinical utility of the test is
defined as its effect on measurable clinical outcomes and usefulness in guiding
decisions about patient care management compared with current management
without genetic testing. When the EWG employs this criteria to assess outcomes of
genetic tests, the outcomes of interest are tailored to each clinical scenario for which
the use of the test is being evaluated.46
The EGAPP definition of clinical utility as an impact on medical management
emphasizes that a critical piece of information required to assess the value of a
genetic test is how it influences the medical decision-making process. The role of
physician behavior in patient health outcomes is also necessary to consider. Once
the results of a diagnostic test are returned, a change in clinical practice (e.g.,
initiation of a treatment change, ordering of other tests, withdrawal of support)
32

precedes a change in patient outcomes (e.g., survival, quality of life, disease
progression, response to therapy). As formulated by Peabody and colleagues,61
physician behavior lies along the causal pathway to patient outcomes.
Due to many of these methodological challenges, there is a lack of robust
economic evaluations of cGS, and the cost-effectiveness of different forms of ES
compared to other diagnostic strategies has not been performed. A systematic
review of health economic evidence on genome sequencing found that the few
studies published through May 2013 are merely cost calculations, and that poor
methodology limits the accuracy of the findings.62 Most studies aim to describe
genetic findings; they do not formally assess costs. Calculations of per-sample costs
are usually incomplete because they do not include the substantial indirect costs
associated with genetic testing such as genetic counseling, clinical geneticist
consultations, bioinformatics pipeline and protocol development, variant validation
tests, and overhead.42
Such gaps in evidence highlight the need for multidisciplinary research in
genomic medicine. From a public health perspective, in order to quantify the full
value of genomic sequencing procedures, assessments must be performed at each
stage of the translation process. A more robust evidence base is necessary to
ensure appropriate applications of genomic medicine that ultimately improve
population health. Currently, T2 stage evaluations of promising applications such as
diagnostics are particularly deficient and needed.11 Absence of an evidence base
hinders the development of practice guidelines and appropriate uptake of genomic
services. As of 2007, it was estimated that three percent or less of research
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published in the area of genomics focuses on evaluation of a genomic application
after it is in use (T2-T4 research), and T2 research in human genetics has been
called “inconsistent and nonsystematic.”63,64 Systematically assessing data from
individual medical centers that have implemented particular genetic applications in
isolation can help develop a foundation for best practices.1 Such assessments can
guide efficient uptake and use of services in other institutions.
Although provider behavior is an essential element of implementation, research
on how ES results inform medical decision making has received even less attention
than costs. In intensive care settings, decisions with especially high stakes may be
made on the basis of ES results (i.e., the decision to withdraw support). Care
decisions involve multiple stakeholders. Clinical judgment of providers plays a
crucial role, but respect for autonomy requires that parents of critically ill infants be
informed of test results and allowed to participate.65 More attention has been
devoted to parental decision support tools to help parents decide whether to have
their child’s exome sequenced than to the parent’s involvement in medical decision
making once results are received.66 Survey data suggest that parents are interested
in the possibility of whole genome sequencing of newborns (integrated with current
newborn screening program).67 However, this might not apply in the context of an
intensive care setting where medical decisions are imminent.

Lack of Robust Economic Evidence
There are several limitations of work to date on evaluations of genomic
sequencing procedures. There is virtually no evidence from large-scale randomized
34

controlled clinical trials. Nearly all studies are retrospective, apart from one recent
prospective parallel study of ES on 40 critically ill infants.26 Even well-designed
retrospective studies to date are based on a small sample size; for example, 35
families met inclusion criteria for the NICU study by Willig and colleagues.23 A
randomized controlled trial of rapid WGS in NICUs is in the design stages, and a
cost-effectiveness analysis is planned to take place alongside the trial.68 However, in
order to harness information from cGS that has already been performed and
because randomized controlled trials will not always be appropriate or pragmatic,
approaches for comparative effectiveness research that utilizes existing records
should be developed.64
Patient heterogeneity within the sample is a substantial analytic hurdle for both
prospective and retrospective study designs. Most studies to date include all patients
(or families) who underwent genetic testing in the analysis, leading to a diverse array
of molecular causes of disease within patients studied. Cost-effectiveness may be
different for different clinical scenarios. The clinical settings or patient groups in
which genomic diagnostics have the highest clinical utility are not yet known.
Determination of these factors has been designated as an important research
focus.64 Knowledge of particular situations in which ES is cost-effective can inform
efficient clinical use and payer policy.
Heterogeneity also exists in provider behavior. While little is known about uptake
of cGS among physicians, there is some evidence of a “silo” approach, which
describes implementation being driven by a particular individual or department within
an institution.1,27 The decision of a physician to order ES may be influenced by
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availability, departmental standards, peers, or individual research interests. Lack of
established practice guidelines on cGS makes choice of comparators difficult
because each provider may order sequencing based on different criteria or at a
different point in the diagnostic pathway, and cost-effectiveness is always dependent
upon the clinical context. Most CEAs of genetic testing use decision analytic
modelling to incorporate available evidence. However, the appropriateness of
parameter values used to perform the analysis has been questioned.48,69
Epidemiologic studies from which parameters are taken is often not properly
considered, and uncertainty in the parameter values is often not properly accounted
for through sensitivity analysis.
Absence of robust economic evidence has created a barrier to clinical ES in
some circumstances. Although costs of next generation sequencing procedures
have substantially decreased, they remain unaffordable for many patients. Out-ofpocket costs are one of the largest practical barriers to translation of ES technology
from bench to bedside. Indeed, insurance coverage has been referred to as the
“fourth hurdle” in technology translation from basic science to clinical use.70 ES
charges can range between $4,500 and $9,000. Even in cases of partial coverage,
the mean out-of-pocket expense for patients involved in one study was $1,082.13
(range $279—$2,500), and some patients who were referred for ES and approved
by clinical review boards decided not to undergo testing after coverage denial.34
Clinical geneticists have expressed concern about insurance coverage and the
lengthy insurance approval process.71 Burdensome administrative requirements or
denial of coverage is a potential barrier to patient access to cGSs.
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Private payers have been reluctant to cover sequencing procedures largely
because they regard the technology as unproven. Insurers require more data on
clinical utility and cost-effectiveness before they will consider genomic sequencing
as anything other than “experimental” or “investigational.” Lack of robust evidence
on clinical utility has been cited as a major barrier to convincing payers to cover the
service.1,61 Little or no evidence exists in the form typically required for coverage of a
new technology or service – namely proof of analytic validity, clinical validity, and
clinical utility, formal health technology assessments, and practice guidelines – for all
of the reasons related to practical and methodological challenges discussed
above.72,73 From a payer perspective, Sabatini and colleagues demonstrated that
whether use of ES was cost-saving or cost-increasing depended upon clinical
features of the patient population, the cost of the test, and where it was incorporated
in the diagnostic pathway.74 Development of practice guidelines is thus an important
component of an evidence-based use and coverage feedback loop.

Public Health Significance
Ability to more quickly and precisely diagnose genetic disorders and provide
appropriate diagnosis-based care can substantially impact public health.
Collectively, rare and genetic-based diseases are associated with substantial
disease burden and societal cost.75,76 Congenital malformations and chromosomal
abnormalities are the leading cause of death for children under one year of age in
the United States.77 Genetic disease diagnoses account disproportionately for
neonatal and pediatric hospital admissions and are consistently associated with
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higher total charges and longer length of inpatient stay.78-80 In 2012, admissions
associated with a suspected genetic disease diagnosis accounted for an estimated
$14–$57 billion, representing 11–46% of total charges for all inpatient admissions of
patients 0 – 20 years of age.76 Based on national estimates, up to 14% of inpatient
pediatric admissions are associated with genetic disease, at a mean cost of up to
$77,000 higher for neonatal admissions and up to $17,000 for pediatric admissions,
compared to patients who did not have a genetic disease diagnosis.76
Tools of precision medicine relate to public health through application of
diagnostics such as clinical genomic sequencing (cGS) to subpopulations who stand
to benefit the most from them, such as critically ill newborns and infants.81 Use of
genomic technology and data-driven approaches to provide care for a defined group
of patients has been conceptualized as a “precision public health” approach.82 cGS
can potentially lead to more efficient diagnosis and effective treatment, with the
anticipated impact of reduced diagnostic odyssey extent, improved outcomes, and
associated cost-savings for the health care system.
This project contributes to the field by synthesizing the evidence to date on
diagnostic cGS application for pediatric populations and associated outcomes and
costs. Further, this study provided a practical example of methods for defining and
matching cohorts of patients to perform comparative analysis. It resulted in creation
of a unique dataset on patients receiving care at a large children’s hospital over a
period of more than 5 years that merged information from multiple sources, including
extensive electronic medical record review. This study quantified the relative
effectiveness and cost-effectiveness of exome sequencing (ES) as a diagnostic
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compared to standard diagnostic care for infants in intensive care. It provided insight
into the relative performance of various genetic diagnostic tools in a broadly defined
patient population with suspected genetic disease. Results can inform clinical policy
and help guide evidence-based precision medicine in neonatology and pediatrics. In
turn, findings may impact patient access to cGS via health care payer medical policy
development, institutional uptake, and public research investment in translational
genomics.

METHODS
The goal of this research was to generate evidence regarding the use of ES
as a clinical diagnostic tool. It examined and synthesized published academic
literature to provide a scoping overview of available evidence on clinical use of ES. It
also provided a practical example of electronic medical record review for outcomes
research on a genomic application. Outcomes were described and compared based
on use of ES in the diagnostic pathway, clinical setting, and relevant patient
characteristics. Cost-effectiveness of diagnostic strategies – no ES versus ES
testing (proband-only, trio, and critical trio) – for infants in an intensive care setting
was estimated by comparing costs of diagnostic pathways and relevant outcome
measures.
Data came from Texas Children’s Hospital (TCH) electronic medical records
(EMR) and administrative databases and Baylor Miraca Genetics Laboratories (BG)
ES result reports. All ES orders from TCH were performed at BG. Each research aim
was designed to contribute information regarding the health impact and value of
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genomic sequencing as a clinical diagnostic tool for infants in an intensive care
setting. This Methods section provides details on the methods used to achieve each
aim.

Study Design
Aim 1
A scoping review of published peer-reviewed literature was performed.
Scoping reviews are intended to provide an overview of the nature of literature on a
topic via structured searches and identify gaps in knowledge. Fewer restrictions for
inclusion are placed on patient population, intervention, outcome, and study design
than in systematic reviews. The review was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines,83
adapted for use in a scoping review as appropriate. CGS is defined to include WGS
and ES. Sequencing may have been performed for the proband (i.e., patient) only or
alongside parents or other family members (duo or trio), in a non-rapid or a rapid
manner with reduced turnaround time. Sequencing was considered clinical rather
than research for the purpose of this review if the report’s stated goal was to make a
diagnosis or otherwise impact medical management of the patient(s). In contrast, if
the objective was gene discovery or disease mechanism elucidation, the sequencing
was considered research.
A search strategy was designed with the assistance of a librarian from the
Texas Medical Center library. PubMed, Embase, and Cochrane Library were
searched. The PubMed search included the following Medical Subject Headings
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(MeSH) terms: Genome; Exome; Sequence Analysis, DNA; Adolescent; Child;
Infant; Diagnostic Techniques and Procedures; Clinical Decision-Making; Diagnosis,
Differential. Items identified through database searches were imported into the web
application Rayyan (Doha, Qatar) for title and abstract screening.84 Title and abstract
of each record were screened by two independent reviewers, and conflicts were
resolved through consensus. Citations selected for full-text review were imported
into EndNote (Clarivate Analytics, Boston, Massachusetts), and full-text articles were
obtained. A full-text review form was completed for each article to determine whether
inclusion/exclusion criteria were met. One author reviewed each full-text article, and
a second reviewer reviewed a randomly selected 10% of the full-text articles.
Articles that met the following pre-determined criteria were included: (1) peerreviewed original research article; (2) published between January 2009 and June
2017 (with an updated search performed in November 2017); (3) proband (if a case
report) or the majority of probands (if more than 5 probands in study) less than 19
years of age at the time of sequencing; (4) described/evaluated the clinical
application of a CGS for diagnostic purposes. Studies of patients who had a clinical
diagnosis of a condition with known genetic heterogeneity, and thereby not
determined to have a “specific” diagnosis, were included. Studies of patients
enrolled in a research protocol performing CGS for a clinical purpose were included
regardless of how costs of sequencing were covered, as the aim of sequencing was
considered more important than the funding arrangement. No restrictions were
placed on study design; clinical reports (individual cases and case series),
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intervention studies (any methodology), and economic evaluations (any
methodology) were included.
Publications with a primary aim of genetic research were excluded as were
publications on population-based screening, tumor genotyping, mitochondrial
genome sequencing only (without the nuclear genome), pharmacogenetic testing,
disease carrier testing, prenatal genetic testing, and targeted exome sequencing
(e.g., “clinical exome” or “Mendeliome”) panels of thousands genes known to be
associated with single-gene disorders. While targeted exomes may be considered
more similar to a whole exome than targeted panel, multiple permutations of such
tests exist. Because there is inconsistency in covered genes, publications on
targeted tests were excluded for comparability of results and feasibility of this review.
Reports on patients who were sequenced post-mortem and those that indicated the
initiation of sequencing but not results were also excluded.

Aims 2 and 3
This was a retrospective cohort study in which ES was the exposure factor.
Two patient cohorts were defined; patients who had ES as part of a diagnostic
workup (ES cohort) were matched based on clinical characteristics and phenotypic
presentation to patients who did not (No-ES cohort).
Data on admission characteristics, demographics, phenotypic presentation,
clinical outcomes, ES order and result return, and ES uptake by attending clinician
was collected through retrospective EMR review. Establishment of a molecular
diagnosis and survival were the primary outcomes of interest. A retrospective
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approach was optimal in order to utilize information on the large number of patients
who had already had ES, ensure follow-up time of at least one year over which to
measure outcomes, and enable comparison of multiple outcomes.

Study Setting
Aim 1
This study was performed in the Department of Molecular and Human
Genetics at Baylor College of Medicine.

Aims 2 and 3
This study was performed in the Department of Molecular and Human
Genetics at Baylor College of Medicine. Clinical care was provided at Texas
Children’s Hospital (TCH) and genomic sequencing was performed at Baylor Miraca
Genetics Laboratories (BG), both located in Houston, TX. TCH is a not-for-profit
health care organization with large acute critical care capacity. Each year, more than
6,000 children are admitted to TCH ICUs, which have 116 intensive care beds. The
TCH NICU is certified level IV, the highest level of care available for premature and
critically ill newborns. BG is one of the foremost genetic testing laboratories in the
US and was the first to describe ES’s application to clinical diagnosis.2,19 It is
accredited by the College of American Pathologists (CAP) certified under the US
Centers for Disease Control and Prevention Clinical Laboratory Improvement
Amendments of 1988 (CLIA) to return clinical-grade results. BG offers proband-only,
trio ES, and critical trio ES, all of which must be ordered by a clinical care provider.
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Each ES report is reviewed by a laboratory director and signed out by a molecular
geneticist.

Study Subjects
Aim 1
Not Applicable.

Aims 2 and 3
The target population for this study is undiagnosed newborns infants in
intensive care with suspected genetic etiology. Patients who had a consultation from
the Genetics service during an intensive care unit inpatient stay at TCH within the
first year of life were included. The study timeframe was December 1, 2011 (when
the first ES order was placed for an infant at TCH, very soon after BG offered it as a
clinical test) through June 30, 2017. A Genetics consultation documented in the
medical record indicated a suspected genetic etiology in the patient. Figure 2
illustrates the flow of patient selection.

Included patients met the following criteria:
•

TCH intensive care inpatient admission within the first year of life

•

Inpatient genetics consultation documented in the medical record

•

Inpatient stay and genetics consultation occurred between December 1, 2011
and June 30, 2017
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ES-cohort patients met the following additional criteria:
•

Received ES (proband-only, trio, or critical trio) as part of the diagnostic
pathway

•

ES ordered within the first year of life

Among all included patients who met the above criteria, patients eligible for
inclusion in the No-ES cohort were defined as patients who did not receive ES in the
diagnostic pathway. They may have received other forms of genetic testing such as
single gene or gene panel tests (e.g., cardiomyopathy panel, BluePrint panel, CHD7
sequencing, Noonan panel, SMA panel), chromosomal microarray, and methylation
studies. A clinician may have ordered ES for patients in the No-ES cohort without it
being performed for reasons such as lack of parental consent or cancelation by lab
due to insufficient blood sample.
Two datasets were combined to define the patient population. The first
dataset, obtained from the hospital, contained medical record numbers of all patients
at TCH who (1) had an intensive care unit inpatient admission within the first year of
life, and (2) had an order for inpatient consultation from the Genetics service. The
second dataset, obtained from the diagnostic laboratory, contained ES report data
for all patients who had ES (1) ordered from TCH, and (2) an ES order date less
than 366 days from date of birth. All ES ordered at TCH is sent to BG. Datasets
were merged on medical record number. Patients appearing in both datasets were
preliminarily designated as the ES cohort; patients appearing only in the hospital
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data were preliminarily designated as the No-ES cohort, subject to verification of
inclusion criteria via EMR review.

Figure 2. Study flow diagram
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EMR review was then performed for all patients. We defined the index
admission as the admission during which the initial Genetics consult was ordered.
Patients for whom a consult order was placed but later canceled were not included.
A consult order and a note from a member of the Genetics service (even if not
electronically filed as a “consult”) indicated consultation.
Patients in the ES cohort had one of 3 forms of ES: sequence analysis of only
the patient (proband), a trio of patient and both parents (trio), or trio of patient and
parents with expedited turnaround time (critical trio). Clinical ES became available in
October 2011 in proband form. The trio test was introduced in October 2014 and
critical trio in April 2015.
To determine comparable cohorts of patients who did and did not have ES, we
calculated a propensity score for each patient. This method allows adjustment for
confounding when assessing multiple outcomes.85,86 The propensity score was used
to represent multiple HPO terms and other relevant factors as a one-dimensional
score.87 We generated a binary variable for each HPO identification (ID) number
appearing in the data. HPO ID numbers were used instead of terms themselves to
ensure synonymous terms did not appear as separate variables. Granularity was
preserved; we did not use hierarchical processing to map to higher order terms
(although in many cases, multiple levels of terms were generated). HPO term
variables with count fewer than 10, meaning that the term was observed in fewer
than 10 patients, were dropped, leaving 340 term variables. Based on clinician
consensus, another 33 term variables were dropped because they related to
transient clinical characteristics, such as fever or emesis, not relevant for making a
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diagnosis. HPO terms were selected for inclusion in the propensity score model
using a backward automated variable selection process (p-value for removal = 0.1).
We calculated a propensity score, which is the estimated probability of having ES
conditional on measured covariates, for each patient using a binary logistic
regression model with ES as the dependent variable that included indicator variables
for: gender, the unit in which the initial Genetics consult was performed, initial
Genetics consult date (quartile of study period), age (days) at first genetics consult
(quarter of year), and HPO terms. After predicting propensity score for each patient,
each ES patient was matched to one most phenotypically similar No-ES patient from
among all potential No-ES patients using a greedy matching algorithm based on the
linear predictor of the propensity score. Compared to differences between ES
patients and the entire group of No-ES patients prior to matching, the matching
procedure successfully reduced differences in covariates between ES and No-ES
patients in the final cohorts.

Study Power
Aim 1
Not Applicable.
Aims 2 and 3
The sample size in this study was fixed and unknown prior to completion of
the data collection process. The statistical power to detect a difference in outcomes
between study arms was calculated prior to performing any data collection. The
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most relevant information to calculate power was from a study of infants admitted to
an ICU at TCH in the first 100 days of life who had ES.3 The 120-day mortality for
patients in the sample was 81/272 (29.8%). The study does not provide any
information on patients who did not have ES.
The ability to detect a difference in effect between a diagnostic pathway that
includes ES and a diagnostic pathway that does not include any form of ES is of
interest. Because this study will utilize matched pairs and 120-day mortality is a
dichotomous outcome, the power calculation is performed for a two-sample pairedproportions test (McNemar’s). Assuming a 120-day mortality of 29.8%, sample size
of 400 pairs, and sum of discordant proportions of 0.50, the power would be 77.7%
to detect a 9.6% difference in 120-day mortality using a two-sided test and alpha of
0.05. In the smallest expected study arm (trio ES), assuming a sample size of 50
patients and all of the above conditions, the power would be 15.8%.
The detectable effects size as an odds ratio at a desired power level of 0.80
can also be calculated. With 400 matched sets of cases and controls and one
matched control per case, assuming a 120-day mortality of 0.298 and a correlation
coefficient for mortality between matched cases and controls of 0.50, and alpha of
0.05, a true odds ratios for impact of ES in patients who died relative to patients who
did not die of 0.576 or 1.615 would be detectable with a power of 0.80. Similarly,
with 50 matched sets, true odds ratios for impact of trio ES of .139 or 3.519 would be
detectable with power of 0.80.
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Data Collection
Aim 1
Key pieces of information were collected from each included article. A data
extraction form was developed and pilot tested, and then two refined versions were
created based on the two types of analyses and reporting encountered. For the
purpose of collecting and presenting results in this review, studies of five or fewer
patients were considered “case reports” and studies of more than five patients were
considered “aggregate analyses.” The cutoff number of five was determined based
on differences in article structure and information presentation according to the
number of patients included. Thus, the data collection form used for each type of
study reflected the way in which facts were reported.
Data items selected for abstraction from articles were broadly based on
parameters recommended for assessment in evaluation of genetic tests.88 The data
collection form for aggregate analyses included the following items: study objective,
country, type of CGS, comparator, clinical setting, study design, outcome measures,
study population, inclusion criteria, exclusion criteria, average age at test, percent of
probands younger than 19 years of age, percent of probands who were male,
diagnostic laboratory, sequencing platform, whether a duo and/or trio approach was
used, turnaround time, molecular diagnostic yield, number of probands with a
change in medical management, discussion of insurance coverage, discussion of
costs or cost-effectiveness, and average cost to diagnosis or cost of potentially
replaced tests. For case reports, the above information was collected on the
individual level as well as the gene implicated and diagnosis. For economic studies,
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the perspective of the analysis, cost data source, and incremental cost per outcome
measure were recorded. Data from all included studies was abstracted into a
spreadsheet. Analysis was performed with Stata IC 13 (College Station, Texas).
Variables to be measured are presented in Table 2.
Table 2. Measurement Matrix for Aim 1
Variable

Definition

Coding Scheme

Publication Year

Year article was published

Numeric

First Author

Name of first author of article

Text

Title

Title of Article

Text
1 = First author is a
geneticist

Indicator of whether the first author was a

0 = Otherwise

First Author Geneticist

geneticist

888 = Cannot determine

Study Objective

Stated objective of article

Text

Country of Origin

Country of the clinical setting

Text

Name of hospital or clinic (or description if
Study Location

name not given)

Text

Beginning and end date of study data
Study Dates

collection period

Text
1 = Single Center

Center

Single versus multicenter study

2 = Multi-center

Type of NGS

ES, WGS

Text

Comparator

What NGS diagnostic tool is compared to

Text

Clinical Setting

NICU, PICU, clinic, lab, etc.

Text

Study Design

Description of study design

Text
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Table 2. Measurement Matrix for Aim 1
Variable

Definition

Coding Scheme

(explicitly as goal of

Whether outcome measures are listed in the

1 = Yes

study)*

text of the article

0 = No

Outcome Measures

Whether an operational definition of outcome

1 = Yes

Defined*

measures is provided in the text

0 = No

Outcome Measures

Outcome measures reported

Text

Study Population

Description of study population

Text

Inclusion Criteria

Description of inclusion criteria

Text

Exclusion Criteria

Description of exclusion criteria

Text

Sample Size

Total sample size of individuals sequenced

Numeric

Number of Patients*

Total number of patients included

Numeric

Number of Families*

Total number of families included

Numeric

Average age at test date (record in units

Text (include unit in

given)

parentheses)

Outcome Measures Listed

Age at Test

Numeric

% of Patients < 18 y.o.*

Percent of patients less than 18 years of age

888 = Cannot determine

at test date

999 = Not Given
Numeric
888 = Cannot determine

Sex (% Male)

Lab

Multi-lab*

Percent of patients sampled who were male

999 = Not Given

Name of laboratory that performed NGS

Text (e.g., BG, Ambry,

(may be more than one)

GeneDX)

Whether samples were sent to more than

1 = More than one lab used

one lab

0 = All samples sent to
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Table 2. Measurement Matrix for Aim 1
Variable

Definition

Coding Scheme
single lab
Text (e.g., Illumina HiSeq

Platform

Sequencing platform used by the lab

2500)
1 = Clinical team consensus
review of results described
0 = No clinical team
consensus review of results
described

Consensus review*

Whether a clinical consensus review process

2 = review by ordering

for discussing laboratory results is described

geneticist
1 = ACMG categories used
0 = ACMG categories not

Use ACMG Variant

Whether ACMG variant pathogenicity

used

Pathogenicity Category

categories are used to categorize findings

999 = Not Given
1 = Trio approach used in at
least some cases

Trio Approach

Whether a trio approach was used to also

0 = Trio approach never

sequence parents or siblings

used
1 = Trio approach

Trio Preferred*

Whether trio approach was

preferred/recommended

preferred/recommended, as indicated by the

0 = Trio approach not

authors

preferred/recommended
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Table 2. Measurement Matrix for Aim 1
Variable

Definition

Coding Scheme
1 = Confirmation by Sanger
sequencing
0 = No confirmation by

Confirmation by Sanger

Whether confirmation of variants by Sanger

Sanger sequencing

Sequencing*

sequencing was performed

999 = Not Given

Average turnaround time of test (record in
Turnaround time

units given)

Numeric
1 = Reported

Whether "incidental" or "secondary" findings

0 = Not reported

Report Incidental Findings

unrelated to clinical phenotype are reported

999 = Not Given

Percent of Patients with

Percent of patients who had incidental

Incidental Findings

findings returned

Numeric
Numeric
888 = Cannot determine

Molecular diagnostic yield*

Overall molecular diagnostic yield (%)

999 = Not Given
0 = Non-diagnostic
1 = Diagnostic
2 = Prompted candidate
gene association studies
3 = Most likely candidate for

Diagnostic‡

Diagnostic outcome of sequencing

clinical presentation

Phenotypic subgroups

Whether analysis is broken down into clinical

1 = Yes

reported*

phenotype subgroups

0 = No

Phenotype‡

Description of patient's phenotype

Text
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Table 2. Measurement Matrix for Aim 1
Variable

Definition

Coding Scheme

Percent of patients classified as a neurologic

Numeric

phenotype

999 = Not Given

Congenital structural

Percent of patients with a congenital

Numeric

anomaly (%)*

structural anomaly

999 = Not Given

Neurologic phenotype (%)*
Neurologic phenotype
diagnostic yield (%)*

Congenital structural
anomaly diagnostic yield
(%)*
Percent of patients with a reported change in
Change in Medical

medical management following return of

Numeric

management*

sequencing results

999 = Not Given

Change in Medical

Change in medical management for the

management description‡

proband described in the case

Text

Ways in which authors report that medical
Description of change in

management was changed following return

medical management*

of sequencing results

Other health outcome

Health outcome metric other than those

measure*

collected in this form

Text

Discussion of medical

Authors discuss that sequencing results may

1 = Yes

management change

impact medical management of the patient

0 = No

Authors discuss economic notions related to

1 = Yes

Discussion of economics

sequencing

0 = No

Discussion of economic

Authors discuss challenges related to health

1 = Yes
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Text

Table 2. Measurement Matrix for Aim 1
Variable

Definition

Coding Scheme

evaluation methodology

economic evaluation of genetic sequencing

0 = No

challenges*
Numeric
Average cost to diagnosis

Average cost to diagnosis via sequencing

. = Not Given

Collective cost of potentially avoided
Cost of potentially

diagnostic testing if sequencing used as a

Numeric

replaced tests

frist-line test

. = Not Given

Discussion of insurance

Authors discuss insurance coverage of

1 = Yes

coverage

clinical genomic sequencing

0 = No

Study strengths from study design
Strength

perspective

Text

Study limitations from study design
Limitations

perspective

Text

*Aggregate analyses only
‡ Case Reports only

Aims 2 and 3
ES uptake and health outcomes were systematically assessed through
retrospective EMR review. A data collection form was designed to collect key pieces
of information from the TCH Epic EMR system. Each patient’s EMR was individually
reviewed, and data were extracted and compiled in a spreadsheet with a single row
of data for each patient that combined EMR and BG data. EMR review was
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completed in August 2018 such that there is at least one year of clinical follow-up
data on all patients.
Variables relevant for matching were collected for all patients who met the
inclusion criteria (cases and potential controls). To address heterogeneity of the
patient population, subgroup analyses were performed. Clinically relevant features
were used to define the strata. Patients were divided into subgroups intended to
generate evidence to inform clinical decision-making and guideline development. We
performed subgroup analyses for patients admitted in 2016 and 2017 after all three
ES forms were available, patients who survived to 28 days of life, patients in the
NICU during the genetics consultation, and patients in the ES-recommended group.
Medical records were filtered for diagnostic-related activities performed during
the patient’s ICU stay and over the year following the initial Genetics consultation
and clinical notes originating from a member of the genetics service (inpatient) or
genetics clinic (outpatient), including notes signed by geneticists, genetics trainees,
and genetic counselors.
Cost data was obtained from the hospital administrative cost reports. Patientlevel costs were reported for the index admission and over the year following the
initial genetics consult order date. As there is no standard diagnostic pathway for this
population of patients, we defined the diagnostic pathway as clinical tests performed
for the purpose of making a diagnosis, rather than routine care or monitoring. An
inclusion rule of “first,” “none,” or “all” was determined for each test on a list of all
laboratory and radiology tests performed in our study sample. The rule was used to
determine which, if any, instance of a specific test in a patient was counted as part of
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the diagnostic pathway and applied to the cost data to sum the cost of diagnostic
pathway investigations. Similarly, to determine the cost of genetic tests, we identified
each genetic test in the list of laboratory tests. In each patient’s cost data, each lineitem for “miscellaneous referred test” was cross-referenced by service date to
miscellaneous referred tests ordered in the EMR to determine whether it was a
genetic test or not. All tests determined to be genetic tests were included in both the
diagnostic pathway and genetic test cost categories. Genetic test and diagnostic
pathway costs are not necessarily inclusive or exclusive of billing categories.
Variables to be measured for Aim 2 and Aim 3 are presented in Table 3 and
Table 4, respectively.

Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

0 = Patient did not

BG; TCH

have ES

Administrative

1 = Patient had ES

Records

Patient Characteristics

ES

Indicates whether patient had ES

TCH
Administrative
Last name

Patient last name

Text

Records
TCH
Administrative

Date of Birth

Patient date of birth

Date
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Records

Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source
TCH
Administrative

MRN

Medical record number

Numeric

Records

Date first order for genetics consult during

TCH

First IP Genetics

ICU stay was placed in TCH EMR from

Administrative

consult order date

TCH records

Date

Records

Ethnicity of patient as listed in
Demographics tab in TCH EMR (or from
H&P or genetics note if not listed in

Ethnicity

Demographics. If genetics note in conflict

Hispanic

with demographics tab facesheet,

Non-Hispanic

deferred to genetics note)

unknown

TCH EMR

American Indian
and Alaska Native
Asian
Black/AfricanAmerican
Native Hawaiian
or Other Pacific
Race of patient as listed in Demographics

Islander

tab in TCH EMR (or from H&P note if not

White/Caucasian

Race

listed in Demographics)

unknown

TCH EMR

Sex

Patient sex as listed in TCH EMR

M = male

TCH EMR
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Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

F = female
U = ambiguous
("none")
Indicator of whether a patient is alive as
determined in TCH EMR through review
of notes. Note that even if a patient is not
marked as deceased in the TCH EMR
system, documentation of communication

Alive

of patient death was used to determine

0 = Deceased

status.

1 = Alive

TCH EMR

Primary language of family as listed in
TCH EMR or as indicated in clinical notes
was spoken with the family (or spoken
through translator). If at least one member

Primary Language

of the family could communicate with

English

medical staff in English, and no translator

Spanish

used, recorded as English.

Other

TCH EMR

Numeric

TCH EMR

Date

TCH EMR

Patient zip code, identified from Detailed
Report for admission from index
Zip code

admission
Date of last follow up or death as

Date of last follow-

determined from encounter list in TCH

up or death

EMR
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Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

Date

TCH EMR

Date

TCH EMR

Numeric

TCH EMR

Date

TCH EMR

Date of death as determined in TCH EMR
Date of Death

from death summary note or other note
Date of index ICU admission (defined as
admission during which initial inpatient
genetics consult order was placed),
identified from Detailed Report for

Date ICU admit

admission
Length of inpatient stay in days for index
ICU admission (defined as admission
during which initial inpatient genetics

Length of inpatient

consult order was placed), identified from

stay

Detailed Report for admission
Date of discharge for index ICU
admission (defined as admission during
which initial inpatient genetics consult

Date ICU

order was placed), identified from

discharge

Detailed Report for admission

Expired
Place where patient was discharged to

Home Health Care

following index ICU admission, identified

Home/Self Care

from Detailed Report for admission as

Hospice

Discharge to

"Disposition"

Other facility

TCH EMR

Admit Service

Service listed under admission

Text

TCH EMR
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Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

Text

TCH EMR

Text

TCH EMR

Text

TCH EMR

Text

TCH EMR

Text

TCH EMR

Text

TCH EMR

Text

TCH EMR

information, identified from Detailed
Report for admission
Principal clinical problem for admission,
identified from Detailed Report problem
Principal problem

list as item with blue square

Principal

ICD-10-CM code for principal problem for

problem_ICD-10-

admission, identified from Detailed Report

CM

problem list as item with blue square
Dx code for Reason for Visit (coded),

Reason for

identified from Detailed Report for

visit_DXcode1

admission
Diagnosis for Reason for Visit (coded),

Reason for

identified from Detailed Report for

visit_DX1

admission

Reason for
Admission -

Primary reason for admission identified

Primary

from Detailed Report for admission
ICD-9 (or ICD-10) code corresponding to

Reason for

the primary reason for admission

admission -

identified from Detailed Report for

Primary_code

admission

Clinical setting

Unit listed in Detailed Report for

(unit)

admission
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Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

Text

TCH EMR

Text

TCH EMR

Insurance
Payer_Epic

Insurance carrier in TCH EMR (at time of

(priority 1)

admission) - priority 1

Insurance
Payer_Epic

Insurance carrier in TCH EMR (at time of

(priority 2)

admission) - priority 2

Clinic or Physician
Referral
Newborn at TCH
Place where patient was admitted from for

Self Referral/Non-

index ICU admission, identified from

Health Care

Detailed Report for admission as "Point of

Facility

Origin"

Transfer Center

TCH EMR

Numeric

TCH EMR

Numeric

TCH EMR

note

Text

TCH EMR

Primary caregiver's marital status,

Living with partner

Primary Caregiver

identified from Social Work, H&P, or other

Engaged

marital status

notes

Married

Point of Origin

Gestational age at birth, identified from
Gestational age

H&P, Genetics, or discharge note

Age of mother

Age of mother at patient's birth, identified

(years)

from H&P or Genetics note
G&P status of mother prior to delivery of
patinet, identified from H&P or Genetics

Mother Parity
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TCH EMR

Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

Separated
Single
Unknown
Age of father

Age of father at patient's birth, identified

(years)

from H&P or Genetics note

Unit_Genetics

Unit listed on initial inpatient Genetics

consult note

consult note

Numeric

TCH EMR

Text

TCH EMR

Text

TCH EMR

Text

TCH EMR

Genetics Consult
Note Chief

Chief complaint listed on initial Genetics

Complaint

Consult Note

Initial Genetics
Consult Note

Author of initial Genetics Consult Note

Author

(Fellow or Resident)

Initial Genetics
Consult Note

Cosigner of initial Genetics Consult Note

Cosigner

(Attending)

Text

TCH EMR

Genetics Consult

Date of initial inpatient Genetics Consult

Date

TCH EMR

ES Genetics

Author of Genetics Consult Note

Consult/Physician

describing ES order (inpatient only)

Note Author

(Fellow or Resident)

Text

TCH EMR

ES Genetics

Cosigner of Genetics Consult Note

Consult/Physician

describing ES order (inpatient only)

Text

TCH EMR

Date of initial
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Table 3. Measurement Matrix for Aim 2
Measured

Variable

Variable

Variable Description

Note Cosigner

(Attending)

Date of ES

Date of Genetics Consult that describes

Genetics Consult

ES order (inpatient only)

Coding/Type

Data Source

Date

TCH EMR

0 = No (ES
ES ordered during

Whether ES was ordered during a

ordered during

different admission

different inpatient admission than the

index admission or

than initial

index admission (inpatient only;

outpatient)

Genetics consult

outpatient = 0)

1 = Yes

TCH EMR

Principal Problem

Principal problem for admission during

for admission

which ES was ordered if ordered during a

during ES ordered

different admission than the index

if different

admission

Text

TCH EMR

Date

TCH EMR

Date

TCH EMR

Date of Admit for
ES admission (if

Date of admission for inpatient stay during

different from

which ES was ordered if different than

index)

index admission

Date of Discharge
for ES admission

Discharge date for inpatient stay during

(if different from

which ES was ordered if different than

index)

index admission

1500 = Proband
1600 = Trio
ES Test Code

ES test code

1722 = Critical
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BG

Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

Trio

Date ES

Date ES was ordered in TCH EMR, as

Ordered_Epic

listed on the order

Date ES

Date ES was resulted in TCH EMR, as

Resulted_Epic

listed on the order

Date

TCH EMR

Date

TCH EMR

Date
"not listed" = no
Date ES Results

Date ES results were viewed in TCH EMR

reviewer

Reviewed_Epic

the first time, as listed on the order

name/date

TCH EMR

Date ES Results

Date ES results were viewed in TCH EMR

Reviewed 2_Epic

the second time, as listed on the order

Date

TCH EMR

ES result

Whether there was an addendum,

addendum/Expand

expanded report, or reanalysis document

0 = No

ed report

scanned into the ES order in TCH EMR

1 = Yes
0 = Returned
during inpatient
admission during
which first

Whether ES results were pending at ICU

Genetics consult

discharge for admission during which

occurred

initial Genetics consult was ordered. Note:

1 = ES result not

ES result pending

always = 1 if ES was ordered after index

returned during

at discharge

admission.

admission during
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TCH EMR

Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

which first
Genetics consult
was ordered
ES Order Clinical
Setting

Inpatient
Clinical setting in which ES was ordered

Outpatient

TCH EMR

Text

TCH EMR

Date

TCH EMR

Text

TCH EMR

Text

TCH EMR

ES ordering
physician if

Name of physician who ordered ES if

outpatient

ordered outpatient
Date that physician recommended ES if

Date ES

ordered outpatient. Note: sometimes a lag

recommended if

before order placed because of insurance

outpatient

authorization process

Result Return

Name of Genetics Service provider who

Geneticist

returned ES results to family

Result Return

Name of Genetics Service provider who

Geneticist_Attendi

returned ES results to family - attending

ng

geneticist

Result Return

Name of Genetics Service provider who

Geneticist_Fellow/

returned ES results to family - genetics

Resident

fellow or resident

Text

Name of Genetics Service provider who
Result Return

returned ES results to family - specialty

Other Provider

other than Genetics

Text
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TCH EMR

Table 3. Measurement Matrix for Aim 2
Measured

Variable

Variable

Variable Description

Result Return

Name of Genetic Counselor who returned

Counselor

ES results to family

Coding/Type

Data Source

Text

TCH EMR

Telephone
Inpatient
Genetics Clinic
Visit
Neurology Clinic
Visit
Metabolic Clinic
ES Result Return
mode

Visit
Mode of delivery of ES results to family

Other

TCH EMR

Date

TCH EMR

Text

TCH EMR

Text

TCH EMR

Date

TCH EMR

Text

TCH EMR

ES Result
communication

Date of first communication of ES results

(first contact)

with patient's family
Notes about how return of results was

ROR Notes

performed

Genetic

Notes from genetic counseling result

Counseling Notes

disclosure

Follow Up in
Genetics

Date patient had in-person follow-up visit

Clinic_date

in the Genetics outpatient clinic

Follow Up in

Clinician who saw patient in Genetics

Genetics

outpatient clinic at follow-up
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Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

Clinic_MD
For control patients only; whether the
Control_ES noted

Genetics consult note had clinician

recommended or

documentation in the plan that they would

1 = Yes

reflex

consider ES in the future or reflex to it

. = No/not noted

TCH EMR

For control patients only; whether the
Parents decline

Genetics consult note had clinician

ANY genetic

documentation that the patient's parents

1 = Yes

testing

declined having any genetic testing

. = No/not noted

TCH EMR

MedicalRefNo_BG

MRN from BG records

Numeric

BG

1500 = Proband
1600 = Trio
1722 = Critical
TestCode_BG

Test code from BG records

Trio

BG

MedicalPresentati

Medical presentation as described by the

on_BG

clinician and given to the lab

Text

BG

SampleDate_BG

ES sample date from BG records

Date

BG

ES order date from BG records

Date

BG

TestOrderDate_B
G

TCH EMR
(retrieved from
Focused Report
Date

scans of BG
Date focused report was faxed from BG
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Date

reports in TCH

Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source
EMR)

ES result fax date from BG records. Date
last report (expanded, addendum,
reanalysis, etc.) was faxed. If no
Last_FaxedDate_

reanalysis, same as date of focused

BG

report.

Numeric

BG

TestTurnAround
(days, FaxedDate
- OrderDate)_BG

ES turnaround time (days)

BG

ClinicalSummary_
BG

Clinical summary from BG

Text

BG

Interpretation_BG

Interpretation of ES results from BG

Text

BG

Clinician

Interpretation of Geneticist who followed

Interpretation of

up with patient after ES results available

Remarkable

Results

from clinic notes

Unremarkable

TCH EMR

Text

TCH EMR

Curated list of HPO terms generated for
the patients via natural language
HPO

processor from genetics consultation,

terms_curated

admission, and discharge notes
Outcome Measures

Molecular
diagnostic result

Molecular diagnosis

Text

TCH EMR

Molecular

Description of molecular diagnosis

Text

TCH EMR
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Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

Text

TCH EMR

diagnosis
description
Molecular

Diagnostic test used to determine

diagnostic tool

molecular diagnosis

Parent Availability

Description of family members who

note

submitted samples to the lab for testing

BG

Clinical diagnosis (may or may not be
Clinical Diagnosis

CMA Completed

molecularly confirmed)

Text

Indicator of whether patient had

0 = No CMA

chromosomal microarray (CMA), either at

performed

TCH or outside hospital (as documented

1 = CMA

in clinical note)

performed

TCH EMR

TCH EMR

Normal
Gain
Loss
AOH (absence of
CMA Result

Result of CMA

heterozygosity)

TCH EMR

Text

TCH EMR

List of other genetic tests performed, as
Other genetic tests

collected from Results Review tab in EMR

0 = No change in
counseling
Change in

Whether there was a change in

1 = Change in

counseling

counseling following ES results

counseling
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TCH EMR

Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

Notes about change in counseling

Text

TCH EMR

Change in
counseling notes

0 = No surgical
intervention
following
molecular
diagnosis from ES
1 = Surgical
intervention
following
Sub-specialty

Whether there was a sub-specialty

molecular

consult

consult initiated following ES results

diagnosis from ES

TCH EMR

Notes about sub-specialty consult

Text

TCH EMR

Sub-specialty
consult notes

0 = No change in
drug therapy
(initiation or
discontinuation)
following
molecular
diagnosis from ES
Change in

Whether there was a change in drug

1 = Change in

medication

therapy initiated following ES results

drug therapy
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TCH EMR

Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

(initiation or
discontinuation)
following
molecular
diagnosis from ES
Change in
medication notes

Notes about change in drug therapy

Text

TCH EMR

0 = No surgical
intervention
following
molecular
diagnosis from ES
1 = Surgical
intervention
following

Surgery/Procedure

Whether there was a surgery or

molecular

procedure performed following ES results

diagnosis from ES

TCH EMR

Surgery/Procedure
notes

Notes about surgery or procedure

TCH EMR

Change in

Whether there was a change in screening

screening

following ES results

Text

TCH EMR

Notes about change in screening

Text

TCH EMR

Change in
screening notes
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Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

0 = No change in
Whether there was a change in diet

diet

initiated following ES results

1 = Change in diet

TCH EMR

notes

Notes about diet change

Text

TCH EMR

Change in

Whether there was a change in prognosis

Prognosis

based on ES results

Text

TCH EMR

Notes about prognosis change

Text

TCH EMR

Change in diet
Change in diet

Change in
Prognosis notes

0 = Palliation not
initiated
Whether palliation was initiated following

1 = Palliation

Palliation

ES results

initiated

TCH EMR

Palliation notes

Notes about palliation

Text

TCH EMR

0 = No BMT
following
molecular
diagnosis from ES
1 = BMT following
Whether there was a bone marrow

molecular

BMT

transplant initiated following ES results

diagnosis from ES

TCH EMR

BMT notes

Notes about BMT

Text

TCH EMR

Surveillance Plan

Whether there was a change in

0 = No change in

TCH EMR
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Table 3. Measurement Matrix for Aim 2
Measured
Variable

Variable
Variable Description

Coding/Type

surveillance plan initiated following ES

surveillance plan

results

1 = Change in

Data Source

surveillance plan
Surveillance plan
notes

Notes about surveillance plan

Text

TCH EMR

0 = No change in
inheritance pattern
thinking

Inheritance pattern

Whether there was a change in thinking

1 = Change in

about inheritance pattern of disease

inheritance pattern

following ES result return

thinking

TCH EMR

Notes about natural history

Text

TCH EMR

Inheritance pattern
notes

0 = No additional
genetic testing of
proband
recommended
1 = Additional
Whether additional genetic testing of

genetic testing of

Additional Genetic

proband was recommended after ES

proband

Testing of Proband

results received

recommended

TCH EMR

Additional Genetic

Notes regarding additional genetic testing

Testing of Proband

of proband recommended after ES results

Text

TCH EMR
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Table 3. Measurement Matrix for Aim 2
Measured

Variable

Variable

Variable Description

notes

received

Coding/Type

Data Source

0 = No family
testing/surveillanc
Whether ES results prompted a

e

recommendation of genetic testing or

1 = Family

Family testing/

medical surveillance in the proband's

testing/surveillanc

surveillance

family members

e recommended

TCH EMR

surveillance notes

Notes about family testing/surveillance

Text

TCH EMR

Other clinical care

Notes about other effects of ES on clinical

effect

care

Text

TCH EMR

Family testing/

Table 4. Measurement Matrix for Aim 3
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

Cost Categories
TCH
Index admission
total cost

Administrative
Total cost of index admission

Continuous

Records
TCH

Year post

Count of encounters over year following initial

encounters

genetics consult

Discrete

Records

Year post total

Total cost of one year following index admission

Continuous

TCH
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Administrative

Table 4. Measurement Matrix for Aim 3
Measured
Variable

Variable
Variable Description

Coding/Type

cost

Data Source
Administrative
Records
TCH

Index and year

Count of index admission + encounters over year

encounters

following initial genetics consult

Administrative
Continuous

Records
TCH

Index and year

Total cost combined (index admission and one

total cost

year following)

Administrative
Continuous

Records
TCH

Day Surgery

Number of post index admissions encounters -

Count Post

day surgery

Administrative
Discrete

Records
TCH

Emergency

Number of post index admissions encounters -

Count Post

emergency

Administrative
Discrete

Records
TCH

Inpatient Count

Number of post index admissions encounters -

Post

inpatient

Administrative
Discrete

Records
TCH

Observation

Number of post index admissions encounters -

Count Post

observation

Administrative
Discrete

Records
TCH

Outpatient Count

Number of post index admissions encounters -

Post

outpatient

Administrative
Discrete
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Records

Table 4. Measurement Matrix for Aim 3
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source
TCH

Renal Series

Number of post index admissions encounters -

Count Post

renal series

Administrative
Discrete

Records
TCH

Series Count

Number of post index admissions encounters -

Post

series

Administrative
Discrete

Records
TCH

Specimen Count

Number of post index admissions encounters -

Post

specimen

Administrative
Discrete

Records
TCH

Index admission cost by UB revenue code
Clinic Index Cost

category - clinic

Administrative
Continuous

Records
TCH

Diagnostic Index

Index admission cost by UB revenue code

Cost

category - diagnostic

Administrative
Continuous

Records
TCH

Emergency Care

Index admission cost by UB revenue code

Index Cost

category - emergency care

Administrative
Continuous

Records
TCH

Laboratory Index

Index admission cost by UB revenue code

Cost

category - laboratory

Med/Surg

Index admission cost by UB revenue code

Supplies Index

category - med/surg supplies

Administrative
Continuous

TCH
Continuous
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Records

Administrative

Table 4. Measurement Matrix for Aim 3
Measured
Variable

Variable
Variable Description

Coding/Type

Cost

Data Source
Records
TCH

Nursing Care

Index admission cost by UB revenue code

Index Cost

category - nursing care

Administrative
Continuous

Records
TCH

OR Periop Index

Index admission cost by UB revenue code

Cost

category - OR periop services

Administrative
Continuous

Records
TCH

Organ Acq Index

Index admission cost by UB revenue code

Cost

category - organ aq

Administrative
Continuous

Records
TCH

OT/PT Index

Index admission cost by UB revenue code

Cost

category - OT/PT

Administrative
Continuous

Records
TCH

Index admission cost by UB revenue code
Other Index Cost

category - other

Administrative
Continuous

Records
TCH

Pharmacy Index

Index admission cost by UB revenue code

Cost

category - Pharmacy

Administrative
Continuous

Records
TCH

Radiology Index

Index admission cost by UB revenue code

Cost

category - radiology

Continuous

Records

Therapeutic

Index admission cost by UB revenue code

Continuous

TCH
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Administrative

Table 4. Measurement Matrix for Aim 3
Measured

Variable

Variable

Variable Description

Index Cost

category - therapeutic

Coding/Type

Data Source
Administrative
Records
TCH

Transport Index

Index admission cost by UB revenue code

Cost

category - transport

Administrative
Continuous

Records
TCH

Post-index admissions' cost by UB revenue code
Clinic Post Cost

category - clinic

Administrative
Continuous

Records
TCH

Diagnostic Post

Post-index admissions' cost by UB revenue code

Cost

category diagnostic

Administrative
Continuous

Records
TCH

Emergency

Post-index admissions' cost by UB revenue code

Care Post Cost

category - emergency care

Administrative
Continuous

Records
TCH

Laboratory Post

Post-index admissions' cost by UB revenue code

Cost

category - laboratory

Administrative
Continuous

Med/Surg

Records
TCH

Supplies Post

Post-index admissions' cost by UB revenue code

Cost

category - med/surg supplies

Administrative
Continuous

Records
TCH

Nursing Care

Post-index admissions' cost by UB revenue code

Post Cost

category - nursing care

Administrative
Continuous
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Records

Table 4. Measurement Matrix for Aim 3
Measured
Variable

Variable
Variable Description

Coding/Type

OR Periop

Data Source
TCH

Services Post

Post-index admissions' cost by UB revenue code

Cost

category - OR periop services

Administrative
Continuous

Organ

Records
TCH

Acquisition Post

Post-index admissions' cost by UB revenue code

Cost

category - organ acquisition

Administrative
Continuous

Records
TCH

Post-index admissions' cost by UB revenue code
OT/PT Post Cost

category - OT/PT

Administrative
Continuous

Records
TCH

Post-index admissions' cost by UB revenue code
Other Post Cost

category - other

Administrative
Continuous

Records
TCH

Pharmacy Post

Post-index admissions' cost by UB revenue code

Cost

category - pharmacy

Administrative
Continuous

Records
TCH

Radiology Post

Post-index admissions' cost by UB revenue code

Cost

category - radiology

Administrative
Continuous

Records
TCH

Therapeutic Post

Post-index admissions' cost by UB revenue code

Cost

category - therapeutic

Transport Post

Post-index admissions' cost by UB revenue code

Cost

category - transport

Administrative
Continuous

TCH
Continuous
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Records

Administrative

Table 4. Measurement Matrix for Aim 3
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source
Records

Index admission

TCH

diagnostics

Count of tests on the "diagnostic pathway" during

count

the index admission

Administrative
Discrete

Index admission

Records
TCH

diagnostics total

Total cost of diagnostic pathway (using "first" and

cost

"all" rules) for the index admission

Administrative
Continuous

Records

Count of tests on the "diagnostic pathway" from

TCH

Year diagnostics

the beginning of the index admission through

Administrative

count

one year after the initial genetics consult

Discrete

Records
TCH

Year diagnostics

Total cost of diagnostic pathway (using "first" and

total cost

"all" rules) for the year

Administrative
Continuous

Index admission

Records
TCH

genetic test total

Total cost of genetic tests during the index

cost

admission

Administrative
Continuous

Records
TCH

Year genetic test
total cost

Administrative
Total cost of genetic tests during the index year

Measured
Variable

Variable Description

Continuous

Records

Variable

Data Source for

Coding/Type

calculation

Variables Used to Perform Subgroup analyses
Patient Characteristics
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Table 4. Measurement Matrix for Aim 3
Measured
Variable

Variable
Variable Description

Coding/Type

Data Source

Categorical
Proband-only

Patient had BG test code 1500

(0/1)

BG

Categorical
Trio ES

Patient had BG test code 1600

(0/1)

BG

Categorical
Critical trio ES

No ES

NICU

Patient had BG test code 1722

(0/1)

Patient did not have ES as part of diagnostic

Categorical

pathway (No-ES Cohort)

(0/1)

Patient had initial genetics consultation in the

Categorical

NICU

(0/1)

Survived to 28
days

TCH EMR

TCH EMR

Categorical
Patient survived to 28 days of life

Survived to 1
year of life

BG

(0/1)

TCH EMR

Categorical
Patient survived to 1 year of life

(0/1)

TCH EMR

2011
2012
2013
2014
2015
2016
Admit year

Year of admission date for index admission

2017

TCH EMR

Categorical

TCH EMR

Outcome Measures
Molecular

Whether a molecular diagnosis was made
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Table 4. Measurement Matrix for Aim 3
Measured
Variable

Variable
Variable Description

Coding/Type

diagnosis

Data Source

(0/1)
Categorical

28-day survival

Patient survived to 28 days of life

(0/1)

TCH EMR

Categorical
1-year survival

Patient survived to 1 year of life

(0/1)

TCH EMR

Data Analysis
Aim 1
Because this scoping review included articles that employed multiple
methodologies and studied diverse patient populations, results across studies were
summarized and narratively described rather than combined statistically in a metaanalysis. Descriptive statistics were calculated on the number of articles on each
type of CGS, characteristics of patients and institutions, clinical scenarios, and
reported outcome measures. Discussion of costs and economic evidence was also
summarized. The Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) checklist was used to assess the quality of reporting in articles with an
economic evaluation focus.89 Two authors assessed each article independently and
arrived at a consensus score.
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Aim 2
Data management and descriptive analyses were performed using Stata/IC
15 (StataCorp, College Station, TX). Detailed electronic medical record review was
performed for all patients who met inclusion criteria. The index admission was
defined as the admission during which the initial genetics consult was ordered and
the index year as the year following the date of initial genetics consultation.
To characterize patient phenotypes, relevant information was extracted from
the initial Genetics consult note (which contains the most extensive and detailed
assessment of the patient’s clinical features) and index admission discharge note. A
natural language processor was used to generate human phenotype ontology (HPO)
terms based on the clinical characteristics of the patients described in notes. Thus,
the set of HPO terms generated for each patient was intended to capture clinical
presentation at the time of the Genetics team’s assessment. Careful attention was
given so as not to include “pertinent negatives,” information from birth or family
history, or phenotypic hallmarks of differential diagnoses described within the note.
A binary variable was generated for each HPO ID number appearing in the
data. HPO ID numbers were used to ensure synonymous terms did not appear as
separate variables. Granularity was preserved; we did not use hierarchical
processing to map to higher order terms (although in many cases, both were
generated). HPO term variables with count fewer than 10 (i.e., terms that were
observed in fewer than 10 patients) were dropped, leaving 340 term variables. On
the basis of consensus among clinicians, another 33 term variables were dropped
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because they related to transient clinical characteristics, such as fever or emesis,
not relevant for making a diagnosis.
A propensity score was then calculated for each patient. The propensity score
is the estimated probability of having ES conditional on measured covariates. It is
used to represent multiple HPO terms and other relevant factors as a onedimensional score.87 Propensity scores may be used to adjust for confounding when
assessing multiple outcomes.85,86 The propensity score was calculated using a
binary logistic regression model that included indicator variables for: the department
in which the initial Genetics consult was performed, quartiles of time since ES
availability, age at first genetics consult by quarter of year, and patient gender. A
backward automated variable selection process (p-value for removal = 0.1) was
used for selection of HPO term variables. Patients who had ES were matched to
phenotypically similar patients who did not have ES using a greedy matching
algorithm based on the natural log of the propensity score. Compared to differences
between ES patients and the entire group of No-ES patients prior to matching, the
matching procedure successfully reduced differences in covariates between ES and
No-ES patients in the final cohorts.
We calculated descriptive statistics on demographics of patients and
characteristics of the index admission. We produced Kaplan-Meier survival curves to
analyze survival to 28 days, 1 year, and to the end of study. We used Cox
regression models to analyze survival times and logistic regression models to
analyze odds of molecular diagnosis.
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Outcomes were analyzed using the appropriate statistical test for the nature
of the data involved to test for a difference in outcome and costs between the study
arms and for subgroup analyses (e.g., Student’s t-test, Chi-square test, Wilcoxon
rank-sum and Kruskall-Wallis tests for differences in cost categories between
cohorts and ES forms, respectively.)
Effects were tallied from the clinical note at the time of ES return of results
and follow-up in the Genetics clinic. Establishment of a molecular diagnosis and
survival were the primary outcomes of interest. Molecular diagnosis was defined as
the identification of a specific genetic change, via analysis of chromosomes
(karyotype, chromosomal microarray, FISH), sequencing of a single gene or a panel
of multiple genes, deletion/duplication analysis, or methylation studies, interpreted
as the cause or probable cause of the patient’s clinical presentation. All results of
molecular diagnostic tests ordered in the year following the date of the initial
Genetics consult were reviewed, and interpretation of findings was verified in clinical
notes. ES cases reported by the laboratory as “solved” and “probably solved” were
considered diagnosed. For ES patients, other changes in medical management were
also tallied through analysis of the clinical note at the time of ES return of results and
follow-up in the Genetics clinic.

Aim 3
Data management and descriptive analyses were performed using Stata/IC
15 (StataCorp, College Station, TX). EMR data was merged with hospital cost data
on MRN, and costs were analyzed using the hospital perspective. Costs and
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outcomes were evaluated over the time horizon of the index admission and index
year.
Establishment of a molecular diagnosis and 1-year survival were the primary
outcomes of interest. A comprehensive list of laboratory and radiology diagnostic
investigations and associated costs and service dates for each patient over the year
following the initial genetics consult order date was obtained from the hospital.
Cost analyses considered costs of the index admission, index admission
diagnostic pathway, index admission genetic tests, total cost of the index year, index
year diagnostic pathway, and index year genetic tests. The total diagnostic cost
included the cost of all activities performed with the goal of making a diagnosis,
including ES, targeted genetic testing (single gene or gene panel), inborn error of
metabolism screening, MRI, ultrasound, and EEG. Diagnostic cost excluded the cost
of other tests performed for non-diagnostic related reasons, such as routine care,
through the systematic application of rules for inclusion of the first instance, all
instances, or no instances of each type of test. The total cost of the inpatient hospital
stay was confined to costs accrued before discharge, even if the patient was
discharged before ES results were returned.
Neither costs nor effects were discounted because all costs and outcomes
are modeled for one year, so there is no need to account for differences in time
preference. All costs were adjusted to 2017 USD$ using the historical Consumer
Price Index for All Urban Consumers (CPI-U): U.S. city average per year.
We account for the skewed distribution of costs by using log transformations
and non-parametric statistical tests. We used ordinary least squares (OLS)
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regression on log transformed total cost of index admission to estimate the impact of
patient characteristics on index admission cost. We employed Wilcoxon rank-sum
and Kruskall-Wallis tests for differences in cost categories between cohorts and ES
forms, respectively. Chi-square and Wilcoxon rank-sum tests were used for other
comparisons as appropriate.
We calculated the cost of the index admission and the diagnostic pathway per
percent 1-year survival. We calculated incremental cost-effectiveness ratios
(ICERs), the ratio of the difference in expected costs and expected outcomes
between one diagnostic strategy and the next most effective is the incremental costeffectiveness.
Cost-effectiveness of ES versus No-ES is presented in the form of an ICER
calculated as:
!"#$ =

! !"#$
! !""#$%&'#(#))

where
! !"#$ = !"#$!" − !"#$!"!!"

and
! !""#$%&'#(#)) = !""#$%&'#(#))!" − !""#$%&'#(#))!"!!"

We calculated ICERs for incremental index admission diagnostic pathways
costs and incremental diagnoses, and for incremental index admission genetic test
costs and incremental diagnoses. For each ICER, 95% confidence intervals were
constructed from 1,000 bootstrap replicates.
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Main Limitations
The scoping literature review performed for Aim 1 was intended to include all
relevant published studies. However, this analysis was limited in that it only included
articles that were published in peer-reviewed academic journals. Descriptions of
clinical experiences with genomic sequencing published in institutional reports or
newsletters would not be detected by the search strategy. Additionally, because the
review only considered English language articles, some relevant studies may not be
included. However, only one relevant article was unavailable in English.
The analysis performed in Aim 2 and 3 had several limitations. It was a
retrospective analysis based on information available in medical records and
administrative records, both of which can be incomplete or have other forms of error.
Because of the retrospective nature of the study, patients were not randomly
assigned to treatment or control group arms. However, this study improved upon
previous research by matching patients who received ES to patients who did not on
important clinical features in an attempt to control for confounding factors. Although
many have called for prospective clinical trials in order to study the patient
populations for which cGS is most effective,90 balancing cohorts by patient
phenotype and other relevant clinical characteristics utilized in this study aimed to
estimate the impact for specific types of patients while utilizing information available
in patient charts.
There were several potential confounding factors that may be important in the
study of mortality, especially 1-year survival. This study was limited to data available
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in the EMR and ES reports. Estimates of the impact of ES were interpreted based on
documentations made in clinical notes, which may have been incomplete. It is
possible that the death of some patients may have occurred outside of the hospital
and not be documented in the EMR. Similarly, patients may have sought care
outside of TCH, in which case costs and encounters would not be documented in the
TCH EMR or cost data.
This study used establishment of a molecular diagnosis as an outcome
measure, which health economists traditionally consider an intermediate rather than
a final health outcome measure. However, receipt of diagnosis is a relevant outcome
in this case for both insurers and clinicians. Payers are highly interested in the costeffectiveness of using these tests to arrive at a diagnosis because it ends the
diagnostic odyssey, which involves both diagnostic tests and various specialist visits.
For clinicians, a molecular diagnosis can help direct medical management and also
provide reassurance about treatment decisions or the decision to discontinue
treatment. For both of these reasons, a diagnosis is a useful measure of health
outcome in and of itself.
The results of this study cannot be used to draw any conclusions about where
in the diagnostic pathway ES should optimally be incorporated (i.e., as a first-line
test or subsequent to other tests if they were unsuccessful in establishing a
diagnosis). This analysis only looks at pathways with and without ES; it does not
attempt to quantify cost-effectiveness for ES at a particular point in the diagnostic
pathway (e.g., as a first-line test versus after other diagnostics have been
performed).
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To address the heterogeneity of the patient population, patients were
matched on phenotypic and clinical characteristics. Even so, the underlying cause of
disease remained diverse within patient groups because of the number of possible
molecular findings associated with any categorization of patients. Unless each
molecular diagnosis is modeled separately, which is not practical for sample size
reasons, patient groupings will necessarily combine individuals with different genetic
etiology. Heterogeneity presents challenges for modelling costs over a longer time
horizon than the inpatient stay because each distinct molecular diagnosis will have
different prognostic and treatment trajectories. As such, costs and outcomes are
only modelled over the time horizon of the index admission and for one year. This
allows time for ES to have an impact on care provision and costs, even if results are
not returned before discharge from the index admission. As the cost of ES
decreases, modelling over a shorter time horizon is more acceptable. Also, from a
payer perspective, the shorter time horizon is more relevant than lifetime cost of care
projections and may be more informative for coverage determination.

Human Subjects Research: Ethical Considerations
This study involves data that includes protected health information that was
collected with patient identifiers. However, because it is a retrospective EMR review
study, the only risk to the patient is the possibility of loss of confidentiality. All Excel
spreadsheets were password encrypted, and data were stored on Box, the secure
online cloud storage and file management service preferred by Baylor College of
Medicine. There are potential benefits to future patients based on the findings of this
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study, as results may influence patient access to cGS through informing the
development of clinical and payer policy. The Baylor College of Medicine Institutional
Review Board approved this research. A protocol was submitted for expedited
review by The University of Texas Health Science Center (UTHSC) Committee for
Protection of Human Subjects and approved.
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ABSTRACT
Purpose: Availability of clinical genomic sequencing (CGS) has generated
questions about the value of whole genome and exome sequencing as a diagnostic
tool. Analysis of reported CGS application can inform uptake and direct further
research. This scoping literature review aims to synthesize evidence on the clinical
and economic impact of CGS.
Methods: PubMed, Embase, and Cochrane were searched for peer-reviewed
articles published between 2009 and 2017 on diagnostic CGS for infant and
pediatric patients. Articles were classified according to sample size and whether
economic evaluation was a primary research objective. Data on patient
characteristics, clinical setting, and outcomes were extracted and narratively
synthesized.
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Results: Of 171 included articles, 131 were case reports, 40 were aggregate
analyses, and 4 had a primary economic evaluation aim. Diagnostic yield was the
only consistently reported outcome. Median diagnostic yield in aggregate analyses
was 33.2% but varied by broad clinical categories and test type.
Conclusion: Reported CGS use has rapidly increased and spans diverse clinical
settings and patient phenotypes. Economic evaluations support the cost-saving
potential of diagnostic CGS. Multidisciplinary implementation research, including
more robust outcome measurement and economic evaluations, are needed to
demonstrate clinical utility and cost-effectiveness of CGS.

Introduction
Genome-scale next-generation sequencing (NGS) is increasingly applied in
clinical settings as a diagnostic tool, indicative of the arrival of an era of medicine
with the capacity to provide patient care guided by genetic makeup.1 Clinical
genomic sequencing (CGS), which includes whole genome sequencing (WGS) and
whole exome sequencing (WES), is unique in the realm of diagnostic tests for two
primary reasons. First, results of a single test can both establish a molecular
diagnosis and inform tailored medical management (i.e., precision medicine) where
applicable. Second, the clinical utility of CGS increases with additional application.
Uptake influences diagnostic effectiveness because as more patients are
sequenced, detected variants are published in case reports and deposited into
public databases, which increases the number of known disease genes and in turn
impacts future diagnostic performance of the test.
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The interplay of these two qualities is important as genetic research is
translated into genomic medicine. Since WES became commercially available as a
clinical test in 2011, uptake has been sufficient to generate real world evidence on
the ability of CGS to provide a molecular diagnosis and impact patient care.
Implementation research is suited to explore the context-dependent and dynamic
nature of such evidence.2 In an analytical framework of technology translation,
synthesis and analysis of reported findings from initial use in the clinic can inform
evidence-based practice guidelines and future clinical application.3 Both case
reports and larger-scale studies of institutional implementation are informative at the
current stage of evaluation. Case reports demonstrate the breadth of clinical areas in
which CGS has been successfully applied. Studies of larger numbers of patients
provide aggregate data on diagnostic yield for different forms of the test (e.g., trio
versus proband-only, rapid versus non-rapid), and patient subgroups according to
phenotype or clinical setting.
Diagnostic potential of CGS has been seen as particularly powerful for infant
and pediatric patients because determination of molecular etiology early in life may
enable more timely and specific intervention with a better chance of improving
outcomes.4,5 Infants who are challenging to diagnose by other modalities because of
incomplete, atypical, or blended phenotypes stand to benefit from the multiplex
nature of CGS because it does not rely on clinical suspicion of the particular gene
implicated. Avoidance of sequential single gene or gene panel testing can save time,
which is valuable because time to diagnosis can impact the availability or
effectiveness of clinical intervention.6
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Establishment of clinical utility of CGS is a primary concern for clinical
implementation and the interdependent development of health care payer policy.
Careful evaluations of CGS utilization can inform optimal integration of genome-wide
sequencing into diagnostic testing algorithms – where and how to best incorporate
CGS into the diagnostic workup for which patients. This involves determining how
CGS fits into the landscape of diagnostic decision-making that includes choices
between forms of genetic investigation, including targeted genetic tests such as
single gene and gene panel tests, complementary tests such as microarrays and
copy number analysis, and CGS,7 which may be performed in addition to or in place
of other non-genetic investigations. Although sequencing has typically been
recommended for patients with nonspecific clinical features that may be associated
with numerous underlying causes (even those which are not yet well established),7,8
it may be possible to more precisely define types of patients who are the best
candidates. Development of such guidelines requires assessment of patients’ clinical
characteristics and effects of CGS on medical management to determine the types
of patients most likely to benefit from CGS and its appropriate position in the
sequence of diagnostics.
Value assessment is an important component consistent with precision
medicine’s goal of choosing the right diagnostic test for the right patient at the right
time, especially as costly new diagnostics become available.9,10 Effectiveness data
generated through clinical application studies are required for translational research
and are an essential input in economic evaluations to determine the value of the
test.3,11 While numerous methodological challenges exist for economic evaluations
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of genomic sequencing tests,12 measurement of patient health outcomes is perhaps
the largest. Difficulty of outcome measurement is not unique to CGS. It exists across
all genetic medicine applications, including targeted and disease-specific genetic
tests, and contributes to the lack of robust economic evidence on these
applications.13 While diagnostic yield is an important outcome, it is only intermediate
measure. More complete assessment of clinical utility would include measures of
patients’ ultimate health outcome following clinical care provided in light of CGS
results.14,15 Determination of CGS’s value for any specific clinically-defined group of
patients is further complicated by to statistical uncertainty about outcomes (including
diagnostic yield) due to small sample sizes, which can obstruct economic model
development.16
An understanding of how CGS has been applied in practice, its effects on
physician decision-making and clinical care, and how outcomes have been reported
is a necessary precursor to full economic evaluation. Technical and cost aspects of
NGS compared to the gold standard dideoxy method have been explored.17 In
contrast, evidence on patient outcomes following CGS application has not yet been
systematically summarized, which this review seeks to address.
The aim of this scoping review is to provide an overview of published peerreviewed articles on the application of CGS for diagnostic purposes in infant and
pediatric patients. The research questions are: (1) what does the literature say about
how diagnostic genome-scale sequencing has been applied in clinical settings for
infant and pediatric patients; (2) how have results of these applications been
reported; and (3) what was the clinical or economic impact? From studies that report
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aggregate-level analyses, information on institutional features, patient population,
reported outcome categories, and impact on those outcomes is summarized. From
case reports, disease areas and the genetic spectrum in which diagnostic CGS has
been applied are synthesized. For studies that aim to estimate the economic impact
of CGS, key findings are outlined and the quality of economic evidence reporting is
assessed. This review provides an overview of the landscape of CGS since 2009,
when proof-of-concept for diagnostic WES was shown.18,19

Materials and Methods
Methods
Scoping reviews are intended to provide an overview of the nature of
literature on a topic via structured searches and identify gaps in knowledge. Fewer
restrictions for inclusion are placed on patient population, intervention, outcome, and
study design than in systematic reviews. This review was conducted according to
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines,20 adapted for use in a scoping review as appropriate. CGS is defined to
include WGS and WES. Sequencing may have been performed for the proband (i.e.,
patient) only or alongside parents or other family members (duo or trio), in a nonrapid or a rapid manner with reduced turnaround time. Sequencing was considered
clinical rather than research for the purpose of this review if the report’s stated goal
was to make a diagnosis or otherwise impact medical management of the patient(s).
In contrast, if the objective was gene discovery or disease mechanism elucidation,
the sequencing was considered research.
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A search strategy was designed with the assistance of a librarian from the
Texas Medical Center library. PubMed, Embase, and Cochrane Library were
searched. The PubMed search included the following Medical Subject Headings
(MeSH) terms: Genome; Exome; Sequence Analysis, DNA; Adolescent; Child;
Infant; Diagnostic Techniques and Procedures; Clinical Decision-Making; Diagnosis,
Differential. Items identified through database searches were imported into the web
application Rayyan (Doha, Qatar) for title and abstract screening.21 Full search
strategies are available online as Supplementary Materials and Methods. Two
independent reviewers (HSS and SC) screened the title and abstract of each record,
and conflicts were resolved through consensus. Citations selected for full-text review
were imported into EndNote (Clarivate Analytics, Boston, Massachusetts), and fulltext articles were obtained. A full-text review form was completed for each article to
determine whether inclusion/exclusion criteria were met. One author (HSS) reviewed
each full-text article, and a second reviewer (SC) reviewed a randomly selected 10%
of the full-text articles.
Articles that met the following pre-determined criteria were included: (1) peerreviewed original research article; (2) published between January 2009 and June
2017 (with an updated search performed in November 2017); (3) proband (if a case
report) or the majority of probands (if more than 5 probands in study) less than 19
years of age at the time of sequencing; (4) described/evaluated the clinical
application of a CGS for diagnostic purposes. Studies of patients who had a clinical
diagnosis of a condition with known genetic heterogeneity, and thereby not
determined to have a “specific” diagnosis, were included. Studies of patients
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enrolled in a research protocol performing CGS for a clinical purpose were included
regardless of how costs of sequencing were covered, as the aim of sequencing was
considered more important than the funding arrangement. No restrictions were
placed on study design; clinical reports (individual cases and case series),
intervention studies (any methodology), and economic evaluations (any
methodology) were included.
Publications with a primary aim of genetic research were excluded as were
publications on population-based screening, tumor genotyping, mitochondrial
genome sequencing only (without the nuclear genome), pharmacogenetic testing,
disease carrier testing, prenatal genetic testing, and targeted exome sequencing
(e.g., “clinical exome” or “Mendeliome”) panels of thousands genes known to be
associated with single-gene disorders. While targeted exomes may be considered
more similar to a whole exome than targeted panel, multiple permutations of such
tests exist. Because there is inconsistency in covered genes, publications on
targeted tests were excluded for comparability of results and feasibility of this review.
Reports on patients who were sequenced post-mortem and those that indicated the
initiation of sequencing but not results were also excluded.
Because this scoping review included articles that employed multiple
methodologies and studied diverse patient populations, results across studies were
summarized and narratively described rather than combined statistically in a metaanalysis. Descriptive statistics were calculated on the number of articles on each
type of CGS, characteristics of patients and institutions, clinical scenarios, and
reported outcome measures. Discussion of costs and economic evidence was also
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summarized. The Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) checklist was used to assess the quality of reporting in articles with an
economic evaluation focus.22 Two authors (HSS and HVR) assessed each article
independently and arrived at a consensus score.

Data Collection Process
We developed and pilot tested a data extraction form, and then created two
refined versions based on the two types of analyses and reporting encountered. For
the purpose of collecting and presenting results in this review, studies of 5 or fewer
patients were considered “case reports” and studies of more than five patients were
considered “aggregate analyses.” The cutoff number of five was determined based
on differences in article structure and information presentation according to the
number of patients included. Thus, the data collection form used for each type of
study reflected the way in which facts were reported.
Data items selected for abstraction from articles were broadly based on
parameters recommended for assessment in evaluation of genetic tests.23 The data
collection form for aggregate analyses included the following items: study objective,
country, type of CGS, comparator, clinical setting, study design, outcome measures,
study population, inclusion criteria, exclusion criteria, average age at test, percent of
probands younger than 19 years of age, percent of probands who were male,
diagnostic laboratory, sequencing platform, whether a duo and/or trio approach was
used, turnaround time, molecular diagnostic yield, number of probands with a
change in medical management, discussion of insurance coverage, discussion of
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costs or cost-effectiveness, and average cost to diagnosis or cost of potentially
replaced tests. For case reports, the above information was collected on the
individual level as well as the gene implicated and diagnosis. For economic studies,
the perspective of the analysis, cost data source, and incremental cost per outcome
measure were recorded. One author (HSS) abstracted data from all included studies
into a spreadsheet. Analysis was performed with Stata IC 13 (College Station,
Texas).

Results
Study Selection
The study selection process is summarized as a PRISMA flow diagram in
Figure 1. Database searches and a hand search yielded 3,039 records after
duplicates were removed. After review of abstracts, 359 records were selected for
full-text review. Following full-text review and resolution of discrepancies by
consensus, 135 articles were included and 224 articles were excluded. The interrater reliability was high (Cohen’s kappa = 0.81) for the 10% of articles receiving a
full-text review by two investigators, suggesting good agreement on
inclusion/exclusion decisions and unbiased selection of articles for inclusion in this
review. The search was updated in November 2017, and an additional 36 articles
were included.
Study Characteristics
Of the 171 total included articles, 131 (76%) were case reports19,24-153 and 40
(24%) were aggregate analyses.5,6,154-191 Four studies had a primary objective of
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economic evaluation and also reported primary effectiveness data.153,189-191 The
number of included articles increased by publication year. One article each year was
included from 2009-2011, 2 from 2012, 7 from 2013, 24 from 2014, 29 from 2015, 48
from 2016, and 58 from 2017. Most studies were conducted in the USA (71) and the
European Union (28), followed by Japan (14), Canada (12), China (7), Australia (6)
and Korea (5). The first author (or co-first author) listed had a clinical or commercial
genetics affiliation for 97 (57%) of articles. Out of 24 items on the CHEERS checklist
recommended for reporting, the economic evaluation articles reported 7, 14, 18, and
17 items.

Syntheses of Results
WES was used in 93% (159/171) of articles, WGS in 6% (10/171), and a
combination of WES and WGS in 1% (2/171). Of the 98 studies that reported the
sequencing platform used, 88% (86/98) were Illumina, 6% (6/98) were Life
Technologies, and 3% (3/98) were Thermo Fisher. The majority (22/40) of aggregate
analyses reported sequence analysis of proband-parent trios for at least some
cases, 5 of which also reported a duo of the proband and mother (or another firstdegree relative) in some cases. Turnaround time from test order to result return was
reported in 25% (10/40) of aggregate analyses and only 2 case reports. The
commercial lab(s) in which sequence analysis was performed was stated in 19
aggregate analyses and 24 case reports, while 16 aggregate analyses and 87 case
reports stated that analysis was performed in-house (some of which were College of
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American Pathologists-accredited and Clinical Laboratory Improvement
Amendments-certified environments).
The 40 aggregate analyses included an average of 225 patients (median =
79; range: 6 – 2,000). Results from the 37 aggregate analyses that did not have a
primary aim of economic analysis are summarized in Table 1. Clinical setting and
patient population varied widely. Clinical settings included genetics referral centers
and hospital specialty clinics (Genetics, Neurology, Epilepsy, Developmental,
Dermatology, Mitochondrial Disorders, Hemophilia Treatment), pediatrics
departments, and intensive care units. The most common setting was
Genetics/Individualized Medicine/Developmental Clinic (12 articles), followed by
non-specific children’s hospital/university medical center clinic (9 articles) and
Pediatric Neurology/Epilepsy/Intellectual Disability Clinic (6 articles). Clinical
laboratory (4 articles) and neonatal/pediatric intensive care unit (3 articles) were also
reported settings. Most large sample studies (33/37) were retrospective medical
record reviews to form a case series (12 of which were sequential) of patients that
met specific inclusion criteria for CGS to be performed. All studies that used data
from diagnostic laboratories reported information for consecutively obtained
samples.
Phenotypic characteristics were used to delineate the types of patients
included in each study. All patients lacked a molecular diagnosis at the time CGS
was performed by virtue of the inclusion criteria for this review. Phenotype
categories were either determined by the study authors, such as organ system
affected, severity of disease, or broad phenotypic class (18 articles), or according to
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human phenotype ontology (HPO) terms (5 articles). Although the specific category
definition varied by study, neurologic phenotypes including intellectual disability
(ID)/developmental delay (DD) were a commonly reported phenotypic group (22/37
articles). Diagnostic yield for neurologic phenotypes is presented in Table S1.
Each aggregate analysis reported diagnostic yield, and it was the only
consistently reported outcome measure. Where defined, diagnostic criteria were
consistent with American College of Medical Genetics and Genomics (ACMG)
guidelines.192 Patients were considered diagnosed if pathogenic or likely pathogenic
variant was detected in a disease gene related to phenotype. Diagnostic yield varied
by patient population and type of test. Trio sequencing had a higher yield than
proband-only when the two were compared (Table 1). Overall diagnostic yield
ranged from 8.4 – 100%, with a median of 33.2%. Other than 3 studies that reported
100% yield, the highest yield was 68.3%.178 Beyond diagnostic yield, other health
outcome measures of the downstream effect of sequencing on medical management
were listed5,6,165,173-175,178,180,182 or presented in a table154,159,172 in 30% of large
sample studies. Of the 12 studies that measured them, 8 studies5,6,172-175,178,182
provided a definition of outcomes, including providing specific examples of the types
of care changes included in each category.
Aggregate analyses typically included a summary and discussion of
molecular findings, and study authors chose clinically interesting examples to
highlight. By nature of the report type, molecular findings dominated the discussion
of outcomes in case reports. Table S2 presents implicated genes and the associated
diagnoses made in case study patients. Among the case studies, 68% (89/131)
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reported a diagnostic finding, 19% (25/131) reported a variant considered by the
authors to be the most likely candidate for the patient’s clinical presentation, and 9%
(11/131) reported a finding that prompted candidate gene association studies. Nondiagnostic findings accompanied by a description of the clinical presentation were
reported in 5% (6/131) of case studies. An expansion of the genetic spectrum or
clinical phenotype associated with a particular condition was reported in 45%
(59/131) case studies.
Overall, 46% (78/171) of articles discussed implications of CGS results on the
medical management of patients. Impact on clinical care was more frequently
discussed in aggregate analyses (53%, 21/40) than in case reports (44%, 57/131).
Likewise, a discussion of economic impact of CGS on the diagnostic workup was
more frequently included in larger studies (70%, 28/40) than case reports (15%,
19/131).
Even among the 37 aggregate analyses that did not have a primary objective
of economic evaluation, 23 referred to the economic impact of CGS on the
diagnostic workup. Several articles specifically stated the need for economic
evaluation of such testing (5 articles),5,6,161,174,185 highlighted that CGS may shorten
the time and cost involved in the diagnostic odyssey or sequential single gene
testing (6 articles),5,156,159,162,168,170 or provided an illustrative example or summary
statistics on the number or cost of negative diagnostic tests performed prior to CGS
(10 articles)156,162,165,168,171,172,175,182,183,185 which could have been averted if CGS had
been utilized as a first-line test. Table S3 summarizes findings from articles that
included quantitative results related to economic impact of CGS but that did not have
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a primary economic evaluation objective. Only 5 of 37 studies included a comparison
group, which was standard diagnostic investigation.6,162,174,175,183 Insurance coverage
of CGS was discussed in 8 large studies and 2 case reports. No formal health state,
quality of life, utility values, or specific instruments to measure such outcomes were
reported.
Results from economic evaluation studies are presented in Table 2. Each
analyzed single-study effectiveness data reported in the same publication. In
general, the results suggest that WES can be cost-saving when performed as a firsttier diagnostic test and thus replace serial performance of single gene, gene panel,
and other tests. The incremental cost-effectiveness ratio may be considered within
acceptable limits even if CGS is employed at later points in the diagnostic trajectory.
For example, one prospective analysis in which standard diagnostics were
performed in parallel with WES found that first-tier WES was associated with an
incremental cost savings of US $1,702 per additional diagnosis, and when WES was
performed after standard diagnostics, the incremental cost per additional diagnosis
was US $6,327.190 Another study estimated incremental savings of US $6,840 per
diagnosis when WES was performed at the initial tertiary clinical visit and
incremental cost of US $4,371 when WES was used after standard diagnostic
investigations.191 These results underline the role of timing and number of other nondiagnostic investigations performed in whether incremental diagnoses via WES lead
to savings or come at an additional cost.
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Discussion
In this examination of the published reports of CGS in the pediatric clinical
setting, authors of included studies convey enthusiasm about the availability of
sequencing technology in the clinic and its potential value as a diagnostic tool.
Investigators highlight instances of success in particularly meaningful or puzzling
clinical cases. Overall, the results show diagnostic CGS’s broad application across
clinical settings, increased uptake since commercial availability as measured by the
number of publications each year, and high success rates for identification of
molecular cause of disease (Table 1). Proliferation of publications appears to reflect
diffusion of this diagnostic technology across geographic areas and clinical
specialties. Findings of economic evaluations suggest that the multiplex nature of
CGS is important for generating value because CGS is capable of replacing other
diagnostic tools. However, even if other non-diagnostic investigations are performed
prior to CGS, the cost to diagnose an additional patient may still look favorable to
decision makers.
Reviewed publications are predominantly retrospective case reports or series
across diverse clinical presentations. Among aggregate analyses, 85% employed a
retrospective design. Reports to date can largely be classified as descriptive,
although quantitative analysis has improved with time and sample size. While there
is work to be done to improve the analytical rigor of analyses, particularly in terms of
outcome measurement and economic evaluation, this is to be expected in the
assessment of a test with paradigm-shifting diagnostic capability. Best practices
should be established for measurement and reporting of outcomes subsequent to
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sequencing. Standardization would allow more robust analyses to demonstrate
clinical utility and cost-effectiveness of CGS. This review suggests multiple
candidate categories of outcomes that could be quantified. For example, it may be
possible to measure major procedures, imaging studies, or pharmacological
intervention averted or initiated as a consequence of GCS results. A framework of
standardized category definitions, including specification of procedures and imaging
studies considered, and means by which changes are assessed would benefit future
research.
Diagnostic yield is the most commonly reported outcome and also the most
feasible and straightforward to capture. Results across studies suggest that patientparent trio sequencing has a higher diagnostic yield than sequencing the proband
only (Table 1). Investigators have begun to look at the downstream consequences
on patient care; however, categories of clinical impact are not consistently defined or
measured. Reported medical management outcomes fall into the following broadly
defined categories: surveillance and testing, change in prognosis/impression,
subspecialty consult, time to diagnosis, pharmacological intervention, procedure
change, imaging change, diet change, palliative care initiation, facility transfer,
clinical trial education, family planning, familial genetic testing initiation, genetic
counseling, end of diagnostic workup, psychological, and personal/social. Specific
wording of outcome categories was not consistent across studies, and details on
how assessments were made were rarely provided. Lack of standardization makes
comparison across articles difficult. The discussion of care impact in reviewed
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articles largely centered on a selected few illustrative cases detailed by study
authors.
Follow-up time presents another impediment to outcome measurement. It
may not be feasible to ascertain all effects of CGS within the study timeframe. The
follow-up period in reported studies was not sufficient to measure potential impacts
over the course of the patient’s lifetime such as access to school and social
programs, disease surveillance, or reproductive decision-making of the proband.
Widespread effects of CGS may extend many years after sequencing and to multiple
members of the proband’s family.
The retrospective nature of the majority of evaluations may introduce
selection bias due to preferential reporting and patient inclusion criteria. For each
article included in this review, results are specific to the particular clinical population
studied. The majority of aggregate analyses employed specific inclusion criteria,
sometimes determined by a clinical approval process for CGS specified by the
institution. For example, patients may have been required to have already
undergone a negative diagnostic workup or meet broadly defined clinical criteria,
such as ID/DD, in order to be eligible for CGS. If clinicians selectively include
patients whom they have determined CGS would be most likely to yield a diagnosis,
the patient sample will not reflect the general patient population. However, the
findings will reflect clinical practice and interpretation of results in light of the
inclusion criteria may be informative for clinical or institutional policy-making.
There is a risk of publication bias across studies, particularly for case reports
and small case series. It is more likely that instances in which CGS was successful
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in determining a diagnosis for the patient will be published in a case report.
Nevertheless, looking across the clinical spectrum where CGS has been
successfully applied can indicate the scope of sequencing as a diagnostic tool. It is
possible that some patients reported in case studies may also be included in the
cohort of patients reported by the treating institution, where both types of
publications exist.
Absence of uniformity in outcome categories and measurement across
studies may lead to ascertainment bias, or systematic error based on how a
particular researcher defines and records a change in medical management.
Similarly, inconsistent methods for costs measurement and medical record data
abstraction may impact results of studies that assess costs or the number of
previous diagnostic tests performed for each patient. Degree of transparent reporting
on cost collection and handling can reveal potential sources of bias, such as how
missing data, statistical uncertainty, and currency conversion and indexing were
handled. One indicator of this is the quality of reporting as measured by number of
items on CHEERS checklist described in the text, which are intended to inform
readers about important aspects of how the analysis was conducted. For studies
that include an economic analysis, the level of reporting of economic evidence was
low, as approximately half of recommended items on the CHEERS checklist were
reported on average. Inconsistency impedes comparison across published studies
and makes it difficult to draw conclusions. For example, the percentage of patients
for whom CGS results affected medical management cannot be directly compared
across studies because it depends upon the types of clinical changes considered
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and reported in each specific article. At the outcome level, this review is limited by
differences in how medical management change is defined by the authors of each
study.
Authors of reviewed studies note that the cost-effectiveness of CGS deserves
further and more rigorous study and that economic evaluations are an important
component of translation to the clinic (Table S3). Discussion of insurance coverage
or economics may not have been considered relevant by authors if sequencing was
performed under a research protocol. Very few studies have performed a thorough
assessment of costs in more than a few example patients. More robust economic
evaluation of CGS is needed to quantify the cost effectiveness of testing and to
guide reimbursement policy. Of the 4 articles with a primary economic evaluation
aim, each limited the cost comparison to the diagnostic odyssey. This may be
because outcomes are not clearly defined or because asking what it costs to
determine a diagnosis is the most appropriate question at the moment. However,
there are numerous cost-related questions that should be explored in future
research, such as the cost consequences of earlier diagnosis that may lead to
earlier intervention or the decision to not perform medical interventions.
Database searches for this review were limited to PubMed, Embase, and
Cochrane. It is possible that additional publications exist outside this search.
However, it would be unlikely that relevant studies would not be indexed, and hand
searches of other resources supplemented the database searches. This review is
limited to articles published in the English language. Inconsistent terminology is a
hindrance to systematic searching. WES applied as a clinical diagnostic tool is
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sometimes abbreviated clinical exome sequencing (CES) or diagnostic exome
sequencing (DES). However, CES is also used to refer to targeted exome
sequencing of known disease genes, rather than the entire exome. It was necessary
to read details of how the analysis was performed to determine whether it covered
the whole exome or only a portion. Additionally, the terms “proband-only” and
“singleton” are used interchangeably to refer to sequencing only the patient, and
tests with expedited turnaround time are referred to as both “rapid” and “critical.”

Conclusions
This review is the first to compile evidence on clinical utility of diagnostic CGS
for infant and pediatric patients. CGS uptake, as measured by the number of
published reports, has substantially and steadily increased since its commercial
debut in 2011. It has been applied in a diverse array of clinical settings and
demonstrated ability to determine the molecular basis of disease, even in patients
who had previously undergone numerous negative diagnostic investigations.
Information on diagnostic yield alone may not be ideal to determine the value
of WGS and WES as diagnostic tools. However, downstream outcomes were not
consistently defined or reported. While commonly reported information on molecular
findings, mode of inheritance, and zygosity are informative for medical geneticists,
they do not capture key aspects of CGS relevant for implementation analysis and
development of clinical guidelines. Reflecting the dearth of outcomes information,
economic analyses have used diagnostic yield as the final health outcome. Lack of
standardized outcomes is an obstacle for evaluation of CGS from a health services
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research perspective, including determination of cost-effectiveness. Challenges for
generating compelling real world evidence of CGS include determination of best
practices for defining, measuring, and reporting patient health outcomes subsequent
to sequencing. Future studies should aim to reach consensus among experts
regarding which outcomes are important and best practices for measurement and
reporting. Focus groups or other forms of structured deliberation among
stakeholders are potential means to advance this discussion.
As CGS moves toward standard-of-care, more robust evidence of clinical
utility and economic and implementation research on CGS are needed. Consistency
in outcome assessment is essential for economic analysis input and as part of the
technology translation feedback loop. The power of CGS as a diagnostic tool derives
from – and must be evaluated within – a dynamic environment that involves both
basic science and application in the clinic.
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Tables and Figures
Figure 1. Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flow diagram of study
selection
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Table 1. Summary of Large Sample Studies
First Author (Year),

Type of

Country

CGS
WGS

Bick D (2017), USA

154

Bowling KM (2017),
USA

155

WGS

WES

Gauthier-Vasserot A

117

157

WES

Mgmt (%)

Suspected Mendelian disorder

3/22 (14); After reanalysis, 8/22 (36)

6/8 (75)

100/371 (27); Trio: 90/309 (29), Duo: 8/42 (19),
DD and/or ID

Proband: 3/20 (15)

diagnostic lab

152/500 (30); Trio: 82/220 (37), Proband: 14/68 (21)

with ID

4/10 (40)

158

WES

diagnostic lab

322/1131 (28)

b

Consecutive patients in genetics

159

WES

center

37/115 (32)

WES

Diagnostic odyssey

15/51 (29)

Lazaridis KN (2016),
USA

160

Consecutive patients referred to
Lee H (2014), USA
Lionel AC (2017),

a

Consecutive samples sent to

Iglesias A (2014),
USA

or comparator yield (%)

Syndromic congenital neutropenia

Helbig KL (2016),
USA

Study Population

Consecutive samples sent to

156

(2017), France

Change in

WES,

Farwell KD (2015),
USA

Overall Diagnostic Yield (%); Sub-analysis by test type

161

WES

clinical lab

213/814 (26); Trio: 127/410 (31), Proband: 74/338 (22)

WGS

Suspected genetic etiology

42/103 (41); Conventional genetic testing: 25/103 (24)

24/37 (65)

b

Canada

162

Meng L (2017), USA

5

WES

Critically ill; suspected monogenetic

102/278 (37); Critical Trio: 32/63 (51), Trio: 13/39 (33),

disorder

Proband: 57/176 (32)

Nambot S (2017),
France

53/102 (52)

128/416 (31) over 3 years with 2 re-analyses; yield per

163

WES

Consecutive CA and ID patients

year ranged 22 – 27%

9/128 (7)

WES

ID/DD, CA, or facial dysmorphisms

6/12 (50)

WES

Neurology clinic

24/50 (48)

8/24 (33)

WES

Drug-resistant epilepsy

1/6 (17)

0/6 (0)

1/5 (20)

Need AC (2012),
USA

164

Nolan D (2015), USA

165

Ream MA (2014),
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USA

166

Romasko EJ (2017),
USA

167

Suspected inherited platelet
WES

disorder

5/21 (24)

WES

ID and microcephaly

11/38 (29)

Rump P (2016),
Netherlands

168

Sawyer SL (2015),
Canada

169

6/105 (6)
WES

Diagnostic odyssey

105/362 (29) families

families

WES

Malignant infantile osteopetrosis

6/6 (100)

2/6 (33)

WES

Outpatient pediatric genetics clinic

24/93 (26)

Shamriz O (2017),
Israel

170

Shashi V (2016),

c

b

USA

171

Soden SE (2014),
USA

172

WES,

53/119 (45) patients, 45/100 (45) families; NICU/PICU:

22/49

rapid

11/15 (73) families by rapid WGS; Ambulatory: 34/85

families

WGS

Neurodevelopmental disorders

(40) families by WES (1 by WGS after negative WES)

(45)

WES

Neurodevelopmental disorders

32/78 (41)

32/32 (100)

WES

Suspected monogenetic disorder

46/80 (58); Standard diagnostics: 11/80 (14)

15/46 (33)

Referred for CMA by clinical

34/100 (34) by WGS; CMA + targeted gene

geneticists

sequencing: 13/100 (13), CMA alone: 8/100 (8)

32/34 (94)

7/7 (100)

Srivastava S (2014),
USA

173

Stark Z (2016),
Australia

174

Stavropoulos DJ

119

(2016), Canada

175

WGS

Takeichi T (2013),
Kuwait

176

Pediatric dermatology genetics
WES

clinic

7/7 (100)

WES

Developmental pediatrics clinics

8/95 (8); CMA: 24/258 (9)

Tammimies K (2015),
Canada

177

Tarailo-Graovac M
(2016), Canada

178

Potential ID with metabolic
WES

phenotype

28/41 (68)

18/41 (44)

WES

Suspected mitochondrial disease

28/53 (53)

0/28 (0)

WES

ID and/or epileptic encephalopathy

14/43 (33); Familial: 6/9 (67)

2/14 (14)

Taylor RW (2014),
UK

179

Thevenon J (2016),

France

180

Trujillano D (2017),
Germany

181

WES

Suspected Mendelian disorder

307/1000 (31)

WES

Diagnostic odyssey

12/40 (30)

Valencia CA (2015),
USA

182

Vissers LE (2017),
Netherlands

Non-acute; neurological symptoms

183

Willig LK (2015), USA

6

WES

with suspected genetic etiology

Rapid

Critically ill; suspected monogenetic

WGS

disorder

120

Wortmann SB (2015),
Netherlands

184

44/150 (29); Standard diagnostics: 11/150 (7)

20/35 (57); Standard genetic testing: 3/32 (9)
42/109 (39); MD gene "virtual panel": 21/42 (50),

WES

Suspected mitochondrial disease

outside gene panel (WES): 28/42 (67)

Consecutive samples sent to
Yang Y (2013), USA

185

WES

diagnostic lab

62/250 (25)

Consecutive samples sent to
Yang Y (2014), USA

186

WES

diagnostic lab

504/2000 (25)

WES

Suspected Mendelian disease

89/149 (60)

Yavarna T (2015),
Qatar

187

Zhang J (2016),
Australia

188

12/12 (100)

Hematological disorders with
WES

suspected genetic etiology

6/6 (100)

13/20 (65)

CGS, clinical genomic sequencing; WES, whole exome sequencing; WGS, whole genome sequencing; CMA, chromosomal microarray; ID,
intellectual disability; DD, developmental delay; CA, congenital anomaly
a
c

b

Change in medical management overall (any change considered by the study’s authors). Author’s calculation based on presented data.

According to diagnostic laboratory; clinician interpretation of definite or likely diagnosis in 22/93 (24) patients.
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Table 2. Summary of Findings in Economic Evaluation Articles
Type of
economic
evaluation;

Clinical

Cost of Potentially Replaced Tests /

First Author (Year)

Type of CGS;

Setting;

Incremental cost per additional Dx by

Country/Perspective

Comparator

Sample size

CGS

Descriptive; Trio

Epilepsy

Total charges for standard diagnostics

USA / Hospital (not

WES; Standard

center; n=4

range $9,015 – $35,483; charge for trio

stated)

diagnostics

(including 2

WES $6,100 / Not Calculated

Joshi (2016)

153

a

siblings)
Monroe (2016)

189

Scenario

Specialty

Average diagnostic odyssey 6.6 years;

Netherlands /

analysis; Trio

center for

average cost of traditional diagnostic

Hospital system

WES; Standard

intellectual

pathway: $16,409. For patients who

diagnostics

disability;

receive Dx, WES to replace genetic tests

n=17

would save $4,986 and to replace
metabolic tests would save $2,553, on
average. For patients who did not receive
Dx, WES to replace genetic tests would
save $5,669 on average. / Not Calculated

Stark (2017)

190

CEA; Proband

NICU, PICU,

Avg. cost per Dx, traditional diagnostics:

Australia / Hospital

WES; Standard

other

$21,099, WES: $3,937 / WES as a first-tier

system

diagnostics

inpatient, and

diagnostic test: savings of $1,702; WES to

outpatient;

replace some diagnostic tests: $2,045;

n=40

WES after all other diagnostic tests:
$6,327

Tan (2017)

191

CEA; Proband

Ambulatory

122

Avg. diagnostic odyssey 6 years, 19 tests,

Australia / Health

WES; Standard

outpatient

cost of $7,509. Cost per patient of WES at

care system (not

diagnostics

clinics; n=44

initial Genetics appointment $3,933. /

stated)

WES at initial tertiary clinical presentation:
savings of $6,840; WES at initial Genetics
consult: savings of $4,143; WES after
standard diagnostics: $4,371

CGS, clinical genomic sequencing; Dx, diagnosis; WES, whole exome sequencing; CEA, costa

effectiveness analysis; NICU, neonatal intensive care unit; PICU, pediatric intensive care unit. All
costs reported in USD.
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Table S1. Neurologic Phenotype Diagnostic Yield
a

First Author (Year)

Neurologic phenotype diagnostic yield (%)

Bowling KM (2017)

Intellectual disability: 93/344 (27)

Farwell KD (2015)

Neurologic organ system involvement: 99/324 (31)

Helbig KL (2016)

Epilepsy: 105/314 (33); Non-epilepsy: 212/817 (26)

b

Autism, developmental delay/intellectual disability,
Iglesias A (2014)

neurological/neurodegenerative disorder, and seizures: 11/49 (22)

b

Global developmental delay in children < 5 years, trio: 45/109 (41);
Lee H (2014)

proband-only: 2/23 (9)

Lionel AC (2017)

Referred from Neurology clinic: 3/3 (100)

Meng L (2017)

Abnormality of the nervous system: 42/100 (42)
Congenital anomaly and intellectual disability: 128/416 (31) over 3 years

Nambot S (2017)

with 2 re-analyses; yield per year ranged 22 – 27%

Nolan D (2015)

Neurodevelopmental symptoms: 21/53 (40)

Sawyer SL (2015)

Neurodevelopmental phenotype: 31/98 (32)

Soden SE (2014)

Neurodevelopmental disorders: 53/119 (45) children, 45/100 (45) families

Srivastava S (2014)

Neurodevelopmental disorders: 32/78 (41)

Stark Z (2016)

Neurometabolic disorder: 14/19 (74)

Stavropoulos DJ (2016)

Developmental delay: 22/57 (39)
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Table S1. Neurologic Phenotype Diagnostic Yield
First Author (Year)

Neurologic phenotype diagnostic yield (%)

a

Tarailo-Graovac M
(2016)

Intellectual developmental disorder and metabolic phenotype: 28/41 (68)
Intellectual disability and/or epileptic encephalopathy: 14/43 (33); Familial:

Thevenon J (2016)

6/9 (67)

Trujillano D (2017)

Abnormality of the nervous system 229/771 (30)
Intellectual disability 78/150 (52); ID with epilepsy or ID with movement

Vissers (2017)

disorder 39/150 (26)

Willig LK (2015)

Neurological anomaly 4/7 (57)
Nonspecific neurologic disorder 20/60 (33); Specific neurologic disorder

Yang Y (2013)

4/13 (31); non-neurologic 7/37 (19)
Neurological 143/526 (27.2); Neurological plus other organ systems
282/1147 (25); Specific neurological 30/83 (36); non-neurological 49/244

Yang Y (2014)
a

(20)

Neurologic diagnostic yield calculated as number of diagnostic cases out of total number of cases

with the phenotype
b

Author’s calculation based on presented data

Table S2. Genes and Associated Diagnoses Reported in Case Studies
Year

First Author

Gene(s)

Diagnosis
Acyl-CoA Dehydrogenase Family Member 9 (ACAD9)

2017

Aintablian HK

ACAD9

deficiency

2017

Andreoletti G

AMMECR1

Not stated

2015

Arboleda VA

KAT6A

None

2017

Ardicli D

CD59

Inherited CD59 deficiency
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Table S2. Genes and Associated Diagnoses Reported in Case Studies
Year

First Author

Gene(s)

Diagnosis

2012

Bacino, CA

WDR35

Sensenbrenner syndrome

2017

Baertling F

VARS2

Valyl-TRNA Synthetase 2 (VARS2) deficiency

Balasubramaniam
2017

S

MTP-ATP6

None

2014

Balboa-Beltran E

VEGFC

Milroy-like disease

2014

Bayer DK

IL7R

IL-7Rα deficient SCID

2017

Bloom JL

SLC29A3

H syndrome

ABCA12,
2017

Bochner R

CAPN12

Likely explanation of clinical phenotype

2017

Boczek NJ

FAM58A

STAR syndrome

2016

Brion M

TAZ

Barth syndrome

2017

Bruel AL

MAB21L1

Likely explanation of clinical phenotype

2016

Çağlayan AO

FTO, CETP

None
ALPK3-associated dilated cardiomyopathy (DCM) that
progressed to hypertrophic cardiomyopathy (HCM); Likely

2017

Çağlayan AO

ALPK3

explanation of clinical phenotype
Charcot-Marie-Tooth disease type 4B2 with early onset

2014

Chen M

SBF2

glaucoma

2017

Chen Q

MMACHC

Cobalamin C (cb1C) deficiency

2015

Chetta M

SMPD1

Niemann-Pick Type A

2016

Chiplunkar S

SLC33A1

Huppke-Brendel syndrome

2016

Chiu ATG

HRAS

Costello syndrome

2009

Choi M

SLC26A3

Congenital chloride diarrhea

2017

Choi R

CPS1

Carbonyl-Phosphate Synthase 1 (CPS1) deficiency
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Year

First Author

Gene(s)

Diagnosis

2015

Choi R

PMM2

Congenital disorder of glycosylation type Ia (CDG-Ia)
CBL syndrome, or Noonan syndrome-like disorder with or

2017

Coe RR

CBL

without juvenile myelomonocytic leukemia

2014

Das AS

RAPSN

Congenital myasthenic syndrome

2016

Demari J

CLTC

Likely explanation of clinical phenotype

2013

Dhamija R

SCN2A

Likely explanation of clinical phenotype

2013

Dinwiddie DL

IL10RA

Very early onset inflammatory bowel disease (VEO-IBD)

2016

Dionisi-Vici C

GPD1

Glycerol-3-phosphate dehydrogenase 1 (GPD1) deficiency

2014

Dyment DA

ASAH1

SMA-PME
Alkaline ceramidase deficiency (potentially a form of

2016

Edvardson S

ACER3

leukodystrophy)

2017

Eskandrani A

AFG3L2

Not stated

2017

Fadus MC

None

None

2014

Fraser JL

TPK

TPK deficiency (Leigh-like encephalopathy)

2015

Gallagher JL

CD40L

X-linked hyper IgM syndrome (XHIGM)

2015

Garg N

AKT2

MORFAN syndrome with hypoinsulinemic hypoglycemia
Early infantile epileptic encephalopathy (EIEE); Likely

2017

Gerald B

GNAO1

explanation of clinical phenotype

2015

Goldstein JHR

SMC1A

Cornelia de Lange syndrome (CdLS)

GATA3,

Hypoparathyroidism and hearing loss (HDR syndrome) and

2016

Goodwin G

STS

X-linked ichthyosis

2016

Guella I

FGF12

Early-onset epileptic encephalopathy (EOEE)

2017

Haberman Y

SI

Congenital sucrase-isomaltase deficiency (CSID)

2015

Harel T

RNF213

Moyamoya disease
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Year

First Author

Gene(s)

Diagnosis

2017

Hasosah MY

NBAS

Infantile liver failure syndrome type 2 (ILFS type 2)

2017

He X

WASP

Wiskott-Aldrich syndrome

2017

Hegde AU

BRAT1

BRAT1-associated epileptic encephalopathy

2017

Hildreth A

NPC1

Niemann-Pick disease type C

2016

Hirabayashi S

MED17

Likely explanation of clinical phenotype
Thioredoxin 2 (TXN2) deficiency; Likely explanation of

2016

Holzerova E

TXN2

clinical phenotype

RPL11,
RPS19,
2017

Ichimura T

RPS7

Diamond-Blackfan anemia (DBA)
Atypical spinal muscular atrophy (SMA) with progressive

2017

Ikeda T

TBCD

cerebral atrophy; Likely explanation of clinical phenotype
Epileptic encephalopathy with EEF1A2 mutation; Likely

2016

Inui T

EEF1A2

explanation of clinical phenotype

2017

Jehee FS

TCF4

Pitt-Hopkins syndrome

PGAP2;

Inherited glycosylphosphatidylinositol (GPI)-anchor

2016

Jezela-Stanek A

PIGN

deficiency (IGD); Likely explanation of clinical phenotype

2017

Johannsen J

MTM1

X-linked centronuclear myopathy (CNMX)
Phosphatidyl inositol glycan biosynthesis class A protein

2016

Joshi C

PIGA

(PIGA) deficiency

2016

Kansal R

MLH3

None

2013

Keller MD

MTHFD1

Severe combined immunodeficiency (SCID)
Glycosylphosphatidylinositol (GPI) anchor-related

2016

Kettwig M

PGAP1

intellectual disability; Likely explanation of clinical
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Year

First Author

Gene(s)

Diagnosis
phenotype

2015

Khromykh A

HSD17B4

D-bifunctional protein deficiency
Early-onset epileptic encephalopathy (EOEE) related to

2017

Kimizu T

SLC35A2

uridine diphosphate (UDP)-galactose deficiency

2015

Kohrogi K

SLC19A3

Biotin-responsive basal ganglia disease

2015

Kuloglu Z

PEPD

Prolidase deficiency (PD)

2016

Kvarnung M

FLVCR2

Fowler syndrome
Kabuki-like syndrome; Likely explanation of clinical

2016

Lange L

HNRNPK

phenotype

2015

Law CY

GNAO1

Infantile-onset epilepsy
HNRNPU-related disorder; Likely explanation of clinical

2017

Leduc MS

HNRNPU

phenotype
SIGMAR1 deficiency; Likely explanation of clinical

2016

Lee JJY

SIGMAR1

phenotype
Alpha-thalassemia X-linked intellectual disability (ATRX)

2015

Lee JS

ATRX

syndrome

2016

Lee JS

ST3GAL5

GM3 synthase deficiency

2016

Li N

CYP11B2

Aldosterone synthase deficiency (ASD)

2014

Lim BC

DKC1

Hoyeraal-Hreidarsson syndrome

2017

Lines MA

VAC14

Yunis-Varon syndrome (YVS)

2014

Makrythanasis P

FGFR3

None

2016

Miyamichi D

HPS6

Hermansky-Pudlak syndrome type 6

2016

Mohammad S

PPP1R15B

PPP1R15B deficiency

2015

Mroske C

MTOR

MTOR-related megalencephaly and cognitive impairment;
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Year

First Author

Gene(s)

Diagnosis
Likely explanation of clinical phenotype

DYRK1A;
KARS;

Developmental and cognitive delay; Likely explanation of

2017

Murray CR

KAT6A

clinical phenotype

2017

Nafisinia M

GARS

Mitochondrial respiratory chain dysfunction

2017

Nakamura Y

SZT2

Early-onset epileptic encephalopathy

2016

Naseer MI

STAMBP

Microcephaly-capillary malformation syndrome

2014

Ohashi T

SCN1A

SCN1A-associated epileptic encephalopathy

2017

Ozkinay F

CENPF

Stromme syndrome
FERMT3-associated malignant osteopetrosis; Likely

2017

Palagano E

FERMT3

explanation of clinical phenotype

2015

Per H

ABCA1

Tangier disease (TD)
Alanyl-TRNA synthetase 2 (AARS2)-related disease; Likely

2017

Peragallo JH

AARS2

explanation of clinical phenotype

Piekutowska2016

Abramczuk D

ADAR

Aicardi-Goutieres syndrome type 6 (ASG6)

2011

Pierson TM

AFG3L2

AFG3L2-related spastic ataxia

2016

Pinto AM

CHD2

CDH2-related neurodevelopmental disorder

2014

Pizzino A

TUBB4A

TUBB4A-related hypomyelination
Early onset epilepsy; Likely explanation of clinical

2016

Popp B

GABRA1

phenotype

FGFR3;
2017

Porntaveetus T

ALPL

Hypochondroplasia (HCH) and hypophosphatasia (HPP)

2017

Powis Z

RBM10

TARP syndrome
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Year

First Author

Gene(s)

Diagnosis

2014

Priest JR

KCNH2

Long QT syndrome (LQTS)

2015

Prontera P

IGF1R

SHORT syndrome type 2
Infantile combined immunodeficiency caused by MALT1

2015

Punwani D

MALT1

deficiency

2014

Purnell SM

TUBB4A

Hereditary dystonia type 4 (DYT4)

2016

Ramakrishnan KA

MTHFD1

MTHFD1 deficiency

2017

Renkema GH

PET117

Mitochondrial complex IV deficiency

2014

Reuter MS

HIBCH

3-hyforxyisobutyryl-CoA hydrolase (HIBCH) deficiency

2010

Rios J

ABCG5

Sitosterolemia

2016

Sangsin A

COL2A1

Spondyloepiphyseal dysplasia congenita (SEDC)

2016

Santra S

PCK1

Phosphoenolpyruvate carboxykinase (PEPCK) deficiency

2016

Seidahmed MZ

ASNS

Asparagine synthase deficiency (ASNSD)

2014

Shimojima K

TUBA1A

Malfunction of cortical development (MCD)
NRAS-related RAS-associated leukoproliferative disease

2015

Shiota M

NRAS

(RALD)

2017

Stanik J

HNF4A

Congenital hyperinsulinism (CHI)

2015

Stiles AR

HIBCH

3-Hydroxyisobutryl-CoA hydrolase (HIBCH) deficiency
Human sodium-dependent multivitamin transporter

2017

Subramanian VS

SLC5A6

(hSMVT) deficiency

2017

Takeda R

GORAB

Geroderma osteodysplastica (GO)

2015

Tamura S

LIG4

DNA ligase 4 (LIG4) syndrome

2015

Thiffault I

POLE1

POLE1-deficiency

2016

Topa A

SBDS

Shwachman–Diamond–Bodian syndrome (SDS)

2017

Tosur M

SLC16A1

Congenital hyperinsulinism; Likely explanation of clinical
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Year

First Author

Gene(s)

Diagnosis
phenotype
Myosin heavy chain 2 (MYH2) deficiency; Likely

2017

Tsabari R

MYH2

explanation of clinical phenotype

2014

Vanderver A

KCNT1

KCN1-related epilepsy

2016

Vanstone JR

DNM1L

DNM1L-related disease

2016

Varma H

POLG2

POLG2-associated mtDNA depletion syndrome

2017

Villeneuve N

FHF1

FHF1-related early onset epileptic encephalopathy
RAF1-associated hypertrophic cardiomyopathy (HCM)

2016

Wang X

RAF1

without Noonan or LEOPARD syndrome

2016

Wasserman H

INS1

Antibody-negative diabetes

2013

Wassner AJ

PROP1

PROP1 deficiency; Likely explanation of clinical phenotype

2015

Wentworth K

GNAS

Likely explanation of clinical phenotype
Alternating hemiplegia of childhood (AHC); Likely

2017

Wilbur C

ATP1A2

explanation of clinical phenotype

2016

Williams HJ

PRX

Dejerine-Sottas syndrome

2014

Xia F

AHCD1

Likely explanation of clinical phenotype

2017

Yamamoto T

ASNS

Asparagine synthetase (ASNS) deficiency

2013

Yourshaw M

PCSK1

Prohormone convertase 1/3 (PC1/3) deficiency
Blepharophimosis-ptosis-epicanthus inversus syndrome

2014

Yu HC

KAT6B

(BPES)

2017

Zrhidri A

SH3PXD2B

Frank-Ter Haar syndrome (FTHS)
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Table S3. Economic Impact Calculations from Large Sample Studies
First Author
(Year)
Country

Discussion of Economics

Cost of Potentially Replaced Tests
Of 43 patients who had other genetic tests prior to

Lazaridis KN

WES, 11 (26%) received diagnosis by WES, at an

(2016)

Average cost of WES

incremental cost per diagnosis of $27,000 (assuming

USA

service $8,000

WES cost $7,000)
In 103 total patients, median of 3 conventional genetic
tests; median of 19 genes sequenced; CMA in 44

Lionel AC

Number and cost of

patients; WES in 9 patients; median cost of

(2017)

negative genetic tests prior

conventional genetic testing $5,173 (range $585 –

Canada

to WGS

$18,361)

Need AC

Cost and reimbursement

(2012)

concerns are a barrier to

One patient had $22,000 in lab tests prior to diagnosis

USA

translation of WES to clinic

by WES

Nolan D

For patients who had WES, average charge for prior

(2015)

Calculate the charge for

non-diagnostic single gene and gene panels was

USA

prior non-diagnostic tests

$2,465.62

Rump P

WES may be more cost-

(2016)

effective than sequential

Average of 2.8 genetic tests (range 0 – 9) performed

Netherlands

single gene testing

per family prior to WES

Concerns about cost and
Shashi V

insurance coverage can be

(2016)

a barrier to uptake in the

All 93 patients had undergone diagnostic testing (range

USA

clinic

1 – 28 tests) prior to WES
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First Author
(Year)
Country

Discussion of Economics

Cost of Potentially Replaced Tests
For ambulatory care patients, average total charge per
family for prior diagnostic testing was $19,100 (range

Estimate the cost-

$3,248 - $55,321) for average of 13.3 (range 4 – 36)

effectiveness of WES/rapid

tests; for NICU/PICU patients, average total charge per

WGS, as determined by

family for prior testing was $9,550 (range $3,873 –

calculating the total cost of

$14,605) for average of 7 (range 1 – 15) tests. Estimate

Soden SE

prior negative diagnostic

that WES for ambulatory patients would be "cost-

(2014)

tests for patients diagnosed

effective," i.e., lower than the cost of non-diagnostic

USA

by WES or rapid WGS

prior tests, at a cost of $7,640 per family.
Average of 3 genetic tests (CMA and two targeted

Stavropoulos

Calculate cost of prior non-

genetic tests) per patient in parallel with WGS; example

DJ (2016)

diagnostic genetic tests for

cases had 3 – 6 tests with a range in total cost of

Canada

illustrative cases

$3,325 – $5,280

Valencia CA

19/40 (48%) of patients had at least 4 genetic tests

(2015)

Calculate cost of genetic

prior to WES, leading authors to conclude “the cost of

USA

testing prior to WES

genetic testing before WES is significant."
For patients with diagnostic WES, average cost of
diagnosis DKK 4,349 (assuming all other genetic tests

Vissers LE

Assessment of WES to

and standard investigations averted); for patients with

(2017)

replace conventional

non-diagnostic WES, costs would be DKK 10,035

Netherlands

diagnostic tests

(assuming all other genetic tests averted)

Yang Y

Need future studies of cost-

For one patient, total charges for prior non-diagnostic
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Discussion of Economics

Cost of Potentially Replaced Tests

(2013)

effectiveness

genetic testing were 3 times the current cost of WES

USA
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Complete Database Search Strategies
PubMed Search:
((((((((((("in patient"[ot] OR "clinic"[ot] OR "clinics"[ot] OR "clinical setting"[ot] OR
office[ot] OR hospital[ot] OR hospitals[ot] OR "NICU"[ot] OR "PICU"[ot])) OR ("in
patient"[tiab] OR "clinic"[tiab] OR "clinics"[tiab] OR "clinical setting"[tiab] OR
office[tiab] OR hospital[tiab] OR hospitals[tiab] OR "NICU"[tiab] OR "PICU"[tiab]))
OR ("Hospitals"[Mesh] OR "Hospital Units"[Mesh] OR "Physicians'
Offices"[Mesh]))))) AND (((((((genom*[ot] OR exome[ot] OR "gene panel"[ot] OR
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"next generation sequencing"[ot])) OR ((genom*[tiab] OR exome[tiab] OR "gene
panel"[tiab] OR "next generation sequencing"[tiab]))) OR ("Genome"[Mesh:NoExp]
OR "Exome"[Mesh] OR "Genome, Mitochondrial"[Mesh] OR "Sequence Analysis,
RNA"[Mesh] OR "Sequence Analysis, DNA"[Mesh]))) AND ((("Sequence
Analysis"[Mesh]) OR (sequence[tiab] OR sequencing[tiab])) OR (sequence[ot] OR
sequencing[ot])))))) AND (((((neonate[ot] OR neonates[ot] OR child[ot] OR
children[ot] OR adolescent[ot] OR adolescents[ot])) OR (neonate[tiab] OR
neonates[tiab] OR child[tiab] OR children[tiab] OR adolescent[tiab] OR
adolescents[tiab])) OR ("Adolescent"[Mesh] OR "Child"[Mesh] OR
"Infant"[Mesh])))))) AND ((((("Diagnostic Techniques and Procedures"[Mesh] OR
"Clinical Decision-Making"[Mesh] OR "Diagnosis, Differential"[Mesh])) OR
(diagnosis[tiab] OR diagnostic[tiab] "clinical decision"[tiab] OR "clinical decision"[tiab]
OR "medical management"[tiab])) OR ("diagnosis"[ot] OR "diagnostic"[ot] OR
"clinical decision"[ot] OR "clinical decision"[ot] OR "medical management"[ot])))

Embase Search:
('genome'/exp/mj or 'exome'/exp/mj or 'whole exome sequence'/exp/mj or 'whole
genome sequence'/exp/mj or 'genome':ab,ti or 'exome':ab,ti or 'whole genome
sequence':ab,ti or 'whole exome sequence':ab,ti or 'next generation
sequencing'/exp/mj) and ('clinical'/exp/mj or 'diagnosis'/exp/mj or 'diagnostic'/exp/mj
or 'differential diagnosis'/exp/mj or 'clinical':ab,ti or 'diagnosis':ab,ti or
'diagnostic':ab,ti) and ('newborn'/exp or 'infant'/exp or 'pediatric'/exp or 'newborn
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intensive care'/exp or 'neonatal intensive care unit'/exp or 'pediatric intensive care
unit'/exp or 'newborn':ab,ti or 'infant':ab,ti or 'adolescent':ab,ti)

Cochrane Search:
#1 [mh genome]
#2 [mh exome]
#3 “next generation sequencing”
#4 whole genome sequencing
#5 whole exome sequencing
#6 gene panel*
#7 #1 or #2 or #3 or #5 or #6
#8 clinic
#9 “diagnosis”
#10 “diagnostic”
#11 #8 or #9 or #10
#12 “newborn”
#13 “neonatal”
#14 “pediatric”
#15 #12 or #13 or #14
#7 and #11 and #15
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Exome Sequencing for Critically Ill Infants Compared to Standard Diagnostics:
A Retrospective Analysis of Clinically Matched Cohorts

Target Journal: Genetics in Medicine
Abstract
Purpose: To estimate the effectiveness of clinical exome sequencing (ES) for
patients with a suspected genetic etiology admitted to intensive care within the first
year of life.
Methods: We analyze ES application at a large children’s hospital over 5 years
using electronic medical record data. We examine uptake of ES forms among
attending Geneticists. We compare outcomes between cohorts of clinically similar,
critically ill newborns and infants with a suspected genetic etiology who had ES
(n=368) and diagnostic workup without ES (n=368). Main outcomes are
establishment of molecular diagnosis and survival over a one-year time horizon.
Results: We found variability in ES ordering practice at the provider level. Molecular
diagnostic yield (25.8% No-ES, 27.7% ES; p=0.56) and 1-year survival (84.8% NoES, 80.2% E; p=0.10) were similar for patients who had ES and patients who had
standard-of-care diagnostic investigations other than ES.
Conclusion: As clinically applied, ES is an important diagnostic tool, as are
chromosomal microarray and targeted genetic testing, for diagnosing patients with a
severe clinical presentation within the first year of life. Further work to define utility of
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ES testing not captured by diagnostic yield is warranted to develop clinical
guidelines for the appropriate application of ES.

Introduction
Clinical genomic sequencing (cGS) has increased capacity to make robust
molecular diagnoses of genetic disorders, even those difficult or impossible to
clinically diagnose.1,2 Exome sequencing (ES) has demonstrated ability to diagnose
critically ill newborns and infants influence medical management, especially when
results are returned in an expedited fashion.1-6 Robust evidence of ES clinical utility
to aid clinical guideline development, however, is currently sparse but is an active
area of investigation.7-9 Very little is known about the impact of ES compared to
standard diagnostics in real-world clinical practice.
Evaluation of patients with suspected genetic disorders is important to pediatric
and neonatology practice due to incidence of genetic diseases that manifest at birth
or soon after. A leading cause of mortality in infancy, genetic disorders afflict more
than one quarter of patients admitted to a level IV neonatal intensive care unit
(NICU) who die before age 5.10,11 Both chromosomal abnormalities and single-gene
disorders contribute to this disease burden.12,13 Diagnostic workup for a suspected
genetic condition is associated with longer NICU stay,11 and diagnoses of geneticbased diseases are associated with longer, more costly pediatric inpatient stays.14,15
Most prior studies of ES have been conducted within a research framework, with
inclusion criteria such as clinician review and prior negative diagnostic testing, more
appropriate to establish efficacy of ES to identify an accurate diagnosis, rather than
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effectiveness. Moreover, most studies do not include a comparison group of patients
who did not have ES,7 which prevents conclusions about relative effectiveness in a
population.
Identification of an appropriate patient population and measurement of outcomes
are both key challenges for generating evidence of cGS effectiveness.8,16-18
Selection of a comparator group of patients is necessary to quantify ES impact
relative to usual care yet difficult in retrospective analyses and in prospective trials
involving critically ill children for whom withholding of sequencing may generate
ethical concerns.19
Outcome measurement is uniquely challenging in evaluations of cGS. Because
ES analyzes changes at a genome-wide scale, it is capable of diagnosing nearly any
of the more than 5,000 different single-gene disorders with a known molecular
basis,20 meaning there is no one natural history of disease which can be modeled.
Further, there is no standardized position of ES in the diagnostic pathway, as the
workup for a suspected genetic disorder is largely left to the discretion of clinical
geneticists caring for a particular patient. Diagnostic yield has therefore most widely
used as a summary measure of outcome,7 as many downstream clinical outcomes
vary at the disease-level. Because many diseases diagnosed by ES are very rare
individually, disease-specific outcomes are sparse.
We aim to evaluate the impact of ES on outcomes compared to standard
diagnostics, including other genetic tests, for critically ill newborns and infants with
suspected genetic disease. We study uptake and use of ES over more than 5 years
at a large children’s hospital, reflective of effectiveness as clinically applied. We
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employ a historical cohort design to enable comparisons between clinically and
phenotypically similar patients who did and did not have ES as part of a diagnostic
workup in the first retrospective, comparative analysis of ES in a large patient
population. In this paper, we (1) describe a population of infants in intensive care
who had a suspected genetic etiology and underwent diagnostic testing; (2) describe
uptake of ES in its various test forms; (3) examine health outcomes, including
molecular diagnostic yield and survival, in critically ill patients who did and did not
have ES in the first year of life.

Patients and Methods
We analyzed ES application at a large children’s hospital during the initial
uptake period of December 2011 through June 30, 2017. The study population is
patients with a suspected genetic etiology who had an intensive care unit admission
within the first year of life. Patients were admitted to Texas Children’s Hospital (TCH)
in Houston, TX, a large children’s hospital with 33,000 total admissions in 2017 and
the highest level of neonatal intensive care (Level IV).21 Documentation of an
inpatient consult from the Genetics service indicated that the patient was suspected
to have a genetic etiology. All TCH ES orders were sent to Baylor Genetics (BG)
diagnostic laboratory. Electronic medical record (EMR) review was completed in
August 2018 such that there is a minimum of one year of clinical follow-up data on
all patients. Data analysis was performed using Stata 15 (StataCorp, College
Station, TX).
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Identification of Eligible Patients
We employ a retrospective cohort study design with ES as the exposure
factor. Two patient cohorts were defined; patients who had ES as part of a
diagnostic workup (ES cohort) were matched, based on clinical characteristics and
phenotypic presentation, to patients who did not (No-ES cohort).
Two datasets were combined to define the patient population. The first
dataset, obtained from the hospital, contained medical record numbers (MRNs) of all
patients at TCH who (1) had an intensive care unit inpatient admission within the first
year of life, and (2) had an order for inpatient consultation from the Genetics service.
The second dataset, obtained from the diagnostic laboratory, contained ES report
data for all patients who had ES (1) ordered from TCH, and (2) an ES order date
less than 366 days from date of birth. Datasets were merged on MRN. Patients
appearing in both datasets were preliminarily designated as the ES cohort; patients
appearing only in the hospital data were preliminarily designated as the No-ES
cohort.
EMR review was then performed for all patients. We define the index
admission as the admission during which the initial genetics consult was ordered. A
consult order and a note from a member of the genetics service constituted
consultation. Data on admission characteristics, demographics, phenotypic
presentation, clinical outcomes, ES order and result return, and ES uptake by
attending clinician was collected from index admission administrative notes and
genetics consult and follow-up notes. Ethnicity was recorded as listed in the EMR
demographics tab; if unlisted or if information in the demographics tab was
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contradictory information to the genetics note, ethnicity was recorded as listed in
genetics note, which contained detailed information on family history and country of
origin.
Patients had one of 3 forms of ES: sequence analysis of only the patient
(proband), a trio of patient and both parents (trio), or trio of patient and parents with
expedited turnaround time (critical trio). Clinical ES became available in October
2011 in proband form. The trio test was introduced in October 2014 and critical trio
in April 2015. Details of the matching procedure used to select No-ES cohort
patients are given in Supplementary Materials and Methods.

Measurement and Comparison of Outcomes
ES uptake and health outcomes were systematically assessed through EMR
review. Because a key assumption in our identification strategy is that clinically
similar patients may have had ES or not based on variability in ordering practice at
the provider-level, we analyzed the pattern of uptake among different attending
Geneticists as different forms of ES (i.e., proband, trio, rapid trio) became available.
We extracted the names of signers (trainees) and cosigners (faculty) of the initial
Genetics consult note and the Genetics consult note during which ES was ordered.
Establishment of a molecular diagnosis and survival were the primary
outcomes of interest. Molecular diagnosis was defined as the identification of a
specific genetic change, via analysis of chromosomes (karyotype, chromosomal
microarray, FISH), sequencing of a single gene or a panel of multiple genes,
deletion/duplication analysis, or methylation studies, interpreted as the cause or
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probable cause of the patient’s clinical presentation. All results of molecular
diagnostic tests ordered in the year following the date of the initial Genetics consult
were reviewed, and interpretation of findings was verified in clinical notes. ES cases
reported by the laboratory as solved and probably solved were considered
diagnosed. For ES patients, other changes in medical management were also tallied
through analysis of the clinical note at the time of ES return of results and follow-up
in the Genetics clinic. A comprehensive list of diagnostic-related investigations
performed for each patient over the year following the initial Genetics consult order
date was obtained from the hospital.
We calculated descriptive statistics on demographics of patients and
characteristics of the index admission. We produced Kaplan-Meier survival curves to
analyze survival time, including survival to 28 days, 1 year, and end of study. We
used Cox regression models to analyze survival times and logistic regression
models to analyze odds of molecular diagnosis.

Results
A total of 368 patients who had ES comprised the ES cohort, and the 368
patients who comprised the No-ES cohort were selected via the matching process
from among 936 patients meeting study criteria who did not have ES (Figure 1).
Patients represented a diverse population with home addresses in 361 unique zip
codes from across the US.
Patient characteristics were well balanced between cohorts after matching
(Table 1). More patients were male, Non-Hispanic, and white. Although race,
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ethnicity, preferred language, gestational age at birth, and parental age at birth were
not included in the propensity score, they are balanced between cohorts with no
significant differences in any of these characteristics. The majority of patients were
in the NICU during the initial Genetics consultation, most of which took place within
the first quarter of a year of life.
Characteristics of the index admission are presented in Table 2. Most patients
were admitted from transfer centers, but admission and Genetics consultation took
place soon after birth, a median of 11 and 13 days of life for the No-ES cohort and
ES cohort, respectively. Length of stay was longer and distributed differently for ES
patients than no-ES patients (Figure 2).

Exome Sequencing Cohort
Form of ES was proband for 227 (61.7%) patients, trio for 54 (14.7%)
patients, and critical trio for 87 patients (23.6%) (Table S2). Median turnaround time
was 13 days for critical trio ES and 87 days for the non-rapid versions (95 days for
proband and 50 days for trio). Critical trio ES was recommended and ordered sooner
after admission (median 9 days) than orders for trio and proband ES (median 25
days, p<0.01).
In addition to clinical acuity, availability of biological parents to submit a DNA
sample was a factor in form of ES order. Two parents submitted DNA samples in
271 cases (73.6%), one parent in 46 (12.5%), and no parents in 51 (13.86%). In 16
cases (4.3%), the lab received parental samples after the initial ES report and issued
an addendum that included interpretation in light of parental sample information. For
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the 203 tests performed after critical trio was available, proband still accounted for
31.0% (63/203) of all tests and was ordered in 16.2% (27/167) of cases with a DNA
sample able to be obtained from two parents.
ES was ordered at the initial Genetics consult for 205 patients (55.7%), a
follow-up Genetics consult during the index admission for 115 (31.3%) patients,
during a subsequent inpatient admission for 25 (6.8%) patients, and during a
subsequent outpatient clinic visit for 23 (6.3%) patients. Among ES orders entered
during the index admission, orders were placed median 24 days before discharge,
which is shorter than the median turnaround time for non-rapid tests.
ES resulted before discharge from the index admission for 106 (28.8%)
patients. A higher proportion of patients who had critical trio were diagnosed before
discharge (24.1%) than patients who had proband or trio tests (5.7%, p<0.01).
After 6 months of uptake (June 2012), mean 6 ES tests of any form were
ordered per month over the study period (Figure S1). Proband ES orders averaged 4
per month prior to availability of trio forms, after which the average total number of
tests ordered per month increased to 7, driven by uptake of trio and critical trio forms
(p<0.001) as proband orders decreased to 3 per month. There were 19 attending
geneticists who rotated on service and authored consult notes over the study period.
Total consults, ES order consults, and molecular diagnostic yield by attending
geneticist are presented in Figure S2, and ES orders by attending geneticist and
form are presented in Figure S3.
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Molecular Diagnostic Yield
Overall, 205 (27.9%) of patients received a molecular diagnosis (Table 3).
There was no difference in molecular diagnostic yield between the cohorts. A
genetic change determined to be causal or probably causal of the patient’s clinical
condition was identified in 95 (25.8%) No-ES cohort patients by genetic tests other
than ES and 102 (27.7%) ES cohort patients by ES. In addition, 8 patients in the ES
cohort were diagnosed by chromosomal microarray (CMA) which are not included in
the ES diagnostic yield calculation. Genetic diagnoses and diagnostic tools with
which they were identified in the No-ES cohort and ES cohort is given in Table S4
and Table S5, respectively. There was no difference in outcomes within the ES
cohort between patients who had different forms of ES (Table S6.) In addition to
diagnostic yield, we assessed changes in management in the ES cohort in the
following categories: subspecialty referral, medication change, screening
recommendation, diet change, redirection of care to comfort care, and surveillance
recommendation (Table S7). A Geneticist recommended at least one management
change in light of ES results for 81 patients, 49 diagnosed and 32 undiagnosed by
ES. In undiagnosed patients, subspecialist referrals and screening
recommendations accounted for most management changes, as inconclusive ES
results may not definitively rule out the need for clinical monitoring.
Molecular diagnosis odds ratios are presented in Table 4. Overall, Hispanic
patients had significantly lower odds of receiving a diagnosis, compared to NonHispanic patients, holding other factors constant (model 1, p=0.002). In the ES
cohort, Hispanic patients had half the odds of diagnosis of Non-Hispanic patients
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(model 4, p=0.007). The odds of diagnosis for patients in the progressive care unit
were approximately 3 times that of patients in the NICU (model 1, p=0.004). Patients
who were referred for admission by a physician had 2.5 times odds of diagnosis for
inborn patients (model 1, p=0.009). ES-by-admission year interaction effect was not
significant and not included in the final model.

Survival
A total of 50 (6.79%) patients expired before 28 days of life, 129 (17.53%)
before 365 days of life, and 166 (22.55%) before the end of the study period. Among
patients who expired, patients in the No-ES cohort expired sooner after birth than ES
cohort patients. Table 3 shows 28-day survival of 91.6% of patients in the No-ES
cohort and 94.8% in the ES cohort. One-year survival was 84.8% in the No-ES
cohort and 80.2% in the ES cohort. At the end of the study period, 80.4% of patients
in the No-ES cohort were alive, whereas 74.5% of patients in the ES cohort were
alive.
Although there was no difference in age of death between cohorts (Table 3),
the pattern of survival shows that a larger proportion of the patients who expired
before 28 days of life were in the No-ES cohort, while the proportion that expired at
later time points was greater in the ES cohort, which is illustrated by the converging
survival curves for the ES and No-ES cohorts (Figure 3). Convergence of the
survival curves indicates violation of the proportional hazards assumption and
prevents statistical comparison of the cohorts’ survival distributions with the log-rank
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test. However, inspection of the Kaplan-Meier curve suggests no meaningful
difference between the curves.
Survival analysis results from Cox regression models are presented in Table
5. When hazard ratios are calculated within hospital unit, the proportional hazards
assumption is satisfied (Table 5, models 4-6). Figure 4 shows Kaplan-Meier survival
curves for all patients by unit. Patients who received a diagnosis had 58% higher
hazard of death than undiagnosed patients (Table 5, model 4, p=0.007). Within the
ES cohort, the hazard for diagnosed patients was 92% higher (model 6, p=0.004).
Figure 5 shows survival curves by cohort and diagnosis category, with lowest 28-day
survival in diagnosed No-ES patients and lowest 1-year survival in diagnosed ES
patients. Older age at the initial Genetics consultation was associated with a
significantly lower hazard rate (Table 5).

Discussion
We estimate the effect of ES for newborns and infants with suspected genetic
disease. This is the first analysis, to our knowledge, to compare a group of patients
who had ES to phenotypically matched controls in order to do so, and the sample
size and comparator group are strengths of the study. Retrospective matching
enables us to study the large number of patients who had ES over more than 5
years while also identifying clinically similar patients who received standard-of-care
diagnostic workup in order to compare outcomes. Although propensity score
matching has been previously suggested as a way to address difficulties in
identification of an appropriate comparator group for ES evaluations,22 we are the
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first to apply this approach to identify counterfactual patients and estimate ES effect.
Matching on phenotype instead of ultimate diagnosis is advantageous from both a
clinical decision-making and study design perspective. The clinical decision point
regarding ES order is prior to establishment of a diagnosis, not after, and decisions
about diagnostic investigations are based upon the patient’s clinical presentation.
Moreover, rarity of most conditions diagnosed by ES limits the possible sample size
of cases matched on diagnosis.
We find evidence of diagnostic utility of genetic testing overall in newborns
and infants with suspected genetic disease, with a molecular etiology identified in
27.9% of patients. We find no difference in diagnostic yield between the cohort of
patients who had ES and the cohort of patients who had a standard genetic workup
not including ES. These results suggest that CMA and other targeted forms of
genetic testing remain important diagnostic tools. CMA has been suggested as the
appropriate comparator by which to measure the value of ES.23 While CMA is firsttier diagnostic standard care, and is therefore an appropriate comparator to evaluate
ES against the status quo, ES and CMA detect different types of genetic changes
(sequence variants and chromosomal abnormalities, respectively). An astute
Geneticist may be able to suspect which type of change a patient has, and therefore
the most appropriate test, based on clinical exam.
This analysis examines the effectiveness of ES for patients with suspected
genetic disease overall. We do not define requirements for sequential order of
testing, diagnostic yield of ES is likely to be higher in the subset of patients with nondiagnostic CMA than we report. While ES is a complementary test to CMA rather
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than a substitute for it, genome sequencing (GS) can potentially replace CMA and
ES. GS is capable of detecting structural changes and identifying diagnoses not
detectable by ES.24 As such, CMA may be a more appropriate comparator for
genome sequencing (GS) than for ES. Further work should be directed toward
defining a more rigorous way of categorizing patients according to likely clinical
impact of ES to develop clinical guidelines for appropriate use of ES.
Our results highlight several other areas for further investigation. In the ES
cohort, Hispanic patients had half the odds of diagnosis of Non-Hispanic patients.
This finding speaks to the need for diversity in databases used for variant curation in
order to better interpret findings in this group of patients and increase the likelihood
of diagnosis.25 That we find no effect of ES-by-admission year interaction on
molecular diagnosis suggests that the rate of molecular diagnosis did not change
over time. In other words, neither experiential learning in terms of ES orders on the
part of the clinician nor increased genetic knowledge in the field overall appear to
have significantly impacted results over our study period.
Our finding of no difference in survival can be interpreted in two ways. First, it
may be due to study design and indicate successful matching of patients on severity.
Neither cohort was more severely ill, in a broad sense, than the other. Second, it
may indicate that ES is not effective at increasing survival compared to standard
diagnostics. This finding is not altogether surprising due to rarity of diseases
detected by ES for which a treatment may not be available.
Our findings regarding timing of death, however, are somewhat unexpected.
No-ES cohort patients expired sooner after birth, yet cGS has been predicted to
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increase 28-day mortality driven by redirection to comfort-care only following
confirmation of severe, untreatable disease.26 Our result is better understood in light
of the diagnoses in the No-ES cohort, including severe chromosomal abnormalities
not compatible with survival, such as trisomy 13, trisomy 18, and other large
unbalanced chromosomal rearrangements, that likely drive the higher death rate in
the early time period.
The hazard rate for diagnosed patients was significantly higher than that for
patients without a molecular diagnosis, driven by results in the ES group. Lower
survival for diagnosed patients, compared to patients who did not receive a
molecular diagnosis is consistent with other studies of genomic sequencing in the
NICU.9 This indicates the severity of diagnoses identified through ES. Similarly,
older age at the initial Genetics consultation was associated with a significantly lower
hazard rate; this implies that the most severely ill patients likely to expire within a
short time after birth are receiving attention from the Genetics team sooner than
patients afflicted with less life-limiting conditions.
We use summary outcome measures of diagnostic yield and survival to
describe a heterogeneous population of patients. However, the myriad nuances of
outcomes important to determine the effectiveness of ES are not captured in the
commonly reported summary measure of diagnostic yield, and this is an active area
of exploration. Need for development of a new approach to outcomes measurement
and evidence generation for precision medicine applications such as ES has been
identified as a top priority by the National Academy of Medicine.27 Definition and
standardization of outcome measures has been recognized by researchers
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attempting these evaluations in practice.28,29 The fact that ES is applicable as a
diagnostic tool for theoretically any patient with suspected monogenetic disease, but
without prior knowledge of which specific disease or implicated gene, makes it both
potentially more effective and more difficult to evaluate at the population level. We
have defined boundaries that allow meaningful analysis while preserving the
features that make ES unique and useful. Our patient sample is diverse and
heterogeneous yet defined by features that stakeholders can use to determine
clinical and coverage policy for a distinguishable group of patients.
Real world effectiveness of ES will likely differ by institution. Upon availability
as a commercial clinical test, without data on clinical care impact, the technological
imperative may have influenced uptake of genomic sequencing of infants.30 Uptake
of genetic testing is influenced by institutional-level factors31 and other elements
which we are not able to systematically study here but should be explored in the
future.
We recognize several limitations related to reliance on EMR and
administrative data. Objectivity and scalability for a large patient population are
advantages of outcome measurement through EMR review, yet potential for
incomplete documentation and difficulty in identification of changes in management
as a result of ES results are disadvantages. We only measured changes where
there was explicit documentation in the note related to the results of ES, whether
diagnostic or non-diagnostic, although not all changes may be documented this way.
Some ways in which ES results may influence clinical care, such as prognostication,
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are especially hard to measure objectively and retrospectively and without the
involvement of the treating clinician.
Relatedly, HPO term generation depended upon the information in clinical
notes. Clinicians may differ in meticulousness, extent, and quality of phenotypic
description, which would, in turn, impact the HPO terms generated from the note.
Moreover, HPO terms assessed individually do not capture syndromic patterns of
features. Although syndromic features may be caused by both monogenic and
chromosomal abnormalities, some patterns may indicate hallmark features of
chromosomal abnormalities to clinically indicate CMA instead of ES.
We do not consider non-health outcomes or impacts of ES not documented in
the EMR which would require further data collection from patients, families, and
clinicians. Empirical data suggest the potential value to families of information, even
without possibility of treatment.32,33 Parents perceive information from ES to have
benefits beyond direct clinical usefulness, such as reassurance regarding a
transition to comfort care-only measures, help with coping, knowing risk for other
family members, and reproductive planning.18,33-39 Incorporation of family
preferences along with objective outcomes can help move toward a more holistic
valuation of the cGS and methodological work is needed in this area.32,40 Moreover,
results of cGS may impact clinical management decisions whether or not a definitive
diagnosis is established.41 Valuation of non-health outcomes should be explored for
patients, families, and clinicians should be further explored to complement this work.
As clinically applied, ES is an important diagnostic tool, as are chromosomal
microarray and targeted genetic testing, for diagnosing patients with a severe clinical
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presentation within the first year of life. Combined, nearly 30% of newborns and
infants in our study received a genetic explanation of the cause of their clinical
features. While this percent may not define the complete spectrum of utility of ES
testing, it represents the importance of various diagnostic tools for patients with
various genetic disease etiologies.
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Tables and Figures
Figure 1. Study flow diagram

DOL, days of life; ES, exome sequencing; IP, inpatient; ICU, intensive care unit
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Table 1. Patient Characteristics
No-ES Cohort

ES Cohort

p-value

Male

203 (55.16)

217 (58.97)

Female

165 (44.84)

151 (41.03)

White/Caucasian

277 (75.27)

289 (78.53)

58 (15.76)

58 (15.76)

22 (5.98)

17 (4.62)

American Indian and Alaska Native

1 (0.27)

1 (0.27)

Unknown

8 (2.17)

3 (0.82)

Non-Hispanic

200 (54.35)

190 (51.63)

Hispanic

162 (44.02)

174 (47.28)

6 (1.63)

4 (1.09)

English

312 (84.78)

294 (79.89)

Spanish

52 (14.13)

69 (18.75)

Other

4 (1.09)

5 (1.36)

0.219

NICU

245 (66.58)

222 (60.33)

0.078

62 (16.85)

70 (19.02)

0.442

Sex, n (%)

0.297

Race, n (%)

Black/African-American
Asian

0.396

Ethnicity, n (%)

Unknown

0.581

Preferred Language, n (%)

Unit of Genetics Consult, n (%)

CVICU
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a

Other

36 (9.78)

36 (9.78)

1.00

PCU

17 (4.62)

25 (6.79)

0.204

PICU

8 (2.17)

15 (4.08)

0.138

302 (82.07)

297 (80.71)

0.636

43 (11.68)

49 (13.32)

0.504

Third

13 (3.53)

12 (3.26)

0.839

Fourth

10 (2.72)

10 (2.72)

1.00

92 (25.00)

92 (25.00)

1.00

105 (28.53)

79 (21.47)

0.027

Third

90 (24.46)

95 (25.82)

0.671

Fourth

81 (22.01)

102 (27.72)

0.073

Gestational Age at Birth, weeks, mean (median)

36.40 (37.29)

37.00 (38.00)

0.0711

Mother’s Age at Birth, years, mean (sd)

28.93 (6.27)

Father’s Age at Birth, years, mean (sd)

31.60 (7.55)

Age at Genetics Consult (quartile of year), n (%)
First
Second

Genetics Consult Date (quartile of study period), n
(%)
First
Second

f

d

28.39 (6.33)

31 (7.78)

e

g

0.251

c

0.357

c

b

ES, exome sequencing; NICU, neonatal intensive care unit; CVICU, cardiovascular intensive care
unit; PCU, progressive care unit; PICU, pediatric intensive care unit
a

b

All p-values from chi-square tests unless otherwise noted; Wilcoxon rank-sum test
c

d

e

f

test; n = 360; n = 362; n = 312; n = 316
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c

Student’s t-

Table 2. Index Admission Characteristics
No-ES Cohort

ES Cohort

p-value

(IQR), mean

1 (0–36), 35.18

2 (0 – 44), 38.30

0.430

b

Age at initial genetics consult, days,

10.5 (2–54.5),

13 (2 -57.5),

median (IQR), mean

44.92

47.30

0.515

b

Transfer Center

167 (45.38)

160 (43.48)

Newborn at TCH

128 (34.78)

136 (36.96)

42 (11.41)

40 (10.87)

31 (8.42)

32 (8.70)

Length of stay, days, median (IQR),

27.5 (10–56),

39 (17–83.5),

mean

50.57

66.86

294 (79.89)

287 (77.99)

51 (13.86)

60 (16.30)

12 (3.26)

15 (4.08)

Home Health Care Service

3 (0.82)

3 (0.82)

Hospice

8 (2.17)

3 (0.82)

a

Age at admission, days, median

Point of Origin, n (%)

Self Referral/Non-Health Care Facility
Clinic or Physician Referral

0.928

<0.001

Discharge Place, n (%)
Home
Expired
Other Facility

Insurance Payer, n (%)
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0.490

b

Public (Medicaid and Tricare)

194 (52.72)

224 (60.87)

Commercial

172 (46.74)

142 (38.59)

2 (0.54)

2 (0.54)

0.058

52 (14.13)

67 (18.12)

0.133

None

c

Second Insurance (public or
commercial)

ES, exome sequencing; IQR, interquartile range
a

All p-values from chi-square tests unless otherwise noted;

test

215

b

c

Wilcoxon rank-sum test; Fisher’s exact

Figure 2. Index admission length of stay (days) for patients who did and did not have ES

ES, exome sequencing
p<0.001
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Table 3. Outcomes

All Patients

No-ES Cohort

ES Cohort

p-

(n = 736)

(n = 368)

(n = 368)

valuea

205 (27.85)b

95 (25.82)

102 (27.72)

0.560

(%)

686 (93.21)

337 (91.58)

349 (94.84)

0.079

Survival to 1 year, n (%)

607 (82.47)

312 (84.78)

295 (80.16)

0.099

period, n (%)

570 (77.45)

296 (80.43)

274 (74.46)

0.052

Age at death, days,

69.5 (18–335),

44.5, (7.5–

121.5 (40–

median (IQR), mean

240.90

335), 247.29

335), 236

Diagnostic yield, n (%)
Survival to 28 days, n

Alive at end of study

0.136c

ES, exome sequencing; IQR, interquartile range
a

All p-values from chi-square tests unless otherwise noted

b

Additional 8 diagnoses made by chromosomal microarray in ES cohort not included

in ES diagnostic yield
c

Wilcoxon rank-sum test
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Table 4. Molecular Diagnosis
(1)

(2)

(3)

(4)

All Patients

All Patients

No-ES

ES Cohort

Cohort
Molecular Diagnosis

OR

OR

OR

OR

Exome Sequencing

1.145

1.000

0.997

1.183

0.841

(0.178)

(0.177)

(0.313)

(0.216)

0.576***

0.579***

0.670

0.499***

(0.103)

(0.104)

(0.175)

(0.129)

0.998

0.998

0.996*

1.001

(0.002)

(0.002)

(0.003)

(0.002)

0.978

0.986

1.574

0.520*

(0.240)

(0.242)

(0.544)

(0.200)

2.047

2.108

2.404

1.943

(0.992)

(1.017)

(2.255)

(1.157)

2.925***

2.983***

2.717*

3.159**

(1.091)

(1.111)

(1.639)

(1.546)

1.322

1.333

0.991

1.398

(0.472)

(0.476)

(0.567)

(0.691)

1.244

1.237

1.028

1.643

(0.258)

(0.256)

(0.307)

(0.502)

(0.201)
Female

Hispanic

DOL Genetics consult

Unit

a

CVICU

PICU

PCU

Other Unit

Point of Origin

b

Transfer Center
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Self Referral

Clinic or Physician Referral

Admission Year

1.217

1.206

0.995

1.495

(0.404)

(0.400)

(0.473)

(0.724)

2.488***

2.465***

2.329

3.264**

(0.859)

(0.850)

(1.208)

(1.608)

1.186

1.157

0.834

2.444

(1.171)

(1.136)

(1.253)

(3.458)

0.504

0.499

0.293

1.436

(0.497)

(0.490)

(0.442)

(2.005)

0.474

0.466

0.276

1.214

(0.465)

(0.454)

(0.412)

(1.692)

0.662

0.648

0.448

1.271

(0.647)

(0.630)

(0.667)

(1.766)

0.412

0.406

0.178

1.223

(0.403)

(0.395)

(0.266)

(1.698)

0.471

0.473

0.139

1.590

(0.469)

(0.469)

(0.219)

(2.224)

0.605

0.658

1.119

0.250

(0.601)

(0.646)

(1.687)

(0.348)

726

726

362

364

c **

2012

2013

2014

2015

2016

2017

Constant

n

ES, exome sequencing; OR, odds ratio; DOL, days of life; NICU, neonatal intensive care unit; CVICU,
cardiovascular intensive care unit; PCU, progressive care unit; PICU, pediatric intensive care unit
a

b

c

NICU base category; Inborn base category; 2011 base category

**Year variables jointly significant at the 5% level in Model 1
Standard errors in parentheses
*** p<0.01, ** p<0.05, * p<0.1
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Figure 3. Survival by ES cohort

ES, exome sequencing
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Table 5. Cox proportional hazards regression model

Survival

(1)

(2)

(3)

(4)

(5)

(6)

All

All

All

All

No-ES

ES Cohort,

Patients,

Patients,

Patients,

Cohort,

Unit

28-day

365-day

Unit

Unit

Strata

Survival

Survival

Strata

HR

HR

HR

HR

1.280

0.608

1.202

1.353*

(0.207)

(0.191)

(0.221)

(0.222)

1.535**

1.153

1.371

(0.260)

(0.378)

1.181

Patients

Exome

a

a

Strata

a

a

HR

HR

1.577***

1.186

1.918***

(0.268)

(0.267)

(0.318)

(0.431)

1.460

1.101

1.184

1.307

0.957

(0.189)

(0.440)

(0.201)

(0.192)

(0.333)

(0.207)

1.125

1.420

1.048

1.098

1.342

1.080

(0.185)

(0.431)

(0.197)

(0.182)

(0.338)

(0.243)

7.006***

20.304**

7.613***

1.000

1.000

1.000

(2.141)

(24.296)

(2.506)

(0.000)

(0.000)

(0.000)

1.369

1.898*

1.473*

1.000

1.000

1.000

(0.285)

(0.640)

(0.339)

(0.000)

(0.000)

(0.000)

1.038

0.000

0.691

1.000

1.000

1.000

(0.383)

(0.000)

(0.365)

(0.000)

(0.000)

(0.000)

0.696

0.000

0.354*

1.000

1.000

1.000

(0.265)

(0.000)

(0.217)

(0.000)

(0.000)

(0.000)

Sequencing

Molecular
Diagnosis

Female

Hispanic

PICU

b

CVICU

PCU

b

b

Other Unit

b
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DOL Genetics

0.997**

0.861***

0.995***

0.996***

0.996*

0.995**

(0.001)

(0.035)

(0.002)

(0.001)

(0.002)

(0.002)

1.367*

1.242

1.360

1.434**

1.272

1.430

(0.233)

(0.387)

(0.262)

(0.247)

(0.329)

(0.339)

724

724

724

724

361

363

consult

Medicaid

n

ES, exome sequencing; HR, hazard ratio; CVICU, cardiovascular intensive care unit; PCU,
progressive care unit; PICU, pediatric intensive care unit; DOL, days of life
a

Survival to end of study period, unless otherwise noted.

b

NICU, neonatal intensive care unit base category

Standard errors in parentheses
*** p<0.01, ** p<0.05, * p<0.1

222

Figure 4. Survival by hospital unit, all patients

ES, exome sequencing; NICU, neonatal intensive care unit; CVICU, cardiovascular intensive care
unit; PCU, progressive care unit; PICU, pediatric intensive care unit
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Figure 5. Survival by diagnosis category and cohort

ES, exome sequencing
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Exome Sequencing for Critically Ill Infants Compared to Standard Diagnostics:
A Retrospective Analysis of Clinically Matched Cohorts

Supplementary Appendices

Supplementary Materials and Methods
Phenotypic Characterization of Patients
To generate standardized information on phenotypic characteristics across
patients, we extracted details about clinical presentation from the initial Genetics
consult note (which contains the most extensive and detailed assessment of the
patient’s clinical features) and index admission discharge note. Relevant information
was entered into a natural language processing application that generated a set of
human phenotype ontology (HPO) terms for each patient, intended to capture
clinical presentation at the time of the Genetics team’s assessment. Careful attention
was given to avoid inclusion of “pertinent negatives,” information from birth or family
history, or phenotypic hallmarks of differential diagnoses contained within the note,
and the HPO terms for each patient were curated by hand for accurate
representation of the note.

Selection of Matched Controls
To determine comparable cohorts of patients who did and did not have ES,
we calculated a propensity score for each patient. This method allows adjustment for
confounding when assessing multiple outcomes.42,43 The propensity score was used
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to represent multiple HPO terms and other relevant factors as a one-dimensional
score.44 We generated a binary variable for each HPO identification (ID) number
appearing in the data. HPO ID numbers were used instead of terms themselves to
ensure synonymous terms did not appear as separate variables. Granularity was
preserved; we did not use hierarchical processing to map to higher order terms
(although in many cases, multiple levels of terms were generated). HPO term
variables with count fewer than 10, meaning that the term was observed in fewer
than 10 patients, were dropped, leaving 340 term variables. Based on clinician
consensus, another 33 term variables were dropped because they related to
transient clinical characteristics, such as fever or emesis, not relevant for making a
diagnosis. HPO terms were selected for inclusion in the propensity score model
using a backward automated variable selection process (p-value for removal = 0.1).
We calculated a propensity score, which is the estimated probability of having
ES conditional on measured covariates, for each patient using a binary logistic
regression model with ES as the dependent variable that included indicator variables
for: gender, the unit in which the initial Genetics consult was performed, initial
Genetics consult date (quartile of study period), age (days) at first genetics consult
(quarter of year), and HPO terms. After predicting propensity score for each patient,
each ES patient was matched to one most phenotypically similar No-ES patient from
among all potential No-ES patients using a greedy matching algorithm based on the
linear predictor of the propensity score. Compared to differences between ES
patients and the entire group of No-ES patients prior to matching, the matching
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procedure successfully reduced differences in covariates between ES and No-ES
patients in the final cohorts.

Supplementary Tables and Figures

Figure S1. Uptake by exome sequencing test form
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Figure S2. Consults and diagnostic yield by attending geneticist
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Initial genetics consult note: percent of initial genetics consult notes among included patients listed as author
ES order consult note: percent of exome sequencing (ES) order consult notes among ES order consult notes listed as author
Molecular diagnosis: percent of patients for whom performed initial genetics consult that received molecular diagnosis by genetic test other
than ES
ES diagnosis: percent of patients for whom ES consult note author who received a diagnosis by ES

Figure S3. Form of exome sequencing orders by attending geneticist

ES, exome sequencing
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Table S4. Genetic diagnoses and the diagnostic tool with which they were identified in the
No-ES cohort

Frequency

Percent

17q25.3 deletion

1

1.05

1p36 deletion

1

1.05

30 Mb duplication seen on 15q11.1q21.2

1

1.05

6q deletion

1

1.05

Aicardi-Goutierres syndrome

1

1.05

Apert syndrome

1

1.05

Autosomal recessive polycystic kidney disease

1

1.05

Biotinidase deficiency

1

1.05

Cat eye syndrome

2

2.11

CHARGE syndrome

4

4.21

Chromosome 1 duplication

1

1.05

Chromosome 1 unbalanced rearrangement

1

1.05

Classic Galactosemia

1

1.05

Cobalamin C deficiency

1

1.05

Complex rearrangement of chromosome 8p

1

1.05

Congenital adrenal hyperplasia

1

1.05

Congenital Central Hypoventilation Syndrome (CCHS)

1

1.05

Congenital Tufting Enteropathy

1

1.05

Copy number gain of chromosome bands 18q11.1 to q11.2

1

1.05

Copy number loss of chromosome band 6q26q27 of

1

1.05

Molecular Diagnosisa
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approximately 6.907 Mb
Cornelia de Lange syndrome

1

1.05

Cystic fibrosis

1

1.05

De novo 2.4 megabase duplication on chromosome 13q14.11

1

1.05

1

1.05

1

1.05

approximately 1.714 Mb

1

1.05

De novo loss on 4q21

1

1.05

DiGeorge/Velocardiofacial syndrome

8

8.42

DMD duplication

1

1.05

Gaucher disease

1

1.05

Hereditary folate malabsorption

1

1.05

Kleefstra syndrome

1

1.05

Large 11Mb deletion of chromosome 1q4.42.34

1

1.05

LOSS of 5q15q23.2 involving the APC gene

1

1.05

Loss on chromosome 17q12

1

1.05

Maternally inherited UPD 14

1

1.05

Microvillus inclusion disease

1

1.05

Miller-Dieker syndrome

1

1.05

Mosaic Trisomy 8

1

1.05

Mosaicism for partial trisomy/tetrasomy of distal chromosome13q

1

1.05

De novo 52 Mb gain on 3q24q29 due to unbalanced 3q;15p
translocation
De novo copy number LOSS within chromosome bands
19q13.42q13.43
De novo gain of chromosome band 5q23.1q23.2 spanning

231

(13q32.3q34)
Mosaicism for trisomy 18

1

1.05

1

1.05

1

1.05

Bixler syndrome

1

1.05

Neurofibromatosis-Noonan syndrome

1

1.05

Noonan Syndrome

2

2.11

Pallister-Killian syndrome

1

1.05

Partial trisomy 18 (~35 Mb)

1

1.05

Rhizomelic condrodysplasia punctata (RCDP)

1

1.05

Russell Silver syndrome

1

1.05

Spinal muscular atrophy

2

2.11

Stickler syndrome

2

2.11

Tetrasomy/AOH of chromosome 9

1

1.05

Duplication of part of CALM2

1

1.05

Trisomy 13

4

4.21

Trisomy 18

3

3.16

Trisomy 21

12

12.63

Trisomy 22

2

2.11

Turner syndrome

1

1.05

Multiple congenital anomalies-hypotonia-seizures syndrome
(MCAHS1)
Multiple copy number GAINS within chromosome band Xq28,
suggestive of a complex rearrangement
Mutation seen in individuals with the clinical diagnosis of Pfeiffer
syndrome (severe), Crouzon syndrome (severe), and Antley-
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Unbalanced translocation

2

2.11

Walker-Warburg syndrome

1

1.05

Williams syndrome

1

1.05

Williams syndrome spectrum

1

1.05

Total

95

100

CMA/FISH/karyotype

68

71.58

Gene panel

9

9.47

Single gene sequencing; deletion/duplication analysis

18

18.95

Total

95

100

Molecular Diagnostic Tool

ES, exome sequencing; CMA, chromosomal microarray; FISH, fluorescence in situ
hybridization
a

solved or probably solved/causal or probably causal
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Table S5. Genetic diagnoses and the diagnostic tool with which they were identified in the ES
cohort

Frequency

Percent

defects and skeletal malformations

1

0.9

Aromatic L-amino acid decarboxylase deficiency (AADCD)

1

0.9

1

0.9

encephalopathy

1

0.9

Bardet-Biedl syndrome 1 (BBS1)

1

0.9

cardiomyopathy, dilated, 1FF

1

0.9

cardiomyopathy, familial hypertrophic 2 (CMH2)

1

0.9

CFAP52-related disorder

1

0.9

CHARGE syndrome

2

1.8

Coffin-Siris syndrome 4

1

0.9

COL12A1 related disorder

1

0.9

Combined oxidative phosphorylation deficiency 12 (COXPD12)

1

0.9

congenital disorder of glycosylation

1

0.9

Costello syndrome

1

0.9

Culler-Jones Syndrome (GLI2)

1

0.9

D-bifunctional protein deficiency

1

0.9

de novo likely pathogenic variant in SHANK3

1

0.9

Molecular Diagnosis by ESa
ABL1-associated syndrome characterized by congenital heart

arthrogryposis, renal dysfunction and cholestasis syndrome 1
(ARCS1)
autosomal dominant profound neonatal hypotonia, seizures and
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de novo missense variant in CTCF

1

0.9

de novo novel variant in BCAP31

1

0.9

Denys-Drash syndrome

1

0.9

epileptic encephalopathy early infantile

4

3.6

Familial Hemophagocytic Lymphohistiocytosis type 2

1

0.9

Fanconi anemia

1

0.9

Fanconi anemia complementation group D1 (FANCD1)

1

0.9

Gaucher disease type 2

1

0.9

generalized arterial calcification of infancy

1

0.9

Glycogen storage disease type Ia

1

0.9

glycogen storage disease type IV (GSD IV)

1

0.9

granulomatous disease, chronic, X-linked (CGD)

1

0.9

hepatic venoocclusive disease with immunodeficiency (VODI)

1

0.9

insulin-like growth factor 1 resistance (IGF1RES)

1

0.9

seizures, and distal limb anomalies

1

0.9

Jeune syndrome

1

0.9

Joubert syndrome

2

1.8

Kabuki syndrome

5

4.5

LAS1L-related intellectual disability

1

0.9

left ventricular noncompaction

1

0.9

lipoyltransferase 1 deficiency

1

0.9

Lowe syndrome

1

0.9

malignant migrating partial seizures of infancy

1

0.9

intellectual developmental disorder with dysmorphic facies,
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mandibulofacial dysostosis with microcephaly

1

0.9

Marshall syndrome (MRSHS)

1

0.9

MECP2 related disorder

2

1.8

Megalencephaly-capillary malformation syndrome (MCAP)

1

0.9

mental retardation, autosomal dominant 31

1

0.9

mental retardation, X-linked 9

1

0.9

microcephaly 5, primary, autosomal recessive (MCPH5)

1

0.9

1

0.9

retardation B1 (MDDGB1)

1

0.9

myopathy, centronuclear, 1 (CNM1)

2

1.8

nemaline myopathy

2

1.8

nephronophthisis 3 (NPHP3)

1

0.9

dysplasia

1

0.9

Noonan syndrome

9

8.11

novel, de novo BICD2 VUS

1

0.9

OFD1 mutation

1

0.9

Ornithine transcarbamylase (OTC) deficiency

1

0.9

Orofaciodigital syndrome

1

0.9

pancreatic agenesis and congenital heart defects (PACHD)

1

0.9

parietal foramina 2 with modulating effects from TWIST1 variant

1

0.9

Pfeiffer syndrome (PS) type 1

1

0.9

Microcephaly with Pontine and Cerebellar Hypoplasia
(MICPCH)
muscular dystrophy-dystroglycanopathy congenital with mental

Neurofibromatosis Type 1 and acamptomelic camptomelic
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Pompe disease

3

2.7

pyridoxine-dependent epilepsy (PDE)

1

0.9

deficiency)

2

1.8

RARS-related leukodystrophy

1

0.9

renal tubular dysgenesis (RTD)

1

0.9

restrictive dermopathy

1

0.9

Rett syndrome

1

0.9

SCN1A-related seizure disorder

1

0.9

(SRTD3)

1

0.9

Smith-Kingsmore syndrome (SKS)

1

0.9

split-hand/foot malformation 6 (SHFM6)

1

0.9

titinopathy

1

0.9

Townes-Brocks syndrome

1

0.9

transient infantile liver failure (LFIT)

1

0.9

transposition of the great arteries dextro-looped 3 (DTGA3)

1

0.9

TRMU-associated transient infantile liver failure

1

0.9

TTN compound heterozygous variants

1

0.9

microcephaly)

1

0.9

Walker-Warburg syndrome

1

0.9

pyruvate decarboxylase E1 component deficiency (PDHE1

short-rib thoracic dysplasia 3 with or without polydactyly

VUS in gene associated with lissencephaly 4 (with
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Molecular Diagnosis by CMA
solved by CMA; 10 Mb loss in 15q11q13

1

0.9

solved by CMA; 5.9 Mb deletion in chromosome 2q37.2q37.3

1

0.9

solved by CMA; de novo, loss of 2p14p13.3 (B<P10)

1

0.9

solved by CMA; loss 4q34.1q35.2

1

0.9

solved by CMA; Trisomy 21

2

1.8

der(6)t(X;6)(q26;q27)

1

0.9

solved by CMA; Xp22.31p22.33 loss

1

0.9

Total

111

100

solved by CMA; unbalanced translocation, 46,XY,

ES, exome sequencing; CMA, chromosomal microarray; FISH, fluorescence in situ
hybridization
a

solved or probably solved/causal or probably causal
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Table S6. Outcomes by exome sequencing test form

Critical Trio
Proband ES

Trio ES

ES

p-

(n = 227)

(n = 54)

(n = 87)

valuea

Diagnostic yield, n (%)

61 (26.87)

13 (24.07)

28 (32.18)

0.523

Survival to 28 days, n (%)

213 (93.83)

52 (96.30)

84 (96.55)

0.544

Survival to 1 year, n (%)

182 (80.18)

45 (83.33)

68 (78.16)

0.757

period, n (%)

163 (71.81)

44 (81.48)

67 (77.01)

0.283

Age at death, days,

133 (36.5–

182.5 (29–

92.5 (52–

median (IQR), mean

399.5), 276.30b

330), 188.40c

181), 130.85d

Alive at end of study

ES, exome sequencing
a

All p-values from one-way ANOVA;

b

n = 64; c n = 10; d n = 20
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0.151

Table S7. Medical management change, ES cohort

ES
All ES Patients

ES Diagnosed

Undiagnosed

Clinical Impact Category, n (%)

(n = 368)

(n = 102)

(n = 266)

Subspecialist or Consult Referral

54 (14.67)

35 (34.31)

19 (7.14)

Surveillance Plan

16 (4.35)

12 (11.76)

4 (1.50)

Screening Recommendation

16 (4.35)

6 (5.88)

10 (3.76)

Medication Change

11 (2.99)

8 (7.84)

3 (1.13)

Redirection of Care

6 (1.63)

3 (2.94)

3 (1.13)

Diet Prescription

5 (1.36)

3 (2.94)

2 (0.75)

Total

81 (22.01)

49 (48.04)

32 (12.03)

ES, exome sequencing
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Cost-Effectiveness Analysis of Clinical Exome Sequencing Compared to
Standard Diagnostics for Critically Ill Infants

Target Journal: Genetics in Medicine

Abstract
Purpose: Estimate the cost-effectiveness of clinical whole exome sequencing (ES)
as a diagnostic tool, compared to usual diagnostic care, for patients with a
suspected genetic etiology admitted to intensive care within the first year of life.
Methods: In this retrospective cohort study, we analyzed ES application at a
children’s hospital December 2011 – June 2017. Diagnostic yield and survival were
compared between cohorts of clinically similar patients who did (n=368) and did not
(n=368) have ES in diagnostic workup, along with total and diagnostic-related costs
of index admission and year.
Results: Molecular diagnostic yield (25.8% No-ES, 27.7% ES; p=0.56) and 1-year
survival (84.8% No-ES, 80.2% ES; p=0.10) were similar between cohorts, while ES
patients had higher cost of admissions, diagnostic investigations, and genetic tests
(all p<0.01). Incremental diagnostic pathway cost per additional diagnosis was
$550,874 for ES patients, which was reduced to $46,489 when comparing ES cohort
to patients for whom ES was recommended but not performed.
Conclusion: ES is an important tool for diagnosing critically ill newborns and
infants, as are chromosomal microarray and targeted genetic testing, yet it does not
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appear cost-effective during initial clinical uptake. Further work is needed to develop
clinical guidelines for appropriate application of ES.

Introduction
Evaluation of patients with suspected genetic disorders is important to
pediatric and neonatology practice due to incidence of genetic diseases that
manifest at birth or soon after. Neonatal intensive care has been upheld as the
setting in which clinical genomic sequencing (cGS) has the most promise for both
clinical and economic impact.1-3 Diagnostic workup for a suspected genetic condition
is associated with longer, more costly neonatal intensive care unit (NICU)
admissions, and diagnosis of genetic-based disease is associated with longer
inpatient stays and higher cost of care compared to other pediatric chronic disease
etiologies.4-6 Based on national estimates, up to 14% of inpatient pediatric
admissions are associated with genetic disease, at a cost of up to $77,000 higher for
neonatal admissions and up to $17,000 for pediatric admissions, compared to
patients who did not have a genetic disease diagnosis.7
Exome sequencing (ES) has demonstrated ability to identify diagnoses in
critically ill newborns and infants, clinical uptake is increasing, and evidence of
overall clinical utility is building.8-12 However, clinical guidelines for ES application
are not yet developed. Compared to the current standard genetic diagnostic workup,
including chromosomal microarray (CMA) and targeted gene sequencing,13,14 very
little is known about the population-level impact of ES on health outcomes or cost of
care. Cost-effectiveness evidence is severely lacking, especially within the US
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health care system.12,15 Economic evaluation can inform appropriate clinical use and
patient access to cGS.
Among the few ES economic evaluations to date, the most robust have been
based on data generated within a research framework on the efficacy of ES to make
molecular diagnoses.16,17 Although the goal of cost-effectiveness analysis is to
assess an intervention’s impact in practice rather than a trial environment,18,19
conclusions of these modeling studies reflect study inclusion criteria, such as clinical
presentation restrictions and requirement of previous non-diagnostic tests.
Therefore, it may not be possible to extrapolate results to the real-world clinical
setting. The impact of clinically applied ES on outcomes and costs compared to
usual diagnostics in a large group of patients with suspected genetic disease has not
yet been examined.
The aim of this paper is to estimate the cost-effectiveness of ES as a
diagnostic tool for infants less than 1 year of life with a suspected genetic etiology in
intensive care settings. We study real-world ES application during the initial 5 years
of uptake at a large children’s hospital by comparing clinically similar cohorts of
patients who did and did not have ES as part of a diagnostic workup. We analyze
and compare cost of care, diagnostic yield and survival outcomes for both cohorts,
and estimate cost-effectiveness using electronic medical record and hospital cost
data over the time horizon of the inpatient hospital stay and within one year of the
initial Genetics service consultation.
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Methods
Study Design
We analyzed ES application at a large children’s hospital located in an
academic medical center from December 2011 through June 2017. The study
population was undiagnosed patients with a suspected genetic etiology who had an
intensive care unit (ICU) admission within the first year of life. Patients were
admitted to Texas Children’s Hospital (TCH) in Houston, TX, a large children’s
hospital with 33,000 total admissions in 2017 and the highest level (Level IV) of
neonatal intensive care.20 All TCH ES orders were sent to Baylor Genetics (BG)
diagnostic laboratory.
Documentation of genetics consultation in the electronic medical record
(EMR) indicated a suspected genetic etiology in the patient. The index admission
was defined as the admission during which the initial genetics consult was ordered,
and the index year was defined as the 365 days after the initial genetics consult took
place. The 1-year time horizon allows estimation of ES impact on care provision and
costs, even if results were not returned before index admission discharge.
We employed a retrospective cohort study design in which ES was the
exposure factor. Included patients met the following criteria: (1) ICU admission within
the first year of life; (2) inpatient genetics consultation documented in the medical
record; (3) inpatient stay and genetics consultation occurred between December 1,
2011 and June 30, 2017. The ES cohort consisted of patients who met the following
additional criteria: (1) received ES as part of the diagnostic pathway; (2) ES ordered
within the first year of life.
244

Among included patients, patients who did not receive ES were evaluated for
inclusion in the comparator cohort (No-ES). Methods for patient matching are
detailed elsewhere.21 Briefly, patients included in the No-ES cohort were those
propensity score-matched to ES cohort patients. The propensity score was
calculated based on patient’s age at first genetics consult (by quarter of year),
hospital unit in which the genetic consult occurred (NICU; pediatric intensive care
unit, PICU; cardiovascular intensive care unit, CVICU; progressive care unit, PCU;
other unit), consult date (by quarter of study period), sex, and phenotypic
characteristics (Human Phenotype Ontology terms).
Data on patient characteristics, genetics consultation, and clinical outcomes
were collected through retrospective EMR review. ES order and report data were
obtained from BG, and cost data were obtained from hospital administrative records.
Data analysis was performed using Stata/IC 15.1 (StataCorp, College Station, TX).

Interventions and Comparator
Patients in the ES cohort had one of three ES forms: sequencing of the
patient only (proband ES), sequencing of the patient and both parents (trio ES) and
sequencing of the patient and both parents with a reduced turnaround time (critical
trio ES). Patients in the No-ES cohort had a diagnostic workup that did not include
ES but may have included other forms of genetic testing such as chromosomal
microarray (CMA), fluorescence in situ hybridization (FISH), single gene or gene
panel sequencing, deletion/duplication analysis, or methylation studies. A clinician
may have ordered ES for patients in the No-ES cohort without it being performed for
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reasons such as lack of parental consent or cancelation by lab due to insufficient
blood sample; we refer to these patients as the ES-recommended group.

Outcomes
Main outcome measures considered in this study were establishment of a
molecular diagnosis and 1-year survival. Molecular diagnosis was defined as the
identification of a specific genetic change interpreted by a clinician as the cause or
probable cause of the patient’s clinical presentation. Subgroup analyses were
performed based on patient characteristics intended to generate evidence to inform
clinical guideline development and decision-making. Subgroups were: patients
admitted in 2016 and 2017 (after all three ES forms were available), patients who
survived to 28 days of life, patients in the NICU during the genetics consultation, and
patients in the ES-recommended group.

Cost Analysis
Costs were calculated using the hospital perspective. We analyzed total index
admission and index year cost, cost by hospital billing category (UB revenue code),
cost of the investigator-defined diagnostic pathway, and cost of genetic tests. To
mitigate the influence of length of stay (LOS) on total index admission cost, we
calculated the proportion of the total index admission cost accounted for by costs in
each billing category, as well as the diagnostic pathway costs and genetic testing
costs, at the patient level.
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As there is no standard diagnostic pathway for the heterogeneous population
of patients in this study, we defined the diagnostic pathway as clinical tests
performed for the purpose of making a diagnosis rather than routine care or
monitoring. An inclusion rule of “first,” “none,” or “all” was determined for each test
on a list of all laboratory and radiology tests performed for study patients. The rule
was used to determine which, if any, instance of a specific test on a patient was
performed as part of the diagnostic pathway and applied to cost data to sum the cost
of diagnostic pathway investigations. Similarly, we identified each genetic test in the
list of laboratory tests and applied these rules to the cost data to determine the cost
of genetic tests. In each patient’s cost data, each line-item labeled “miscellaneous
referred test” was cross-referenced by service date to tests ordered in the EMR as
miscellaneous referred tests to determine whether it was a genetic test or not. All
tests determined to be genetic tests were included in both the diagnostic pathway
and genetic test cost categories. Genetic test and diagnostic pathway costs are not
necessarily inclusive or exclusive of the hospital administrative billing categories.
For analysis of cost data, which has a skewed distribution, we used log
transformations and non-parametric statistical tests. We used ordinary least squares
(OLS) regression on logged total cost of index admission to estimate the impact of
patient characteristics on index admission cost. We employed Wilcoxon rank-sum
and Kruskall-Wallis tests to compare cost categories between cohorts and ES forms,
respectively. Chi-square and Wilcoxon rank-sum tests were used for other
comparisons as appropriate. Relevant cost analyses were performed for each
subgroup of patients.
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We describe cost of index admission, index year, and diagnostic pathway and
genetic test during the index admission and the year. We calculated the cost of the
index admission and the diagnostic pathway per diagnosis and percent 1-year
survival. We calculated incremental cost-effectiveness ratios (ICERs) for incremental
index admission diagnostic pathways costs and incremental diagnoses, and for
incremental index admission genetic test costs and incremental diagnoses. For each
ICER, 95% confidence intervals were constructed from 1,000 bootstrap replicates.22
All costs were adjusted to 2017 USD$ using the historical Consumer Price Index for
All Urban Consumers (CPI-U): U.S. city average per year.

Results
Outcomes
The patient matching process successfully reduced variation in observable
characteristics between patients in the No-ES and ES cohorts. Outcomes are
reported elsewhere in more detail.21 Characteristics of the patient population are
given in Table 1. Molecular diagnostic yield (25.8% No-ES, 27.7% ES; p=0.56) and
1-year survival (84.8% No-ES, 80.2% ES; p=0.10) were similar for both cohorts
(Table 2). In the ES cohort, 8 additional diagnoses were made with CMA not
included in the ES diagnostic yield. Among patients admitted in 2016 and 2017,
molecular diagnostic yield (p=0.02) was higher in the ES cohort than the No-ES
cohort, as there was lower yield in the No-ES cohort over this period (Table 3).
In the ES cohort, ES resulted before discharge from the index admission for
106 (28.8%) patients. A significantly higher proportion of patients who had critical trio
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were diagnosed before discharge (24.1%) than patients who had proband or trio
tests (5.7%, p<0.01). Prior to the lab reporting results, 46 (12.5%) patients were
deceased, and 11 patients who expired while in the hospital later had a diagnostic
finding. For ES results communicated after patient discharge, results were returned
121 days (median) after discharge.

Costs
Distributions of total cost of index admission and index year by cohort are
presented in Figure 1 and Figure 2, respectively. Index admission total cost,
diagnostic pathway cost, and genetic test cost were higher for ES patients than NoES patients (Table 2). Cost of the index admission diagnostic pathway per diagnosis
were $24,763 [95% bootstrapped CI $19,956—$29,569] for the No-ES cohort and
$60,869 [$49,749—$71,953] for the ES cohort. ES cohort Incremental index
admission diagnostic pathway cost per additional diagnosis was $550,874. The
incremental cost of index admission genetic tests per additional diagnosis was
$410,614.
Index year total cost, diagnostic pathway cost, and genetic test cost were also
higher for the ES cohort. Controlling for length of stay and other features of
hospitalization, ES was associated with approximately 17.7% higher total cost of
index admission (p<0.01, Table S1). Within the ES cohort, genetic diagnosis was
associated with higher index admission costs (p<0.01).
Subgroup analyses showed similar results. Among patients admitted in 2016
and 2017, costs in all categories (total, diagnostic pathway, and genetic tests) were
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significantly higher in the ES cohort (Table 3). For patients who survived longer than
28 days, costs were higher in the ES cohort in all categories (Table S2). Among
patients with genetics consultation in the NICU, costs were significantly higher in the
ES cohort (Table S3). Within the ES cohort, total cost of the index admission and
index year were not significantly different between patients with each form of ES, but
the cost of diagnostic pathway and genetic testing was significantly higher for
patients with critical trio ES (Table S4).
Within the No-ES cohort, there were 36 patients for whom ES was
recommended but not performed. Table 4 compares costs for the ES-recommended
group and ES cohort. Molecular diagnostic yield was significantly higher in the ES
cohort (102, 27.7%) than the ES-recommended but not performed group (2, 5.6%).
This difference in effectiveness results in a lower incremental cost per diagnosis.
Therefore, even though costs were higher in the ES group, the incremental
diagnostic pathway cost per additional diagnosis was lower for ES-recommended
than for other comparator groups at $46,489. The incremental genetic test cost per
additional diagnosis was $36,246.
A comparison of cost components of the index admission is presented in
Table 5 and Figure 3. As a proportion of the index admission total cost, cost of the
diagnostic pathway was higher for the ES cohort (12.7%) than the No-ES cohort
(7.9%, p<0.001). Similarly, genetic tests accounted for 8.4% of the index stay cost in
the ES cohort and 3.7% in the No-ES cohort (p<0.001). By billing category,
diagnostic UB revenue code cost was not different between cohorts, but laboratory
cost made up a larger share of admission cost in the ES cohort (15.2%) than the No250

ES cohort (9.9%, p<0.001). Nursing care accounted for the largest share of index
admission total cost in both cohorts, although it represented a smaller share in the
ES cohort (56.2%) than the No-ES cohort (60.7%, p<0.001). Pharmacy, radiology,
and therapeutic billing categories made up similar shares of admission cost in both
cohorts (all p>0.58).
Diagnoses of 4 conditions were made in both cohorts: CHARGE syndrome,
Noonan syndrome, Walker-Warburg syndrome, and Gaucher disease. Mean cost of
the diagnostic pathway and genetic tests, as well as the total cost of the index
admission and year, were higher for patients with the same ultimate diagnosis in the
ES cohort for each diagnosis (Table S5; individual data not shown). Average length
of index admission stay was longer for patients in the ES cohort than patients with
the same diagnosis in the No-ES cohort for 3 of the 4 diagnoses.

Discussion
Our findings suggest that ES is not cost-effective, in terms of summary effect
measures of diagnostic yield and percent survival, as applied during the initial 5
years of clinical uptake at one large academic children’s hospital. ES patients had a
longer and more costly index inpatient admission than clinically similar patients who
did not have ES, on average. Our broad patient population of newborns and infants
with suspected genetic disease allowed analysis of the real-world impact of ES on
costs. Our findings suggest that ES is not cost-effective when applied generally to
critically ill patients with suspected genetic disease presentations within the first year
of life. Because the contribution of large chromosome structural rearrangements and
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gene copy number variations present in this population, chromosomal analyses
identified a diagnosis in a roughly equal proportion of patients and were associated
with lower costs.
Although the number of diagnoses out of the total number of patients in each
cohort was similar, the diagnoses made in each cohort were qualitatively different
based on the types of changes identifiable by tests used in each group (e.g.,
structural changes in the No-ES cohort versus single-gene sequence variants in the
ES cohort). Some patients in the No-ES cohort may not have had ES because the
clinician determined ES was not necessary or was the inappropriate genetic
diagnostic tool to use.
However, for some patients in the No-ES cohort, not having ES was the result
of factors external to the clinical decision-making process, which makes these
patients plausibly the best comparison group to ES patients. In these cases where
ES was recommended but not performed, diagnostic yield was significantly lower
than in the ES cohort. Among all of our subgroup analyses, the ICER for diagnosis is
most favorable when comparing the ES cohort to the ES-recommended group of NoES cohort patients. Comparing diagnostic pathway cost in these two groups, an
incremental cost of $46,489 per additional diagnosis may be deemed reasonable by
decision makers, especially considering the backdrop of the high cost of admission
for these patients.
Our identifying assumption that a similar patient may have had ES or not
depending upon who performed the consultation was supported by findings in prior
work in which we find evidence of variability in ES uptake among attending
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geneticists.21 However, we cannot rule out the potential, and results reported herein
suggest, that ES was applied with bias toward more complex patients overall. In the
absence of formal guidelines for ES use, it is difficult to map out details of the clinical
decision-making process regarding ES order, yet it appears that clinicians have
recommended ES in appropriate patients, all things considered. A formal
characterization of this population from a phenotype and clinical presentation
perspective, using more nuanced details than we were able to capture
retrospectively through HPO terms, should be the subject of future work to develop
guidelines for use in other institutions that may have less prior research-based
familiarity with ES than academic physicians ordering ES in this study.
Research that has found ES cost-effective has identified patient populations
in which ES is the correct test by, for example, requiring clinician consensus, study
enrollment, prerequisite non-diagnostic tests, and by using parallel, prospective
study design to analyze the diagnostic pathway with and without cGS for the same
patients.16,23 Results from a cost-effectiveness modeling study in an Australian infant
cohort suggest that ES performed as a first-line test may be cost-saving.16
Evaluating costs in such a setting is analogous to economic evaluation conducted
alongside a randomized controlled trial in that there are threats to external validity
because ES is applied as appropriately as possible. From a payer perspective,
Sabatini and colleagues demonstrated that whether use of ES was cost-saving or
cost-increasing depended upon clinical features of the patient population, the cost of
the test and where it was incorporated in the diagnostic pathway.24 Other studies
have summed costs of non-diagnostic workup prior to diagnostic ES,25-27 that can be
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informative descriptions but lack a necessary comparator group for formal costeffectiveness analysis.
We make a different contribution than studies of controlled ES application by
evaluating impact for a broadly defined patient population. Our approach was
optimal in order to utilize information on the large number of patients who had
already had ES, ensure follow-up time of at least one year over which to measure
outcomes, and enable comparison of multiple outcomes. The time frame of the study
shows early adoption and implementation in the absence of clinical guidelines about
application. Although uptake was variable during early stages of implementation, it is
because of this property that we are able to construct a clinically similar comparison
cohort that did not have ES before ES becomes standard-of-care. In the already
high-cost setting of the NICU, availability of technology should not replace careful
clinical assessment as to whether the patient is a good candidate for ES or not. CMA
and other chromosomal tests remain important diagnostic tools for this patient
population given the substantial burden of chromosomal abnormalities for children
under one year of age in the United States.28,29
Results from the ES-recommended group can support the hypothesis that ES
might be most cost-effective when applied in patients that are difficult or impossible
to diagnose with other modalities. This speaks to the original intended use of ES
upon its availability as a clinical test for patients characterized as “hard to diagnose”
and for whom other tests such as CMA are non-diagnostic. Clearer definition of how
to identify such patients and quicker sequencing turnaround is needed to save cost.
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Limitations
Our study is limited by reliance on outcome data and clinical notation
documented in the EMR, which may not be comprehensive. Administrative cost
data, although reflective of the billing process, may not be entirely accurate or
consistent. For example, there was variability in clinicians’ ES order entry in the
EMR and how ES costs appeared in the cost data. This variability is a hurdle to
performing a sensitivity analysis of the cost of care without ES in the ES cohort, and
the degree to which higher costs for the ES cohort are attributable only to the cost of
ES will be explored further. We are not able to account for care patients received at
other institutions unrecorded in our EMR and administrative system. While this does
not impact our ability to analyze the index admission, we may not capture all
relevant costs over the index year.
Results of this study cannot be used to draw conclusions about optimal
placement of ES within the diagnostic pathway, such as use as a first-line test or
subsequent other non-diagnostic investigations. This analysis only examines
pathways with and without ES; it does not attempt to quantify cost-effectiveness for
ES at a particular point in the diagnostic pathway. Lack of established practice
guidelines on ES makes choice of comparators difficult because each provider may
order sequencing based on different criteria or at a different point in the diagnostic
pathway, and cost-effectiveness is always dependent upon the clinical context.
The majority of ES patients did not have ES results returned during the index
admission, meaning there was little potential for impact on care provision or the
associated cost that would be captured in the cost of the index admission. Some of
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the largest estimated cost savings as a result of neonatal cGS have come from
saving inpatient days in hypothetical counterfactual cases when rapid sequencing
results are returned while patients are admitted (median 23 days from order).30
Because not all ES are ordered as a rapid test, we study the one-year follow-up
period to allow return of results and potential for impact on care. For lengthy index
admissions, the index admission almost entirely eclipses the index year. However,
for patients with shorter, more frequent admissions and clinic visits, we are able to
capture more of the ES impact. The higher costs for the index year ES group mirror
the higher index admission costs. If return of ES results impacted care over the
longer term, we would expect the cost of the index year to be proportionately higher
than the index admission for the No-ES group.
To address the heterogeneity of the patient population, patients were
matched on phenotypic and clinical characteristics, which successfully reduced
observable differences between the cohorts. Even so, the underlying cause of
disease remained diverse within cohorts. Unless each molecular diagnosis is
modeled separately, which is not practical for sample size reasons, patient
groupings will necessarily combine individuals with different genetic etiology.
Heterogeneity presents challenges for modeling costs over a longer time horizon
than the inpatient stay because each distinct molecular diagnosis will have different
prognostic and treatment trajectories. One interpretation of the insignificant
difference in survival supports that the patients were well-matched in severity.
However, more nuanced observations of diagnoses, costs, and clinical course (using
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LOS as a proxy) suggests ES patients may still differ in some unexplained way from
No-ES patients, on average, even for patients with the same ultimate diagnosis.
While diagnostic yield was similar for ES and No-ES patients, we are not able
to address differences in importance of availability of ES as a diagnostic tool with the
ability to test for and detect rare disorders that it, among clinical tests, can uniquely
identify. As highlighted by 2 recent systematic literature reviews of genomic
sequencing, there is a need for more systematic outcomes measurement to enable
health services research and economic evaluation of genomic sequencing.12,15 An
important consideration is the potential utility of ES results – both diagnostic and
non-diagnostic – and implications for the patient and patient’s family that may fall
outside the realm of medical actionability. Number of diagnoses made does not
necessarily convey the perceived utility of the results for either clinical decisionmaking or the patient’s family. Clinicians may use ES results differently than results
from other diagnostic tests, an unremarkable ES result that does not pinpoint a
diagnosis may be more important than non-diagnostic results from other
investigations, and clinicians may perceive outcomes outside of the traditional notion
of medical management changes to be important results of ES.31 Moreover, families
value genetic information for personal as well as medical purposes.32 Further
development of methods to measure clinical utility, in a broader sense, of cGS is
warranted.
There are possible 5 channels to increase cost-effectiveness of ES. First,
reduced turnaround time for results, which would allow greater potential for impact
on LOS and medical management. Second, development of clinical guidelines to
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rule out certain kinds of diagnoses first, such as a requirement of non-diagnostic
CMA, prior to ES order. Third, reanalysis of genetic data and a longer time horizon
over which to measure costs, which can lead to increased diagnostic yield upon
reanalysis of the patient’s previously generated sequence information and potential
impact on care.33,34 Fourth, reduction of ES cost, which may be possible with
increased automation of result interpretation. Fifth, consideration of broader effects
of ES which may flow from both diagnostic and non-diagnostic results. Systematic
categorization and documentation of changes in medical management as a result of
ES results to provide a robust description of utility would advance work in this area.
Development of tools to measure utility to the patient and family should also be
investigated.

Conclusion
ES demonstrated important diagnostic utility for patients with monogenic
disease, yet other genetic tests, especially chromosomal microarray, remain
important given the burden of chromosomal abnormalities in this population. As
clinically applied over the first 5 years, ES does not appear cost-effective as a
diagnostic tool for the broad population of newborns and infants with suspected
genetic disease. Further work is needed to develop outcome measures to capture
utility of both diagnostic ES results and non-diagnostic ES results for clinicians,
patients, and patients’ families and to specify clinical guidelines for appropriate ES
application.
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Tables and Figures
Table 1. Patient Characteristics
No-ES

ES Cohort

p-value

Cohort
Sex, n (%)
Male

203 (55.16)

217 (58.97)

Female

165 (44.84)

151 (41.03)

White/Caucasian

277 (75.27)

289 (78.53)

58 (15.76)

58 (15.76)

22 (5.98)

17 (4.62)

American Indian and Alaska Native

1 (0.27)

1 (0.27)

Unknown

8 (2.17)

3 (0.82)

Non-Hispanic

200 (54.35)

190 (51.63)

Hispanic

162 (44.02)

174 (47.28)

6 (1.63)

4 (1.09)

English

312 (84.78)

294 (79.89)

Spanish

52 (14.13)

69 (18.75)

4 (1.09)

5 (1.36)

0.297

Race, n (%)

Black/African-American
Asian

0.396

Ethnicity, n (%)

Unknown

0.581

Preferred Language, n (%)

Other

Unit of Genetics Consult, n (%)

264

0.219

a

NICU

245 (66.58)

222 (60.33)

0.078

62 (16.85)

70 (19.02)

0.442

Other

36 (9.78)

36 (9.78)

1.00

PCU

17 (4.62)

25 (6.79)

0.204

PICU

8 (2.17)

15 (4.08)

0.138

302 (82.07)

297 (80.71)

0.636

43 (11.68)

49 (13.32)

0.504

Third

13 (3.53)

12 (3.26)

0.839

Fourth

10 (2.72)

10 (2.72)

1.00

92 (25.00)

92 (25.00)

1.00

105 (28.53)

79 (21.47)

0.027

Third

90 (24.46)

95 (25.82)

0.671

Fourth

81 (22.01)

102 (27.72)

0.073

Gestational Age at Birth, weeks, mean (median)

36.40 (37.29)

37.00 (38.00)

0.0711

Mother’s Age at Birth, years, mean (sd)

28.93 (6.27)

Father’s Age at Birth, years, mean (sd)

31.60 (7.55)

CVICU

Age at Genetics Consult (quartile of year), n (%)
First
Second

Genetics Consult Date (quartile of study period), n
(%)
First
Second

f

d

28.39 (6.33)

31 (7.78)

g

e

0.251

c

0.357

c

b

ES, exome sequencing; NICU, neonatal intensive care unit; CVICU, cardiovascular intensive care
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unit; PCU, progressive care unit; PICU, pediatric intensive care unit
a

b

All p-values from chi-square tests unless otherwise noted; Wilcoxon rank-sum test
c

d

e

c

Student’s t-

f

test; n = 360; n = 362; n = 312; n = 316

Table 2. Costs by cohort

a

All Patients

No-ES Cohort

ES Cohort

(n = 736)

(n = 368)

(n = 368)

p-value

95 (25.82)

102 (27.72)

0.560

686 (93.21)

337 (91.58)

349 (94.84)

0.079

607 (82.47)

312 (84.78)

295 (80.16)

0.099

272,600 (401,499)

218,503 (338,489)

326,698 (449,887)

< 0.001

d

338,179 (421,266)

266,768 (357,009)

409,591 (466,617)

< 0.001

d

11,632 (9,429)

6,393 (5,243)

16,871 (9,773)

< 0.001

d

13,886 (10,398)

7,584 (6,018)

20,188 (10,034)

< 0.001

d

Molecular
diagnosis, n (%)

205 (27.85)

b

c

Survival to 28
days, n (%)
Survival to 1 year,
n (%)
Total cost of index
admission, mean
(sd)
Total cost of index
year, mean (sd)
Total cost of index
admission
diagnostic
pathway, mean
(sd)
Total cost of index
year diagnostic
pathway, mean
(sd)
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Total cost of index
genetic tests,
mean (sd)

6,322 (6,533)

2,417 (2,905)

10,227 (6,817)

< 0.001

d

7,239 (7,265)

2,627 (3,633)

11,851 (7,061)

< 0.001

d

Total cost of index
year genetic tests,
mean (sd)

1,499,755
Cost (index admission) per percent 1year survival [95% CI]

e

Cost (index year) per percent 1-year
survival [95% CI]

e

Cost (index admission diagnostic
pathway) per diagnosis, [95% CI]

e

948,413

[1,251,970—

[779,806—1117022]

1,747,540]

1,157,910

1,880,285

[9,77,368—

[1,606,999—

1,338,451]

2,153,570]

24,763

60,869

[19,956—29,569]

[49,784—71,953]

Incremental cost-effectiveness ratio for
index admission diagnostic pathway
diagnoses [95% CI]

e

550,874
[-5,651,018—6,752,766]

Incremental cost-effectiveness ratio for
index admission genetic testing
diagnoses [95% CI]

e

410,614
[-4,106,198—4,927,426]

ES, exome sequencing
a

All costs reported in 2017 USD$

b

Additional 8 diagnoses made by chromosomal microarray in ES cohort not included in ES diagnostic

yield
c

chi-square test;

d

e

95% CI, confidence intervals constructed from 1,000 bootstrap replicates

Wilcoxon rank-sum test
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Table 3. Costs, Patients admitted in 2016 and 2017

a

All Patients

No-ES Cohort

ES Cohort

(n = 257)

(n = 119)

(n = 138)

p-value

19 (15.97)

39 (28.26)

0.019

c

233 (90.66)

102 (85.71)

131 (94.93)

0.011

c

206 (80.16)

92 (77.31)

114 (82.61)

0.288

c

Total cost of index

280,491

217,571

334,747

0.003

d

admission, mean

(370,566)

(273,630)

(430,933)

Total cost of index

338,516

256,202

409,497

year (mean)

(389,571)

(294,373)

(444,964)

Total cost of index

13,048 (8,389)

6,358 (4,249)

14,585 (8,912)

7,671 (5,850)

Molecular

61 (23.74)

b

diagnosis, n (%)
Survival to 28
days, n (%)
Survival to 1 year,
n (%)

(sd)
<0.001

d

18,818 (6,599)

<0.001

d

7,483 (5,107)

20,708 (6,661)

<0.001

d

2,395 (2,206)

12,221 (3,838)

<0.001

d

admission
diagnostic
pathway, mean
(sd)
Total cost of index
year diagnostic
pathway, mean
(sd)
Total cost of index
genetic tests,
mean (sd)
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Total cost of index

8,113 (5,921)

2,749 (2,831)

12,739 (3,472)

<0.001

d

year genetic tests,
mean (sd)
ES, exome sequencing
a

All costs reported in 2017 USD$

b

Additional 2 diagnoses by chromosomal microarray in ES cohort not included in ES diagnostic yield

c

chi-square test

d

Wilcoxon rank-sum test

Figure 1. Total cost of index admission by cohort

ES, exome sequencing
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Figure 2. Total cost of index year by cohort

ES, exome sequencing

270

Table 4. Costs by ES recommended but not performed

a

No-ES Cohort, ES

ES Cohort

recommended (n = 36)

(n = 368)

p-value

Molecular diagnosis, n (%)

2 (5.56)

102 (27.72)

0.004

Survival to 28 days, n (%)

32 (88.89)

349 (94.84)

0.142

Survival to 1 year, n (%)

28 (77.78)

295 (80.16)

0.733

Length of stay, median

35.5, (9.5—58), 43.28

39 (17—83.5), 66.87

0.107

178,135 (172,766)

326,698 (449,887)

0.057

246,097 (263,362)

409,591 (466,617)

0.008

6,568 (5,087)

16,871 (9,773)

<0.001

7,704 (5,147)

20,188 (10,034)

<0.001

2,194 (3,000)

10,227 (6,817)

<0.001

2,450 (3,373)

11,851 (7,061)

<0.001

c

(IQR), mean
Total cost of index
admission, mean (sd)
Total cost of index year,
mean (sd)
Total cost of index
admission diagnostic
pathway, mean (sd)
Total cost of index year
diagnostic pathway, mean
(sd)
Total cost of index genetic
tests, mean (sd)
Total cost of index year
genetic tests, mean (sd)
Incremental cost-effectiveness ratio for index

46,489 [16,701—76,278]

admission diagnostic pathway diagnoses [95% CI]

d

Incremental cost-effectiveness ratio for index
admission genetic testing diagnoses [95% CI]

36,246 [14,578—57,915]
d
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b

ES, exome sequencing; IQR, interquartile range
a

All costs reported in 2017 USD$

b

Wilcoxon rank-sum test unless otherwise noted; chi-square test

d

95% CI, confidence intervals constructed from 1,000 bootstrap replicates

c
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Table 5. Cost drivers, index admission

Cost Category

b

Diagnostic Pathway

a

All patients

All

Mean %

No-ES

Mean %

ES

Mean %

Any

with any

patients,

admission

Cohort,

admission

Cohort,

admission

cost,

cost, mean

mean (sd)

cost, all

mean (sd)

cost, No

mean (sd)

cost, ES

p-

n

(sd)

(n = 736)

Patients

(n = 368)

ES Cohort

(n = 368)

Cohort

value

11,632

11,632

(9,429)

(9,429)

12.73

< 0.001

8.43

< 0.001

736

7,584
10.33

6,322
Genetic Tests

736

273

6322 (6,534)

(6,534)

4,703

4,562

(6,018)

20,188
7.94

2,417
6.08

(2,905)

c

(10,034)
10,227

3.73

3,647

(6,817)
5,477

Diagnostic

714

(6,475)

(6,428)

2.42

(5,691)

2.44

(6,976)

2.41

0.715

Emergency Care

138

1,135 (365)

213 (4,70)

0.47

217 (481)

0.59

208 (460)

0.35

0.796

22,067

22,067

(32,051)

(32,051)

15.21

< 0.001

11,142

10,733

(22,816)

(22,491)

3.16

0.285

155,983

155,983

(222,073)

(222,073)

56.20

< 0.001

Laboratory

736

Medical/Surgical
Supplies

Nursing Care

709

736

13,277
12.55

(20,014)

30,857
9.88

8,662
3.22

(16,834)

12,803
3.27

128,833
58.43

(193,753)

(38,754)

(26,853)
183,133

60.65

(244,435)

Operating Room
Perioperation
Services

616

Organ Acquisition

13

Occupational/Physical
Therapy

595

Pharmacy

736
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Radiology

725

Therapeutic

659

14,360

12,019

9,557

(23,061)

(21,752)

133,468

2,357

(20,665)

(17,790)

4,982

4,027

(6,419)

(6,095)

34,916

34,916

(94,333)

(94,333)

5,180

5,103

(6,094)

(6,081)

18,744

16,783

(44,974)

(42,939)

4.03

(33,989)

4.07

(44,974)

77 (1,373)

0.06

77 (1,272)

0.05

3,952

3,758

(5,995)

(5,909)

4.52

(15,620)

14,480
4.60

1,326
0.31

(12,848)

(4,938)

0.21

(93,880)

1.75

(5,012)

0.41

0.163

1.63

0.313

7.82

0.600

2.77

0.582

(50,154)

4.00

0.861

77 (1,469)

0.07

0.565

1.50

0.553

(21,601)

(6,980)
40,688

8.05

4,088
2.75

0.038

4,832

29,143
7.93

4.44

3,389

3,222
1.64

(26,296)

(94,560)
6,118

2.72

13,481

(6,847)
20,085

18,816
Transport

3

Other

700
a

2,971
1.66
b

(4,259)

4,547
1.82

(7,109)

ES, exome sequencing; All costs reported in 2017 USD$; Cost categories other than Diagnostic Pathway and Genetic Test are by UB
c

Revenue Code; Wilcoxon rank-sum test

Figure 3. Mean index admission total cost by cost category and cohort
(a) Dollar amount

(b) Mean proportion of total index admission cost by cost category and cohort

ES, exome sequencing
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Table S1. Cost of Index Admission Regression Model
(1)
ln(total cost index admission)

(2)

(3)

No-ES
All Patients

Exome Sequencing

Cohort

ES Cohort

0.020***

0.022***

0.022***

(0.001)

(0.001)

(0.001)

-0.00002***

-0.00002***

-0.00003***

(0.000)

(0.000)

(0.000)

-0.122**

-0.094

-0.182***

(0.051)

(0.079)

(0.059)

0.0006

0.001

0.001

(0.000)

(0.001)

(0.000)

0.545***

0.599***

0.454***

(0.062)

(0.096)

(0.071)

0.748***

0.470

0.860***

(0.145)

(0.294)

(0.141)

0.230**

0.371**

0.240**

(0.108)

(0.183)

(0.117)

0.055

0.035

-0.013

(0.092)

(0.143)

(0.108)

0.026

0.023

0.022

0.163***
(0.045)

Length of Stay

Length of Stay

2

Molecular Diagnosis

DOL Genetics consult

Unit

a

CVICU

PICU

PCU

Other Unit

Point of Origin

b

Transfer Center
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(0.052)

(0.080)

(0.060)

-0.088

-0.111

-0.092

(0.086)

(0.130)

(0.102)

-0.407***

-0.628***

-0.203*

(0.096)

(0.153)

(0.109)

10.647***

10.555***

10.806***

(0.051)

(0.073)

(0.057)

736

368

368

R-squared

0.767

0.734

0.829

RMSE

0.598

0.651

0.489

Self Referral

Clinic or Physician Referral

Constant

n

a

b

NICU base category; Inborn base category

Standard errors in parentheses
*** p<0.01, ** p<0.05, * p<0.1
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Table S2. Costs by 28-day survival
No-ES
Did not

Cohort,

ES Cohort,

Survived to

survive to

Survived to

Survived to

28 days

28 days (n

28 days

28 days

(n = 686)

= 50)

p-value

(n = 337)

(n = 349)

p-value

16 (32.00)

0.387

85 (25.22)

96 (27.51)

0.497

29 (12—

43 (19—

59), 54.49

83), 70.13

229,052

339,874

(346,186)

(458,052)

281,397

427,076

(364,304)

(472,681)

6,508

17,050

(5,367)

(9,946)

a

Molecular
diagnosis, n
(%)

187 (27.26)

b

c

Length of
stay,
median
(IQR),

36 (15–71),

6 (3–10),

mean

62.44

7.56

admission,

285,433

84,673

mean (sd)

(410,426)

(71,592)

index year,

355,510

100,393

mean (sd)

(428,858)

(17,0197)

diagnostic

11,871

8,351

pathway,

(9,602)

(5,730)

<0.001

<0.001

Total cost of
index

<0.001

<0.001

Total cost of

<0.001

<0.001

Total cost of
index
admission

0.026

279

<0.001

mean (sd)
Total cost of
index year
diagnostic
pathway,

14,289

8,351

mean (sd)

(10,548)

(5,730)

tests, mean

6,397

5,291

(sd)

(6,639)

(4,807)

tests, mean

7,381

5,291

(sd)

(7,395)

(4,807)

<0.001

7,808

20,547

(6,156)

(10,123)

2,416

10,240

(2,935)

(6,948)

2,647

11,952

(3,716)

(7,187)

<0.001

Total cost of
index
genetic

0.580

<0.001

Total cost of
index year
genetic

0.132

<0.001

ES, exome sequencing; IQR, interquartile range
a

Wilcoxon rank-sum test unless otherwise noted;

b

Additional 6 diagnoses made by chromosomal microarray in ES cohort not included in ES diagnostic

yield
c

chi-square test
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Table S3. Costs, NICU patients only

a

All Patients

No-ES Cohort

ES Cohort

(n = 467)

(n = 245)

(n = 180)

p-value

59 (24.08)

56 (25.23)

0.775

c

430 (92.08)

221 (90.20)

209 (94.14)

0.115

c

387 (82.87)

207 (84.49)

180 (81.08)

0.329

admission, mean

214,503

176,466

256,480

(sd)

(290,247)

(254,405)

(320,630)

Total cost of index

268,196

223,439

317,590

year (mean)

(312,489)

(285,002)

10,435 (9,133)

Molecular
diagnosis, n (%)

120 (25.70)

b

Survival to 28
days, n (%)
Survival to 1 year,
n (%)
Total cost of index

<0.001

d

(333,997)

<0.001

d

5,463 (3,919)

15,922 (10,064)

<0.001

d

12,480 (10,047)

6,451 (4,480)

19,135 (10,292)

<0.001

d

6,134 (6,607)

2,387 (2,800)

10,269 (7,117)

<0.001

d

Total cost of index
admission
diagnostic
pathway, mean
(sd)
Total cost of index
year diagnostic
pathway, mean
(sd)
Total cost of index
genetic tests,
mean (sd)
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Total cost of index
year genetic tests,
mean (sd)

6,990 (7,219)

2,469 (2,930)

11,981 (7,262)

<0.001

d

a

All costs reported in 2017 USD$

b

Additional 5 diagnoses made by chromosomal microarray in ES cohort not included in ES diagnostic

yield
c

chi-square test;

d

Wilcoxon rank-sum test
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Table S4. Costs by form of ES

a

Proband ES

Trio ES

Critical Trio ES

(n = 227)

(n = 54)

(n = 87)

p-value

61 (26.87)

13 (24.07)

28 (32.18)

0.523

213 (93.83)

52 (96.30)

84 (96.55)

0.079

182 (80.18)

45 (83.33)

68 (78.16)

0.727 b

309,380 (455,314)

353,907 (450,153)

354,996 (438,161)

0.222

c

392,935 (471,912)

434,570 (471,404)

437,545 (452,828)

0.347

c

15,783 (10,630)

15,778 (6,538)

20,390 (8,241)

< 0.001

c

19,858 (11,147)

17,767 (6,245)

22,551 (8,336)

< 0.001

c

9,370 (7,781)

10,412 (3,821)

12,347 (4,868)

< 0.001

c

Molecular
diagnosis, n (%)

b

Survival to 28
days, n (%)

Survival to 1
year, n (%)
Total cost of index
admission, mean
(sd)
Total cost of index
year (mean)
Total cost of index
admission
diagnostic
pathway, mean
(sd)
Total cost of index
year diagnostic
pathway, mean
(sd)
Total cost of index
genetic tests,
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mean (sd)

Total cost of index
year genetic tests,
mean (sd)

11,693 (8,348)

10,928 (3,317)

a

All costs reported in 2017 USD$

b

One-way ANOVA; Kruskal-Wallis H test

c
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12,835 (4,614)

< 0.001

c

Table S5. Costs by diagnosis

a

No-ES Cohort

ES Cohort

CHARGE syndrome

n=4

n=2

Length of stay, index admission, mean (days)

91

84

Survival to 1 year, n (%)

3 (75.0)

2 (100)

Total cost of index admission, mean (sd)

431,360 (283,787)

317,590 (333,997)

Total cost of index year (mean)

456,497 (290,059)

400,245 (266,596)

mean (sd)

8,142 (2,741)

15,266 (15,746)

Total cost of index year diagnostic pathway, mean (sd)

8,778 (2,141)

20,951 (8,782)

Total cost of index genetic tests, mean (sd)

2,983 (552)

7,739 (7,856)

Total cost of index year genetic tests, mean (sd)

2,983 (552)

11,517 (2,512)

n=3

n=9

Length of stay, index admission, mean (days)

27

54

Survival to 1 year, n (%)

3 (100)

6 (66.7)

Total cost of index admission, mean (sd)

102,819 (120,924)

212,770 (198,847)

Total cost of index year (mean)

109,584 (121,021)

336,825 (301,821)

mean (sd)

5,511 (4,989)

9,931 (5,083)

Total cost of index year diagnostic pathway, mean (sd)

5,568 (4.911)

16,276 (6,979)

Total cost of index genetic tests, mean (sd)

2,894 (2,481)

5,496 (4,583)

Total cost of index year genetic tests, mean (sd)

2,894 (2,481)

9,062 (4,890)

Walker-Warburg syndrome

n=1

n=1

Total cost of index admission diagnostic pathway,

Noonan syndrome

b

Total cost of index admission diagnostic pathway,

285

Length of stay, index admission (days)

31

36

Gaucher disease

n=1

n=1

Length of stay, index admission (days)

4

29

ES, exome sequencing
a

All costs reported in 2017 USD$

b

includes Neurofibramatosis-Noonan syndrome, and Noonan syndrome 1, 3, and 5 diagnoses
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CONCLUSION
This project presents evidence, both through literature review and analysis of
a newly assembled dataset through systematic collection and merging of data, on
the impact of clinical ES on the cost of care for infants undergoing a diagnostic
workup for suspected genetic disease. Uptake of clinical genomic sequencing has
occurred quickly and without robust, systematic evidence regarding either outcomes
or costs from comparative studies to inform its application. In the patient population
studied herein, ES demonstrated important diagnostic utility for patients with
monogenic disease, yet other genetic tests, especially chromosomal microarray,
remain important diagnostic tools given the burden of chromosomal abnormalities in
this population. As clinically applied over the first 5 years, ES does not appear costeffective as a diagnostic tool for the broad population of newborns and infants with
suspected genetic disease as compared to standard diagnostics. Further work is
needed to develop outcome measures to capture utility of both diagnostic ES results
and non-diagnostic ES results for clinicians, patients, and patients’ families and to
specify clinical guidelines for appropriate ES application.
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